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General Introduction and Outline of the Thesis 
 
 
Vessel wall injury 
 
September 16, 1977, Andreas Gruentzig performed the first balloon angioplasty of a 
stenotic coronary artery in a conscious human (1). Since then techniques have changed 
but the principle is still the same. During percutaneous coronary intervention (PCI) the 
atherosclerotic plaque causing the coronary stenosis is broken by high pressure balloon 
inflation in the coronary lumen and mainly pushed into the coronary artery wall. 
As the coronary artery wall is elastic, the balloon will not only push the plaque material into 
the vessel wall, but also stretch the whole vessel wall increasing its diameter during 
dilatation. Substantial vessel wall injury can be inflicted by balloon oversizing (2).  
The major drawbacks of balloon angioplasty were acute elastic recoil after balloon 
deflation, late constrictive vessel remodelling and neointimal proliferation as a reaction to 
the vessel wall injury (3-5). This led to a very high percentage of restenosis within 6 
months after PCI. 
To overcome these problems intracoronary stents were introduced. The stent struts 
prohibit early and late recoil, but the struts can cause considerable damage to the vessel 
wall and severity of vessel wall injury was correlated to restenosis by Schwartz et al. (2). 
The healing response to this vessel wall trauma, resulting in neointimal proliferation inside 
the stent is responsible for the in-stent restenosis. 
Despite these drawbacks, coronary stenting has been shown to be superior to balloon 
angioplasty only (6, 7). Restenosis rates were reduced to 20- 30 % at 6 months.  
A new promising technique emerged to treat the very therapy resistant in-stent restenosis, 
intracoronary irradiation therapy. Both gamma- and beta-emitters confirmed their 
effectiveness in randomized trials (8- 13). However, long-term results are disappointing, 
showing 60 % major adverse cardiac events at 4 years, mainly due to late occlusions (14-
16). Delayed vascular wall healing after radiation therapy with long-lasting thrombogenicity 
is thought to be the main reason.   
Beta-radiation as adjunctive therapy to balloon angioplasty or stenting of de novo lesions 
did not show reduction in clinical events either and again a high rate of late thrombotic 
occlusions (17, 18).  
The major breakthrough in preventing in-stent restenosis was the introduction of the 
sirolimus-eluting stent and later the paclitaxel-eluting stent. Both drugs with different anti-
proliferative mechanisms are released from a polymer stent coating and reduced in-stent 
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restenosis percentages to single digit numbers for non-complex lesions (19- 22).  Despite 
the impressive results, in-stent restenosis still occurs, especially in challenging lesions. In 
the early days of sirolimus-eluting stents, 3.0 mm was the largest available diameter. This 
led to frequent post-dilatation to achieve a diameter of 1 mm larger or even more.  In-stent 
restenosis has been reported after stent fracture of overdilated stents. This is probably 
caused by the combination of less local drug concentration because of overstretching of 
the stent, combined with polymer damage and direct vessel wall damage caused by the 
broken stent struts.  
 
The aim of the first part of the thesis was to study vascular injury and healing response 
after stent implantation. 
Chapter 2 describes the different phases of vessel wall injury and healing response after 
coronary stenting.  
Chapter 3 quantifies vessel wall injury after implantation of different types of stents. 
Chapter 4 shows a case-report of a patient with a very late occlusion, five years after 
balloon angioplasty and additional beta-radiation therapy. 
Chapter 5 reports a case, were overstretching of a drug-eluting stent led to stent fracture, 
resulting in restenosis at follow-up. 
 
 
Endothelial dysfunction after PCI. 
 
Normal endothelial function is very important for optimal myocardial function and 
prevention of cardiac events. Endothelium has a key function in the regulation of vascular 
tone (23), anti-thrombogenicity and prevention of development of atherosclerotic lesions 
(24, 25). Endothelial dysfunction has been correlated with worse long-term outcome of 
coronary artery disease (26). Endothelial dysfunction results amongst others in a loss of 
vasodilatory capacity.  This loss of endothelium-dependent vasodilatation has been found 
in patients with risk factors for atherosclerosis like smoking, aging, hypercholesterolemia, 
hypertension, hyperglycemia, a family history of premature atherosclerotic disease and 
obesity (24, 27-29) and reflects one of the earliest asymptomatic states of atherosclerotic 
disease.  
PCI results in acute vessel wall injury and (partial) endothelial denudation of the treated 
segment. Within several weeks re-endothelialization is completed (30). However, a new 
endothelial confluent layer does not mean restoration of normal endothelial function (31, 
32).  
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 After PCI a vessel wall healing response is elicited. However, adjunctive radiation therapy 
to prevent restenosis, does not only decrease or delay neointimal proliferation, it also 
delays the healing response (33, 34). Caramori et al. showed long-term endothelial 
dysfunction of the coronary segment distal to the PCI site (35). 
As mentioned above, drug-eluting stents like the sirolimus-eluting stent and the paclitaxel-
eluting stent significantly decreased the rate of in-stent restenosis. However, some data 
suggest delayed wound healing together with delayed recovery of endothelial function after 
implantation of these stents (36- 38), exposing the patients to a higher risk of late stent 
thrombosis and delayed in-stent restenosis.  
Endothelial cells are aligned along the flow direction in the coronary artery. Flow 
turbulence caused by a stenosis or branching of the coronary tree causes areas of low and 
high shear stress at the interface of the lumen and coronary artery wall and areas of low 
shear have been related to endothelial dysfunction in vitro (39-43). However, a relation 
between local endothelial dysfunction and low shear stress has never been shown in vivo, 
neither in animal models nor in humans. 
 
The aim of the second part of the thesis was to study endothelial function early and late 
after different coronary interventions (balloon, bare stent, brachytherapy, DES), as well as 
to link endothelial dysfunction to shear stress. 
In Chapter 6 endothelial permeability as an indicator of abnormal function was 
investigated in porcine coronary arteries, late after balloon angioplasty injury or stenting. 
In Chapter 7 endothelium-dependent vasomotion of an atherosclerotic human coronary 
segment was studied directly and 6 months after intracoronary beta-irradiation therapy. 
In Chapter 8 endothelial functional recovery 6 months after stenting with sirolimus-eluting 
stents was evaluated compared to recovery after bare stent implantation. 
Chapter 9 attempted to correlate local endothelial function with local shear stress in 
patients during 6 months follow-up coronary angiography after implantation of a sirolimus-
eluting stent, using three-dimensional vessel reconstruction and coronary flow 
measurements during intracoronary acetylcholine infusions. 
 
 
Coated stents and drug-eluting stents 
 
Stent thrombosis is a serious event and was the reason for the dampened enthusiasm for 
stenting after the early attempts of 1986 (44) and the years after. In the early days of 
stenting, very rigorous anti-coagulant regimes were used including heparinization after the 
procedure, oral anticoagulant therapy and dextran infusions, to overcome the risk of early 
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stent thrombosis. The higher risk of bleeding complications with this regime led to attempts 
to make the stent less thrombogenic. Only after resolving the problem of stent thrombosis 
without significantly increasing risks of major bleeding by the BENESTENT pilot trial (45, 
46) using heparin-coated stents and others (47-49), stenting gained popularity and by 
2004 most lesions are stented in the Western world. Though excellent results on anti-
thrombogenicity, heparin-coated stents did not fulfil the promise of reduction of in-stent 
restenosis. It was thought that reduction of stent-strut adherent thrombus in the early days 
after stenting would reduce late restenosis because the adherent thrombus could be a 
nidus of growth factors and inflammatory cytokines, stimulating neointimal proliferation.  
 
 Despite the excellent data on drug-eluting stents, concern has been raised regarding the 
risk of stent thrombosis in drug-eluting stents.  Experimental data showing delayed 
vascular healing after PCI and reports of stent thrombosis have led to longer double anti-
platelet therapy. In bare stents 1 month was the standard, in drug-eluting stent patients 6 
to 12 months of double anti-platelet therapy has become the rule. Though concerns about 
stent thrombosis even led to an official FDA warning in 2003 (50), increased risk compared 
to bare stents could never be substantiated.  
The general concern led to very cautious use in acute coronary syndromes, because of the 
higher “thrombotic state” of these patients, inherent to the acute coronary syndrome. 
 
The aim of the last part of the thesis was to study safety and efficacy of withdrawing 
rigorous anticoagulant regimes when using heparin-coated stents as well as thrombotic 
risk and long-term outcome of drug-eluting stents.  
Chapter 10 reports the findings of the use of a heparin-coated stent in porcine coronary 
arteries. This preclinical study led to the clinical BENESTENT 2 pilot and trial. 
Chapter 11 gives an overview of subsequent research and trials with different heparin-
coatings, conducted up till 2004. 
Chapter 12 is a summary of the available data on drug-eluting stent studies by January  
2004,  written for the course book of “ The Paris Course on revascularization 2004”. 
Chapter 13 and 14 investigated safety and efficacy of the use of sirolimus-eluting stents 
(Ch 13) and paclitaxel-eluting stents (Ch 14) in the percutaneous treatment of acute 
myocardial infarction patients. 
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Late-Late Occlusion After Intracoronary Brachytherapy
Georgios Sianos, MD; Nico Mollet, MD; Sjoerd Hofma, MD;
Pim J. de Feyter, MD; Patrick W. Serruys, MD
A57-year-old man with a history of anterior myocardialinfarction in April 1997, initially treated with successful
thrombolysis, underwent cardiac catheterization due to per-
sistent postinfarction angina. A single-vessel disease, with a
significant lesion in the left anterior descending coronary
artery (LAD), was found. The patient was treated with
balloon angioplasty followed by intracoronary beta radiation
therapy according to the Beta Energy Restenosis Trial
(BERT). He received 16 Gy at 2 mm from the centerline of
the 90Sr/90Y source. He remained asymptomatic for 41/2
years. During this period, he underwent control angiography
with the use of Intravascular Ultrasound (IVUS) at 6 months
and 3 years, as mandated by protocol. After this period, he
again developed angina, and an exercise test was positive for
ischemia. Diagnostic coronary angiogram at almost 5 years
revealed single-vessel disease, with totally occluded LAD
with collateral filling from the right coronary artery. The
angiographic sequence is presented in Figure 1. The IVUS
images are presented in Figure 2. Before the reintervention, a
16-row, electrocardiographic-gated, cardiac, multislice spiral
CT scan was also performed (Figure 3). An attempt at
percutaneous recanalization was not successful, and the
patient underwent coronary artery bypass surgery with im-
plantation of the left internal mammary artery in the LAD.
Figure 1. The LAD, filmed at the left anterior oblique and cranial projection. At baseline a severe focal lesion just before the bifurca-
tion of the second diagonal branch (D2) with a septal perforator branch (S) was observed. A big first diagonal branch (D1) can also
be seen. The patient was treated with balloon angioplasty (single dilatation with a 312-mm balloon at 12 atm) followed by
catheter-based irradiation with the use of the 30-mm-long, 90Sr/90Y Beta-Cath source, with a good final result. The balloon and the
radiation source were filmed in the right anterior oblique and cranial projection. The irradiated segment (IRS) is indicated by the 2
black horizontal lines in the “final result” frame. Control angiogram at 6 months and 3 years revealed well-preserved result without
restenosis. At 5 years, there is severe lumen compromise throughout the length of the irradiated segment, with minimal contrast
penetration up to the D2 and complete occlusion after its takeoff (arrow).
From the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
Movies are available in the online-only Data Supplement at http://www.circulationaha.org.(Circulation. 2003;108:e69-e70.)
Correspondence to Prof P.W. Serruys, MD, PhD, Department of Interventional Cardiology, Erasmus MC Rotterdam, Thoraxcenter Bd 404, Dr
Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. E-mail serruys@card.azr.nl
(Circulation. 2003;108:e69-e70.)
© 2003 American Heart Association, Inc.
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Figure 2. Left panels, Longitudinal intravascular ultrasound reconstruction of the LAD at 6 months follow-up, corresponding to the
angiographic projection in Figure 1. The left main coronary artery (LM) is on top of the image and the distal LAD at the bottom. a, Slice
showing the bifurcations with the left circumflex coronary artery (LCx) and the first diagonal branch (D1). b, Slice showing the bifurca-
tions with the second diagonal (D2) and the septal (S) branches. There is a 60-degree difference between the planes of slices shown in
panels a and b. Right panels, Longitudinal intravascular ultrasound reconstruction of the LAD at 3 years follow-up. Slice shown in panel
e corresponds to that in panel a. Slice shown in panel f corresponds to that in panel b. Middle panel, Cross-sectional images corre-
sponding to the site of the initial stenosis at baseline, just before the bifurcations of the LAD with the D2 and the septal branches, as
indicated by the yellow and red horizontal lines at the longitudinal reconstructions shown in the lower half of the other panels, at 6
months (c) and 3 years (d). The red line delineates the external elastic membrane and the green line the lumen surface. Between 6
months and 3 years, a reduction in the total vessel area (TVA) can be observed (negative remodeling) with accompanying reduction in
the plaque area (PA) (plaque regression). This results in an unchanged lumen area (LA) between 6 months and 3 years.
Figure 3. a, Electrocardiographic-gated multislice CT 3D volume-rendered image of the heart and the great vessels. The aortic root
(Ao), the pulmonary artery (PA), and the left ventricle (LV) are clearly visible. b, Detailed picture of the left coronary artery corresponding
to the angiographic frames in Figure 1. The left main coronary artery (LM) is divided into the left anterior descending (LAD) and the left
circumflex (LCx) coronary arteries. A severe stenosis at the ostium of the LAD (double arrowhead) can be seen. This lesion was not
obvious in the angiographic images presented, because of overlap of the ostium of the LAD with LCx. More distally, the LAD is
occluded (arrowhead) after the takeoff of the first diagonal branch (D1), at the site of previous treatment with balloon dilatation and beta
irradiation.
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INTRODUCTION
Coronary stents, initially reserved for bailout situa-
tions, are now used in more than 80% of all cases.
However, their efficacy is limited by the occurrence of
in-stent restenosis, ranging from 15% to 35% of cases,
depending on lesion morphology [1–3]. Recently, drug-
eluting stents have been proven very effective in sup-
pressing neointimal proliferation and reduced restenosis
to single digit numbers [4–6]. We report two cases of
treatment failure with sirolimus-eluting stents (SESs)
related to stent fractures.
CASE REPORTS
Case 1
A 45-year-old male with hypercholesterolemia and
hypertension presented with stable angina class II–III
according to the classification of the Canadian Cardio-
vascular Society (CCS) and a positive exercise test. In his
past medical history, he had an inferior wall myocardial
infarction in 1994, followed by elective balloon angio-
plasty of the right (RCA) and left circumflex (LCx)
coronary arteries. Coronary angiography revealed a long
complex lesion in the mid RCA.
The RCA was engaged with a 6 Fr guiding catheter
(Mach1 FR 4.0, Boston Scientific Scimed, Maple Grove,
MN) using the standard femoral approach. A 0.014 PT
Graphix Intermediate guidewire (Guidant, Santa Clara,
CA) was used to cross the lesion. The vessel was treated
with direct BX Velocity SES implantation (Cypher, Cor-
dis Europe, Roden, The Netherlands), 2.75  8 mm
distally, 3.0 33 mm in the middle part, and 3.0 8 mm
proximally. All stents were deployed at 18 atm. The
proximal stents were postdilated with a 3.5 mm balloon
(Adante 3.5  20 mm; Boston Scientific Scimed) up to
20 atm with a good angiographic result (Fig. 1). Post-
procedural intravascular ultrasound (IVUS; Avanar F/X,
Jomed, Beringen, Switzerland) examination with auto-
mated pullback (Trak Back 2, Jomed) speed of 0.5 mm/
sec revealed good stent apposition with 1 mm gaps
between the three stents. The patient was enrolled in the
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardi-
ology Hospitals (RESEARCH) registry and agreed to
undergo control angiography at 6 months postprocedure.
He was discharged next day on aspirin for life and
clopidogrel for 6 months.
The patient remained asymptomatic for 6 months. The
diagnostic angiogram revealed a very focal stenosis (4.95
mm long), 66% by quantitative coronary angiography
(QCA), in the middle part of the 3  33 mm long stent
(Fig. 1). IVUS investigation (Atlantis SR, 40 MHz; Bos-
ton Scientific) revealed significant neointimal formation
at the point of the angiographic stenosis with lumen
compromise [minimal luminal area (MLA), 2.8 mm2]
and absence of stent struts corresponding to fracture of
the stent (Fig. 2). There was very effective suppression of
the neointima formation throughout the rest of stent
length and also in the stents deployed proximal and
distally. Minimal formation of neointima hyperplasia
was observed in the gap between the distal and the mid
stent (MLA with IVUS measurements was 4.8 mm2).
During the examination, the IVUS catheter was occlusive
and the patient experienced angina.
Based on these findings and despite the absence of
symptoms until his presentation, the lesion was treated
with implantation of 3.0  8 mm Cypher stent deployed
at 16 atm and postdilated with a 3.5 mm  20 mm
balloon (Worldpass, Cordis Europe) up to 16 atm.
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Fig. 2. Top left: Angiogram of the RCA at 6-month follow-up.
The arrow indicates the restenotic lesion. Bottom left: View of
the stents without contrast. The yellow lines represent a sche-
matic diagram of the relative position of the stents: (1) Cypher
3.0  8 mm, (2) Cypher 3.0  33 mm, and (3) Cypher 2.75  8
mm. The gaps between the stents are clearly visible. The per-
pendicular yellow line in the middle of stent 2 corresponds to
the point of the stent fracture and restenosis. Top right: Longi-
tudinal IVUS reconstruction of the RCA; the yellow vertical line
and b correspond to the point of the restenosis. The right
ventricular branch (RV) is clearly visible. Bottom right: A, B, and
C are cross-sectional images corresponding to the positions a,
b, and c at the longitudinal reconstruction. In A and C, proximal
and distal from the stenosis, respectively, there are six stent
struts visible (yellow dots) with complete absence of neointimal
hyperplasia. Cross-section B at the restenotic site shows a
large concentric plaque, with the RV branch visible at 11
o’clock. No stent struts are visible at this cross-section, indi-
cating the stent fracture. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
Fig. 1. Angiographic image of the right coronary artery at
6-month follow-up. Left: End-diastolic frame. Middle: End-sys-
tolic frame. The inserts in the left shows the RCA at baseline
before (pre) and after (post) treatment. The arrow indicates the
restenotic lesion. Right: Schematic diagram showing the differ-
ence in geometry of the Cypher 3  33 mm stent during the
heart cycle. In end-diastole (ED), a much greater angle is
formed between the two arms of the fractured stent compared
to end-systole (ES). The arrowhead indicates the breakpoint of
the stent and the position of the restenosis. [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
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Case 2
A 48-year-old male patient presented with unstable
angina class IIB according to Braunwald classifica-
tion. His medical history consisted of an inferior non-
Q-wave myocardial infarction 2.5 years ago. Due to
postinfarction angina, coronary angiography was per-
formed, revealing an occluded right coronary artery
(RCA). Successful recanalization followed during the
same session with implantation of three Carbostents
(Sirius, Sorin Biomedica, Saluggia, Italy) 3.0  25
mm distally, 3.0  25 mm in the middle, and 3.0  9
mm proximally (Fig. 3C). He remained asymptomatic
for 2 years and then developed effort angina CCS class
III. Repeat catheterization revealed ostial reocclusion
of the RCA (Fig. 3A) that was treated with repeat
percutaneous intervention.
The right coronary artery was cannulated with a 6 Fr
Judkins Right 4.0 guiding catheter (Vista Brite, Cordis
Europe) using the right radial artery approach. Crossing
with a guidewire was difficult and was finally achieved
with a 0.014 Crosswire NT guidewire (Terumo, Tokyo,
Japan). Afterward, predilatation was performed with a
2.5  30 mm balloon (Worldpass, Cordis Europe) fol-
lowed by Cypher stent implantation. Three stents were
deployed: 3.0  33 mm distally, 3.0  33 mm in the
middle, and 3.0  18 mm proximally, with good final
angiographic result (Fig. 3A). The 3.0 mm stents were
postdilated with a 3.5 mm  20 mm balloon (Adante,
Boston Scientific Scimed) up to 22 atm. The patient was
discharged on aspirin for life and clopidogrel for 6 months.
Five months after the index procedure, the patient was
readmitted due to unstable angina. Coronary angiography
Fig. 3. The insert in A shows the totally occluded right coro-
nary artery at baseline (pre). A: Final result after recanalization
and stent implantation. B: Result at follow-up. There are four
very focal lesions, a to d, from proximal to distal, giving the
vessel a beaded appearance. The difference in vessel geometry
from hemispherical postintervention to a wave shape at fol-
low-up is clearly visible, indicative of stent fracture. C: View of
the RCA without contrast in the same projection as in frame B
with a schematic diagram of the stents implanted during the
two interventions. The white lines correspond at the stents
implanted during the first intervention: (l) Carbostent 3.0  9
mm, (2) Carbostent 3.0  25 mm, and (3) Carbostent 3.0  25
mm. There was an overlap between stents 1 and 2 and a gap
between stents 2 and 3. The yellow lines correspond to the
stents deployed during the second intervention. (4) Cypher
3.0  18 mm, (5) Cypher 3.0  33 mm, and (6) Cypher 3.0  33
mm. There was a gap between stents 4 and 5 (asterisk, corre-
sponding to the proximal, a, restenotic lesion) and an overlap
between stents 5 and 6 (cross). The three stent fractures are
indicated by the small horizontal lines and they correspond
anatomically to the restenotic lesions b, c, and d in frame B. It
is important to note that the proximal stent fracture in stent 5
occurred at the gap between its overlap between stent 2 and 3
and the two distal fractures at both sides of overlap between
stents 5 and 3. Right: IVUS cross-sectional images with the
lumen plaque detail corresponding to the restenotic lesions in
B. Note that the smallest lumen area is observed in frame c. The
IVUS interpretation is described in detail in Figure 4. [Color
figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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revealed an unusual pattern of restenosis with four discrete
restenotic lesions throughout the length of the stents and
complete absence of any restenotic tissue in between (Fig.
3B). IVUS examination (Atlantis SR, 40 MHz; Boston
Scientific) revealed local neointimal formation with absence
of metallic stent struts at the distal three restenotic lesions,
corresponding to areas of stent fracture. The fourth most
proximal one corresponded at the location of the known gap
Fig. 4. Top: Longitudinal IVUS reconstruction of the right cor-
onary artery with a schematic diagram of the stents corre-
sponding to the description in Figure 3. The most proximal
Carbostent 1 and part of the proximal Cypher stent 4 were not
visualized due to selective position of the guiding catheter in
the ostium of the RCA. Middle: The same longitudinal recon-
struction. The focal formation of neointimal hyperplasia is vis-
ible and corresponds to the angiographic, identically lettered,
restenotic lesions a to d described in Figure 3B. There is com-
plete absence of tissue formation in between the lesions. Bot-
tom: Cross-sectional IVUS images of the four restenotic le-
sions. The yellow dots correspond to the visible stent struts. In
cross-section a, the tissue accumulation in the gap between the
Cypher stents 4 and 5, one layer of struts is visible. They are the
struts of the Carbostent 2. In cross-section b, only two stent
struts can be observed, indicating partial fracture of the 33 mm
long Cypher stent 5 in its proximal part. In cross-section c, no
stent struts are visible, which means complete fracture of both
the Cypher stent 4 at its distal part and complete fracture of the
peripheral Carbostent 3. It is the restenotic lesion with the
larger plague burden and smallest luminal area. The cross-
section e, adjacent to cross-section c, shows the overlap of the
two long Cypher stents and the Carbostent 3. Three overlap-
ping layers of struts are visible without any neointimal hyper-
plasia. In cross-section d, only one strut can be seen, with
moderate plaque formation, corresponding to the partial frac-
ture of the distal 33 mm long Cypher stent 6. As indicated by the
short inclined lines in the top, the two distal fractures were
observed at the extremities of stent overlapping and the third in
a gap of the previous noneluting stents. [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
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between the proximal and mid sirolimus-eluting stents.
There was complete absence of neointimal hyperplasia in
between the restenostic lesions (Fig. 4).
The patient was treated with implantation of four
3.0  8 mm Cypher stents. During the procedure, intra-
venous IIb/IIIa glycoprotein inhibitor abciximab was ad-
ministered and continued for 12 hr after the procedure.
Clopidogrel medication was prescribed for another 6
months.
DISCUSSION
Drug-eluting stents, given their outstanding perfor-
mance in controlled clinical trials, seem set to revolu-
tionize the percutaneous treatment of coronary artery
disease. Angiographic restenosis is well below the range
of 10% and reported cases have generally involved por-
tions of the vessel that have been subjected to balloon
injury but were not covered by the stent, such as reste-
nosis in an unintentional gap between adjacent stents or
just proximal or distal to the stent. Given these results,
SESs and lately taxol-eluting stents are the standard
treatment in our institution for all the patients undergoing
percutaneous interventions.
The two cases reported here suggest the existence of a
new potential mechanism of restenosis after implantation
of sirolimus-eluting stents for either de novo atheroscle-
rotic lesions or for in-stent restenosis, namely stent frac-
ture with restenosis in the unstented gap.
Stent fractures have been reported in both nonvas-
cular settings, such as the biliary tract [7,8] and esoph-
agus [9,10], and vascular settings, such as the iliac
artery [11] and in the subclavian artery and vein [12].
Excessive mechanical stress due to extreme flexion of
the vessel or compression by tissue (tumor growth in
esophageal stents) is the proposed cause of these frac-
tures.
Stent fracture has also been reported after pulmonary
artery stenting for pulmonary artery stenosis in congen-
ital heart disease [13]. For stents positioned near pulsatile
structures such as the heart or the proximal great vessels,
a fracture rate of 15–30% has been reported [14–16]. In
a recent randomized trial that compared autoexpandable
nitinol stents with or without a sirolimus coating for the
treatment of diffuse superficial femoral disease, stent
fractures occurred in 6 of 33 patients and were equally
distributed in coated and noncoated stents. No clinical or
angiographic consequences were reported [17].
A case of coronary stent fracture was recently reported
in a venous bypass graft (18). In vein grafts, mechanical
stresses can be very high, depending on the curvature of
the graft, the presence of perigraft fibrosis, and the in-
trathoracic space available.
Recently, a warning was issued after seven cases of
fractures of NIRoyal coronary stent, occurring between 3
weeks and 9 months after implantation, were reported.
Five of them were implanted in native coronary arteries
and two in vein grafts. All stents were long, 25 and 32
mm, and in four cases there were two or more overlap-
ping stents. Six out of seven patients presented with
recurrent symptoms related to restenosis and three of the
fractured stents were totally occluded (www.medical-
devices.gov.uk).
To our knowledge, this is the first report of fracture of
SES in coronary arteries. This resulted in an unusual
pattern of very focal in-stent restenosis with complete
abolition of neointimal hyperplasia in the rest of the stent
length. Since the effectiveness of the SES is related to the
release of an active therapeutic compound, local under-
dosage due to the stent fracture in combination with
increased mechanical irritation are the most probable
causes of the very focal restenosis.
All fractured stents were long (33 mm) and were
postdilated with larger balloons at high pressures. In
the first case, the stent was fractured in its middle part
at the point of maximal vessel curvature and move-
ment. In the second case, two of the fractures were
observed at the extremities of stent overlapping and
the third in a gap of the previous noneluting stents.
This means that all fractures occurred around areas of
increased rigidity due to metal overlapping that may
have acted as a fulcrum for metal deformation due to
vessel movement. Longer stents covering longer ves-
sel areas are subjected to higher radial forces com-
pared to shorter stents and may be more prone to
fracture, especially when placed in tortuous vessels or
calcified lesions. Stent overexpansion could also have
contributed to the stent fracture.
In conclusion, this report illustrates an unusual cause
of restenosis with sirolimus-eluting stents, the stent frac-
ture. The very effective suppression of neointimal for-
mation within the stent causes an unusual pattern of very
focal restenosis at the point of fracture. Further studies
with intravascular ultrasound should be performed to
clarify whether this is an important issue or a sporadic
observation.
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Objectives. To compare percutaneous transluminal coronary
angioplasty (PTCA) and stent implantation with respect to the
long-term changes they induce in the newly formed endothelium
in porcine coronary arteries by studying both morphological and
functional parameters of the endothelium at 2 weeks and 3
months after intervention.
Background. Problems affecting PTCA or stent implantation
have been overcome to a large extent by means of better tech-
niques and the availability of new drugs. Late problems, however,
still exist in that restenosis affects a large number of patients.
With an increasing number of patients being treated with stents,
the problem of in-stent restenosis is of even greater concern, as
this seems difficult to treat. A functional endothelial lining is
thought to be important in controlling the growth of the underly-
ing vascular tissue. We hypothesized that the enhanced neointi-
mal hyperplasia observed after stenting is associated with a more
pronounced and prolonged endothelial dysfunction.
Methods. Arteries were analyzed using a dye-exclusion test and
planimetry of permeable areas. Thereafter, the arteries were
processed for light and scanning electron microscopy for assess-
ment of morphology and proliferative response.
Results. Leakage of the endothelium for molecules such as
Evans blue-albumin as well as prolonged endothelial proliferation
is observed as late as 3 months after the intervention, and is more
pronounced after stenting. Permeability is associated with distinct
morphologic characteristics: endothelial retraction, the expres-
sion of surface folds, and the adhesion of leukocytes.
Conclusions. Stenting especially decreases long-term vascular
integrity with respect to permeability and endothelial prolifera-
tion, and is associated with distinct morphologic characteristics.
(J Am Coll Cardiol 1998;32:1109–17)
©1998 by the American College of Cardiology
Problems affecting percutaneous transluminal coronary angio-
plasty (PTCA) or stent implantation such as acute closure,
stent thrombosis, or bleeding complications due to the strin-
gent anticoagulation protocols from the early days of stent use
have been overcome to a large extent by means of better
techniques and the availability of new drugs (1–4). Late
problems, however, still exist in that restenosis affects approx-
imately 15–20% of patients after primary stenting and 30–50%
after PTCA alone. With an increasing number of patients
being treated with stents (up to 50%), the problem of in-stent
restenosis is of even greater concern as this seems difficult to
treat.
Every intervention aimed at increasing lumen size inevita-
bly leads to damage of the vessel wall. The subsequent healing
response, necessary to pacify the inflicted wound, triggers the
growth of a neointimal thickening (NI). Excessive growth of
this NI is only one of the contributors to restenosis after
PTCA, but is likely the sole responsible factor when dealing
with in-stent restenosis. PTCA mechanically damages the
endothelial cells and induces endothelial dysfunction that
persists for several weeks both in the laboratory animal and in
patients (5–7). A functional endothelial lining is important in
controlling the growth of the underlying vascular tissue (8),
and it may well be that the enhanced neointimal hyperplasia
observed after stenting is associated with a more pronounced
and prolonged period of endothelial dysfunction.
The objective of the present study was, therefore, to
compare PTCA and stent implantation with respect to the
long-term changes they induce in the newly formed endothe-
lium in porcine coronary arteries. We therefore studied both
morphological (as assessed by general pathology, morphome-
try, histochemistry, electron microscopy [EM]) and functional
parameters of the endothelium (barrier function and prolifer-
ative status).
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Methods
Animal care. Experiments were performed under the reg-
ulations of the animal care committee of the Erasmus Univer-
sity Rotterdam and in accordance with the “Guide for the Care
and Use of Laboratory Animals” (9).
Animal preparation. Experiments were performed in
Yorkshire pigs (25–30 kg; HVC). After an overnight fast, the
animals were sedated with 20 mg/kg ketamine hydrochloride.
After induction of anesthesia with thiopental (12 mg/kg) and
after endotracheal intubation, the pigs were connected to a
ventilator that administered a mixture of oxygen and nitrous
oxide (1:2 [vol/vol]). Anesthesia was maintained with 0.5–
2.5 vol% isoflurane. Antibiotic prophylaxis was administered
by an intramuscular injection of 1,000 mg of a mixture of
procaine penicillin-G and benzathine penicillin-G.
Under sterile conditions, an arteriotomy of the left carotid
artery was performed and a 9-F introduction sheath was
placed. Then 10,000 IU heparin sodium were administered
followed by left coronary angiography using the nonionic
contrast agent iopamidol (Iopamiro 370) after intracoronary
administration of 1 mg isosorbide dinitrate.
Coronary interventions. From the angiograms (analyzed
on-line using a quantitative coronary angiography analysis
system), arterial segments of 2.5–3.5 mm in diameter were
selected in the left anterior descending and/or left circumflex
coronary arteries. Typically, balloon sizes were chosen
0.2–0.5 mm larger than the recipient artery. The stents (PS
153, Palmaz-Schatz Coronary Stent; JJIS, and Wiktor stent;
Medtronic) were placed as described before (10,11). PTCA
was performed in a similar way, using identical inflation
parameters. After repeat angiography of the treated coronary
arteries, the guiding catheter and the introducer sheath were
removed, the arteriotomy was repaired, and the skin was
closed in two layers. The animals were then allowed to recover
from anesthesia.
Experimental groups and follow-up. Interventions were
performed in four groups of animals, as shown in Table 1. In
groups 1 and 2 (a subset of animals from a previously published
study [10]) the animals received a Palmaz-Schatz stent only
and were followed for 4 and 12 weeks, respectively, to assess:
1) the “molecular window,” i.e., to which extent the barrier
function of the endothelial lining was impaired, and 2) whether
this “window” of permeability changed in time. In groups 3 and
4, both PTCA and stent implantation were performed in each
animal. These animals were followed for 2 and 12 weeks to
assess the morphologic determinants correlating with the
impaired barrier both in morphologically immature and ma-
ture endothelium, and to study differences between the two
types of intervention.
Assessment of cell proliferation. To assess the proliferative
response to stent implantation and PTCA in comparison with
control coronary arteries, five animals each in groups 3A, 3B,
4A, and 4B were given three intramuscular injections of BrdU
(Sigma Chemical Co.) at 100, 50, and 50 mg/kg at 8-h intervals,
starting 24 h before sacrifice. Using light microscopy (LM), the
total number and number of BrdU-positive cells were counted
for each section in several high-power fields both proximal and
distal in the treated arteries. The right coronary artery served
as a control.
Assessment of intimal permeability at follow-up. In this
test (Fig. 1, dye-exclusion test) Evans blue (EB) (Sigma
Chemical Co.) was used in two configurations (12,13).
EB-albumin. To subject the arteries to the large molecular
marker (70 kD), 300 mL of EB in saline (0.3% [wt/vol]) was
administered intravenously, to allow for EB binding to albu-
min. The infusion was given for 30 min, and then 1 h was
allowed for recirculation of the EB-albumin complex.
Binding control. During and after the EB infusion, arterial
blood samples were taken, proteins precipitated with tri-
chloric acid (final concentration 20%), and then spun down to
check the supernatant for unbound dye.
EB-saline. To subject the arteries to the small molecular
marker (1 kD), 300 mL of EB in saline (0.3% [wt/vol]) was
administered directly into the coronary circulation after a
saline flush. After completion of the EB infusions, the coro-
nary arteries were flushed with approximately 300 mL saline
Abbreviations and Acronyms
BrdU  bromodeoxy uridine
EB  Evans blue
EM  electron microscopy
LM  light microscopy
NI  neointimal thickening
PTCA  percutaneous transluminal coronary angioplasty
Table 1. Study Groups
Group Intervention Follow-up n Molecular Weight Study Objective
1 Palmaz-Schatz stent 4 weeks 10 1 and 70 kD Window of permeability
2 Palmaz-Schatz stent 12 weeks 10 1 and 70 kD Window of permeability
3A Wiktor stent 2 weeks 9 70 kD Morphologic determinants
3B PTCA 2 weeks 9 70 kD Morphologic determinants
4A Wiktor stent 12 weeks 5 70 kD Morphologic determinants
4B PTCA 12 weeks 5 70 kD Morphologic determinants
n  number of arteries.
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before pressure fixation in situ (approximately 100 mm Hg)
with 500 mL 4% buffered formaldehyde. Then the heart was
excised, and the treated and control coronary arteries (not
treated with balloon or stent) were dissected from the epicar-
dial surface.
Macroscopic assessment. The excised treated and control
coronary arteries were opened longitudinally and checked
under a dissection microscope for penetration of the blue dye.
The arteries were documented on film and used for planimet-
ric analysis of the permeable areas. Thereafter, both proximal
and distal areas of the specimen were divided for EM and LM.
Routine histology. To check for abnormal vascular reac-
tions to the interventions and for a general assessment of the
histological appearance, all specimens were processed for
routine histology as described before (10). Sections were
stained with hematoxylin-eosin as a routine stain and resorcin-
fuchsin as a collagen and elastin stain.
Histochemistry. Lectin- and immunocytochemistry. This
was performed to confirm the identity of the endothelium and
smooth muscle cells as described before (14).
Detection of BrdU incorporation. After acid DNA denatur-
ation and elimination of endogenous tissue peroxidase activity,
rehydrated paraffin sections were exposed to mouse anti–BrdU
antibody (Becton Dickinson & Co.), dilution 1:80, to detect
BrdU-positive cells. As a second antibody, HRP-labeled rabbit
anti–mouse antibody (Dakopatts) was used, with 670 g/ml Di
Amino Benzidine (Sigma Chemical Co.) in phosphate-buffered
saline as a detecting reagent.
Morphometry. Intimal and medial thickness was deter-
mined along the length of the treated arterial segments. A
distinction was made between intimal and medial thickness
within and outside the PTCA lesion area and the media
underneath or between the stent struts. Data were analyzed
using elastin-stained sections and assessed on a microscopy
image analysis system (Impak C, Clemex vision Image analysis
system; Clemex Technologies Inc.) as described before (11). In
addition, lesion length was determined in the arteries treated
with PTCA, which was defined as the percentage of the
internal elastic lamina containing discontinuities or associated
with an intimal and/or medial thickening (15).
Scanning and transmission EM. To study endothelial mor-
phology (scanning EM) and to assess endothelial cell-cell
contact (transmission EM), selected tissues were fixed with
2.5% glutaraldehyde in 0.15 M cacodylate buffer, postfixed
with 0.1 M cacodylate buffer containing 1% OsO4 and 50 mM
ferricyanide (K3[Fe{CN}6]), and further processed as de-
scribed before (18). Specimens were examined in a JSM25
scanning electron microscope (Jeol Ltd.) and a CM100 trans-
mission microscope (Philips).
Statistical analysis. Analysis was performed using Sigma-
stat (versions 1.0 and 2.0, Jandel Scientific). Data are given as
mean standard deviation. Morphometry was analyzed with a
Figure 1. EB can be administered both intravenously and intracoro-
narily. Intravenous administration results in the spontaneous binding
of EB to albumin, and subjection of the arterial wall to the 70-kD large
complex. Intracoronary administration after a saline flush to remove
serum proteins results in subjection of the arterial wall to the smaller
1-kD molecule. Blue staining of the arterial wall indicates a breach in
the luminal barrier.
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one-way ANOVA, the planimetry and angiography with a
one-way repeated measures ANOVA, and followed by an
all-pairwise comparison in case of statistical significance using
a Student Neuman Keuls or Tukey test. A p value of0.05 was
considered statistically significant.
Results
Procedural outcome. A total of 39 animals were enrolled in
the study. In group 3, one animal died suddenly within 1 h after
the procedure due to stent thrombosis. In group 4, four
animals died: one animal died during the procedure due to
ventricular fibrillation, one died within a few hours after the
procedure due to stent migration and subsequent stent throm-
bosis, one animal due to respiratory problems during recovery
from anaesthesia, and one animal died at 3 weeks after the
procedure ex causa ignota (not stent related). The remaining
34 animals were used for analysis, as summarized in Table 1.
Quantitative angiographic measurements are shown in Table
2. Quantitative coronary angiography (QCA) confirmed that
all stent and balloon sizes closely matched coronary artery
vessel size with a balloon-artery ratio between 0.95 and 1.1.
Intimal permeability. Binding control confirmed that com-
plete binding of EB to the albumin was achieved.
The “window” of permeability (groups 1 and 2). Macroscopy
(Fig. 2A and B) revealed that both the 1- and 70-kD markers
were able to stain the vessel wall at 4 as well as at 12 weeks post
stenting. This indicates that there is a wide window of perme-
ability that does not change during the first 3 months.
The “extent” of permeability (all groups). Except for occa-
sional small areas distal to side branches, where the endothe-
lium is often subject to hemodynamic stress, the control
arteries did not reveal staining (Fig. 2A). Both stent- and
balloon-treated arteries, however, did reveal a distinct staining
of the vessel wall (Fig. 2B–D). In the stented arteries staining
of the intima was generally observed over the stent wires, while
between the stent struts a much lower level of staining was seen
(Fig. 2B and C). Both the Wiktor stent and the Palmaz-Schatz
stent, however, revealed a specific staining pattern. In the
Palmaz Schatz stent staining was seen over the stent struts in
the area of the stent ends and in the area of the coupler (Fig.
2B), while in the Wiktor stents staining was observed over the
wire along the whole length of the stent (Fig. 2C). These
patterns did not change during the observation period. In
group 3B (2 weeks after PTCA alone) there were also areas
that revealed staining albeit less prominently (Fig. 2D). In
group 4B (12 weeks after PTCA) the pattern was the same but
the staining intensity was less.
Planimetry. Planimetry of the area permeable to EB at 2
weeks showed that the percentage was 35.4  19.7% for the
stented arteries (p 0.05 vs balloon and control), 10.1 6.8%
for the PTCA treated arteries, and 2.5  2.2% for the control
arteries.
Electron microscopy and the endothelial barrier function.
Both scanning and transmission EM were performed on
groups 3 and 4. It confirmed that, in contrast to normal
endothelium (Fig. 3A), at 2 weeks after either stent implanta-
tion or PTCA the endothelial covering was still incomplete.
The areas covering the stent struts especially showed missing
cells, often in association with adhesion of leukocytes and
platelets. These areas were highly permeable to the EB dye.
The more diffusely permeable areas were characterized by an
endothelial layer where the cells appeared “retracted” (Fig.
3B). Transmission EM showed small or nonexistent intercel-
lular junctional complexes (Fig. 3C) in the areas with retracted
cells. Twelve weeks after the interventions, scanning EM
showed that the endothelial covering was complete in all
groups, and transmission EM now showed more extensive
junctional complexes even with tight junctions (Fig. 3D).
Permeability was now associated with a different phenomenon,
namely an endothelial layer with adhesion of leukocytes with a
rounded morphology that were also often seen penetrating the
endothelium as well as surface folds (Fig. 3E), which indicates
an increased endocytotic activity, although endothelial retrac-
tion was still observed occasionally.
Morphometry and assessment of cell proliferation. Mor-
phometric analysis is summarized in Table 3. At 2 weeks after
stenting (group 3A) there is a trend (p  0.05) toward a larger
NI over the stent struts than after PTCA at the site of the
lesion (group 3B). At 12 weeks both the Wiktor stent (group
4A) and the Palmaz-Schatz stent (group 2) do induce a
statistically significant larger NI than after PTCA. Also, the
Wiktor stent induces a significantly more pronounced NI as
compared with the Palmaz-Schatz stent. Morphometric analy-
sis of the medial layers show that the stents significantly
impress the media, whereas at the site of the PTCA lesion the
media has thickened. At 4 and 12 weeks (groups 1, 2, and 4A)
the media has thickened between the stent struts and is now
Table 2. QCA Assessment of Arterial and Balloon Diameter at the Site of Intervention
Group Pre Balloon Ratio Post Fu
1 (n  10) 3.05 0.28 2.98  0.38 0.95  0.07 3.06  0.33 2.37  0.39
2 (n  10) 3.11 0.21 3.03  0.30 0.97  0.06 3.02  0.17 3.12  0.27
3A (n  9) 2.87 0.27 3.02  0.41 1.02  0.09 2.74  0.29 2.65  0.28
3B (n  9) 2.95 0.31 2.85  0.32 0.95  0.05 2.66  0.34 2.79  0.48
4A (n  5) 2.61 0.46 2.92  0.39 1.08  0.06 2.67  0.30 2.80  0.25
4B (n  5) 2.58 0.25 2.65  0.42 1.04  0.06 2.28  0.28 3.08  0.42
Data are in mm and given as mean  SD. Pre, Post, Fu: mean coronary lumen diameter at the site of intervention before, directly after, and at follow-up,
respectively. Balloon: mean diameter of the contrast filled balloon during maximal inflation. Ratio: balloon to artery ratio.
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similar to the lesion area in the balloon-treated arteries at 2
and 12 weeks.
For assessment of cell proliferation, the BrdU-positive and
total number of cells were counted in several sections. For each
artery this amounted to 200–400 endothelial cells; 200–400
(balloon group) and 1500–5500 (stent group) intimal cells;
1000–4000 medial and adventitial cells. The percentage of
BrdU incorporation is summarized in Table 4, and shows that
at 2 weeks after intervention the stent (group 3A) induced a
higher percentage of BrdU incorporation as compared with
PTCA in all tissue layers (p 0.05). In the PTCA vessels (both
lesion area and nonlesion area) there was a trend (p  0.05)
toward a higher percent proliferating cells as compared with
control (not injured) values. Twelve weeks after intervention
the levels of BrdU incorporation had decreased in all groups.
Only the endothelium overlying the stent struts was still
significantly higher as compared with control values (4.8 2%;
p  0.05).
Microscopy. There were no adverse or unexpected vascular
reactions to the interventions as performed in groups 1–4, and
in general the tissue response was as described before (10,11).
In short, the stented arteries in groups 1, 2, and 4 were covered
by a variable intimal thickness consisting of smooth muscle
cells in a collagenous matrix and covered by endothelium.
Inflammatory reactions were limited for groups 1 and 2. In
group 4A, there were areas where the stent strut lacerated the
media, a phenomenon associated with a diffuse inflammatory
response. At 2 weeks (group 3A), the stent was embedded in a
mass of organizing thrombus, containing leukocytes and mac-
rophage giant cells, and was covered by an incomplete layer
of endothelial cells. There was medial hyperplasia (medial
thickening and longitudinal orientation of smooth muscle
cells) in association with BrdU incorporation between the
stent struts.
PTCA. At 2 weeks after PTCA (group 3B), there were
focal areas with a limited amount of neointima, which con-
sisted of smooth muscle cells in a collagenous matrix. In these
areas we observed fragmentation of the Lamina Elastica
Interna (LEI) and significant medial hyperplasia in association
with incorporation of BrdU (Fig. 4A). These lesions encom-
passed approximately 30% of the measured circumference.
The endothelial covering (as confirmed by lectin histochemis-
Figure 2. Macroscopy of the dye-exclusion test. A, Control right
coronary artery, shows a clean surface with occasional small blue areas.
B, Group 2, Palmaz-Schatz stent, 1 kD. For both molecular weights,
blue staining is found mainly at the stent ends and in the area of the
coupler (arrows). C, Group 3A Wiktor stent. Blue staining is seen
especially in the region of the intimal tissue covering the stent struts
(arrows). D, Group 3B, PTCA. Randomly stained areas (arrows) are
found in the arterial segment treated with PTCA and are more
apparent and intense in group 3B than 4B.
Chapter 6 
60
try) was incomplete and had a variable morphology. At 12
weeks after PTCA (group 4B), there was still a limited amount
of intimal hyperplasia. Although the media was still thickened
in these areas and the lesions still encompassed approximately
30% of the measured circumference, there was no incorpora-
tion of BrdU, nor a clear fragmentation of the LEI. On the
contrary, we often observed an additional internal elastic mem-
brane under the newly formed endothelium (Fig. 4B). The
adventitia was unremarkable.
Discussion
In contrast to restenosis after PTCA, which is dictated both
by constrictive remodeling and tissue growth (16,17), resteno-
Figure 3. EM of groups 3 and 4. A, Scanning EM of a nonblue area
showing normal endothelium. B, Endothelial cell retraction at 2 weeks
after stenting as illustrated by scanning EM, shows fingerlike projec-
tions between adjacent endothelial cells (arrowhead). Some have
broken during critical point drying (asterisk). C, Transmission EM at
2 weeks after stenting shows loose junctions (arrow) between adjacent
endothelial cells. D,At 12 weeks after stenting, transmission EM shows
tight junctions (arrow). E, The permeable areas in the endothelium at
12 weeks after stenting are characterized by surface folds as observed
with transmission EM (arrow). N  nucleus.
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sis after stenting is the result of tissue growth alone. With
increasing numbers of patients being treated with stents (up to
50%), the problem of in-stent restenosis is becoming more and
more of a problem, as this seems more resistant to effective
treatment.
Vascular dysfunction and in particular endothelial dysfunc-
tion has been described after PTCA both in humans and
animals (5–8). As one of the first changes in the etiology of
atherosclerosis, endothelial dysfunction might also be involved
in the ongoing tissue growth after angioplasty procedures
(8,18). The aim of our study, therefore, was to investigate
endothelial function after stenting and compare this with
PTCA alone by assessing both morphologic and functional
parameters.
The main finding in our study is that both PTCA and stent
implantation result in an impairment of the vascular barrier
function at least up to 3 months after the procedure as
evidenced by the uptake of the EB dye. This loss of barrier
function is more pronounced after stenting than after PTCA,
and showed a stent-specific pattern. This breach was charac-
terized by specific endothelial morphologic correlates: in the
early phase by incomplete endothelialization and endothelial
retraction or loose intercellular connections. The late phase
was characterized by the expression of surface folds and the
adhesion of leukocytes. Both phenomena were also observed
in stented human vein grafts (19).
Transport routes across the endothelial lining. The extrav-
asation of (macro)molecules, such as EB bound to albumin,
proceeds mainly by two routes. One is through diffusion via the
cellular junctions, i.e., paracellular exchange (20,21), and the
other is by vesicle-mediated transport, i.e., transcellular trans-
port (22).
Paracellular exchange is morphologically associated with
small interendothelial gaps caused by contractile forces in the
cell and by disintegration of cell–cell junctions (23,24). This
process is regulated by actin fibers, which are connected to
other proteins anchoring the cells to their neighbors and to the
extracellular matrix (25,26). Vasoactive agents and thrombin
can affect the integrity of the endothelium through phosphor-
ylation of specific target proteins. As a consequence, actin
reorganization may occur through RhoA– and protein kinase
C–activated pathways. The interaction between actin and
nonmuscle myosin, activated by phosphorylation of the myosin
light chain, subsequently causes contraction and gap formation
(24,27). Interaction of leukocytes with the endothelium, which
is enhanced by inflammatory mediators, can enhance this
response (28). In addition to the effects of vasoactive agents,
paracellular permeability can also be enhanced by the lingering
proliferative response of the endothelium itself. Cell retraction
associated with cell mitosis causes paracellular gaps in arterial
endothelial cells in vivo (29). Because cell division is found
until at least 3 months after intervention, particularly in areas
overlying stent struts, it may contribute to the observed leakage
of EB-albumin complex. Both endothelial barrier function and
proliferation are under control of the extracellular matrix.
Remodeling of the extracellular matrix by proteases can re-
Table 3. Morphometry
Group
NI
Media
Stent or PTCA Lesion
Underneath PTCA Lesion
or Stent Struts
Between Stent Struts or
PTCA Lesion/Nonlesion
1 (stent) 259 104*3a,3b,4b 99  22 187  28*3a,3b,4a
2 (stent) 192.1 63.3*3b,4b 109.8  21.6 184.3  16.3*3a,3b,4b
3A (stent) 114  60 71  40 122  26
3B (PTCA) 33  11 221  77*1,2,3a,4a 119  15
4A (stent) 305  155*3a,3b,4b 73  29 182  29*3a,3b,4b
4B (PTCA) 19  12 181  53*1,3a,4a 128  33
*p  0.05 vs group . . ., ANOVA-Tukey test. Data are in m and given as mean  SD. The NI was measured on top
of the stent struts and compared with the NI in the PTCA lesion. Media thickness was measured underneath and between
the stent struts and compared with the media thickness in the PTCA lesion and nonlesion area.
Table 4. Assessment of Cell Proliferation (% BrdU-Positive Cells)
Group (n) EC NI M ADV
Control (n  6) 0.4  0.1 Nonexistent 0.9  0.1 1.07  0.1
3A (n  6) 22.2 7.5* 18.8  2.7* 6.5 1.2* 7.9  2.1*
3B: lesion area (n  5) 5  3.8 6.14  8.2 2.66 2.62 3.98  4.41
3B: non-lesion area (n  6) 2.64  2.65 Nonexistent 0.86  0.43 0.98  0.78
4A (n  5) 3.5 1.1 2.7  1.1 1.6 1 2.3  1.1
4B: lesion area (n  4) 1.3  1.5 1.2  0.91 1.5 0.67 0.75  0.76
4B: non-lesion area (n  5) 0.3  0.6 Nonexistent 0.99  0.91 0.64  0.54
EC endothelial cells; Mmedia; ADV adventitia. *p 0.05 vs. all groups, ANOVA-student neuman keuls test.
Data are mean  SEM.
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duce the firm interaction between cell and matrix. This reduc-
tion may enhance the efficacy of endothelial permeability-
increasing agents (25,30).
Transcellular (vesicle-mediated) transport is the second
major route for macromolecular exchange across the endothe-
lial lining. Both paracellular and transcellular exchange of
albumin are increased by VEGF (31), a growth factor that is
induced in injured arteries (32,33). Further studies have to
elucidate whether and for how long VEGF is induced in
stented coronary arteries.
In vivo (34,23) and in vitro studies (35,36) have shown that
an increase in endothelial permeability in the microcirculation
can be reversed by exposing the endothelium to cAMP-
elevating agents. In preliminary experiments we found that
intracoronary administration of 1 mM dibutyryl-cAMP within
10 min indeed partly normalizes the barrier function in areas of
increased permeability covering and adjacent to the implanted
stents (Fig. 5). The areas that were permeable because of
missing endothelial cells were not affected by this treatment. A
reduced cellular cAMP concentration/content has been re-
ported in arterial cells in intimal tissue affected by atheroscle-
rosis (37). However, it remains to be established whether this
also occurs in the new layer of endothelial cells in stented
arteries. The reduction in endothelial permeability by eleva-
tion of cellular cAMP levels indicates that a major part of the
leakage of EB-albumin occurs via impaired junctional com-
plexes between endothelial cells. However, the current state of
knowledge does not permit exclusion of a minor contribution
by vesicular transport.
Permeability after PTCA takes place preferentially in the
area designated as the lesion area containing intimal hyperpla-
sia. Clearly these are areas where the endothelium is attached
to a changed basement membrane or extracellular matrix. In
the stented segments, the intima covering the stent struts is
also constantly changing during the process of scar maturation,
which might explain permeability over the stent struts in
general but not the differences between stent designs. Whereas
the Wiktor stent shows preferential dye-uptake over all of the
stent wires throughout the whole stent, the Palmaz-Schatz
stent shows dye-uptake preferentially over the stent struts at
both stent extremities and over the area of the coupler. It
would seem that these specific patterns of dye-uptake are a
reflection of the design of the stent. The Wiktor stent has a
more open design than the Palmaz-Schatz stent, and as
permeability seems to occur in areas where theoretically
movement between the tissue and the stent struts may occur,
Figure 4. LM. A, Group 3B. At 2 weeks after PTCA, focal lesions can
be found with BrdU incorporation (arrow), especially underneath the
endothelial lining but also elsewhere in the intima (i) and media (m).
HRP-DAB with hematoxylin counterstain. Bar 50 m. B,Group 4B.
At 12 weeks after PTCA, there is still a limited NI, sometimes with an
additional elastic membrane underneath the endothelium (arrow).
Resorcin-Fuchsin, i  intima, m  media. Bar  50 m.
Figure 5. Macroscopy c-AMP–treated arteries. Macroscopy of the
coronary arteries at 2 weeks after implantation of a Wiktor stent.
While a “control” artery (A) was not exposed to db-c-AMP, but only to
EB, the c-AMP-treated artery was first exposed to 1 mM db-c-AMP
and then to EB with a molecular weight of 1 kD (B), showing an
improvement especially in the areas between the stent struts.
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this may be a factor influencing the chronic vascular irritation
by the stents. From the literature it is known that mechanical
instability of healing bone fractures, for instance, affects the
composition of the extracellular matrix with respect to the level
of sulfate incorporation in the glycosaminoglycans (38). If
these processes also take place in the vessel wall it would
certainly influence endothelial function and permeability.
Conclusions. This study indicates that especially stenting
decreases long-term vascular integrity with respect to perme-
ability. Leakage is observed with molecules such as EB and
EB-albumin complex, and is associated with prolonged endo-
thelial proliferation and distinct morphologic characteristics
such as endothelial retraction, the expression of surface folds,
and the adhesion of leukocytes.
The authors wish to thank Robert H. van Bremen for his technical assistance and
Johnson & Johnson Interventional and Medtronic Inc. for supplying the stents.
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Abstract
Purpose
Mechanical injury from balloon angioplasty and stenting is known to cause prolonged 
endothelial dysfunction, even distal to the injured segment. Intravascular irradiation 
therapy is associated with delayed healing response and may therefore also impede 
endothelial functional recovery. This study was conducted to assess endothelial function 
late after irradiation of atherosclerotic coronary arteries. 
Methods and Materials 
In 15 patients (8 with additional radiation and 7 patients with stenting only) directly after the 
intervention and at 6 months follow-up, endothelial function of the distal segment was 
studied by assessment of coronary diameter after  intracoronary acetylcholine. Coronary 
flow reserve and intravascular ultrasound investigation was performed for unequivocal 
interpretation of angiographic data. 
Results
No significant different response to acetylcholine could be detected at baseline nor at 
follow-up (-17 ± 14 % vs. - 17 ± 15 % for radiation vs. non-radiation at baseline, p = 1.0; - 8 
± 11 % vs.  - 9 ± 13 % at follow-up, p = 0.8). IVUS data revealed more constrictive 
remodeling in the non-radiation patients, but minimal increase in mean plaque area in the 
radiation patients compared to significant decrease in non-radiation patients ( + 4 % vs. – 
25 %, p = 0.02). 
Conclusions
Irradiation of atherosclerotic coronary arteries doesn’t affect endothelium-dependent 
vasodilatation acutely or at 6 months. Irradiated segments demonstrated less negative 
remodeling  but higher plaque burden than controls. 
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Introduction
Vascular endothelium plays a crucial role in normal vasomotor function (1). Next to this, it 
is of  importance in anti-thrombogenicity of the blood vessel wall as healthy endothelium 
produces for example nitric oxide and prostacyclin with anti-platelet aggregation activity, as 
well as pro- and anti-fibrinolytic factors (2). 
Mechanical injury by balloon angioplasty but especially stenting has been shown to cause 
prolonged injury and endothelial dysfunction up to 6 months after the procedure (3-7). Also 
intracoronary irradiation to treat or prevent in-stent restenosis has been associated with a 
delayed healing response of the vessel wall after the intervention (8, 9).   
As late effectiveness of intracoronary radiation is hampered by the high occurrence of late 
thrombotic occlusions and excess of adverse events (10-12), it is hypothesized that the 
trauma of stenting with additional irradiation therapy may cause severe long-lasting 
endothelial dysfunction. This may be caused by the chronic trauma combined with 
radiation-dependent delayed healing and re-endothelialization. 
The purpose of this study was to assess whether coronary irradiation alone, could be 
responsible for endothelial dysfunction, leading to late sequelae of therapy. Endothelial 
function was studied distal to the implanted stent in patients who received stenting with 
additional intracoronary irradiation therapy, compared to patients who received a stent 
without additional irradiation therapy. Studies were performed directly after the procedure 
and at 6 months follow-up. 
Methods
Patient selection 
23 patients were prospectively included in the study, of which 16 patients were randomized 
to stenting followed by intracoronary irradiation or stenting alone in de-novo lesions in the 
BRIDGE trial. BRIDGE (Beta-Radiation Investigation with Direct stenting and Galileo in 
Europe) is a randomized multi-center study, evaluating the effect of additional beta-
irradiation with a P-32 source after successful stenting of a de-novo coronary lesion, less 
than15 mm in length (13). Two patients received irradiation therapy without stenting for in-
stent restenosis and 5 patients received stents without irradiation for de-novo lesions 
outside the BRIDGE protocol. Of the 23 patients initially included, 3 patients refused 
follow-up studies, 4 patients were excluded at follow-up because of in-stent restenosis and 
1 patient received follow-up angiography in another center, without study protocol. 
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In total 15 patients could be included in the analysis, with both angiographic studies at 
baseline as well as at 6 months follow-up: 8 patients receiving a stent or balloon 
angioplasty with additional irradiation and 7 patients receiving a stent only.  
The study was approved by the Medical Ethics Committee of the Erasmus Medical Center 
and written informed consent was obtained from all patients. 
Procedure
Direct stenting was performed in all patients, except for 2 patients who were treated with 
balloon angioplasty to treat in-stent restenosis. After the procedure was completed, 
patients received additional irradiation therapy as part of the BRIDGE protocol (n=6) or 
were treated with compassionate use irradiation therapy (n=2) or no additional therapy 
(n=7). Then endothelial function testing of the coronary segment distal to the stent was 
performed, followed by measurement of coronary flow reserve (CFR). Finally intravascular 
ultrasound (IVUS) evaluation was performed.  
All patients received dual platelet therapy consisting of acetylsalicylic acid 80 mg once 
daily and clopidogrel 75 mg once daily for the duration of the follow-up. 
Angiography was repeated followed by endothelial function testing, CFR and IVUS at 6 
months follow-up study. 
Radiation specification 
 Beta-irradiation to the treated segment of the coronary artery was delivered by the 
GalileoTM Intravascular Radiotherapy System (ACS/Guidant, Houston, TX, USA).  This 
system comprises a 32P 0.018” source wire, a centering catheter and the GALILEO TM 
Source Delivery Unit. The Source Delivery Unit is a high dose rate afterloader, designed 
specifically for coronary radiotherapy. The  centering balloon catheter is 32 mm long and 
the source wire was automatically advanced first to the distal position and then more 
proximal, radiating a total length of 40 mm. Radiopaque markers (proximal and distal to the 
balloon) allowed for precise positioning of the centering catheter at the lesion site.  In total, 
20 Gy was delivered at 1 mm depth in the vessel wall and dwell time to do so was 
automatically computed based on the average Reference Lumen Diameter. Full dose 
radiation was received by a segment length of 32 mm; with a total radiation length of 40 
mm. Fall-off dose was received by 4 mm of vessel length at both sides. 
In the BRIDGE protocol, 18 mm stents were used, which means that approximately 11 mm 
of vessel segment on both sides of the stent received radiation, of which 7 mm on both 
sides received full dose (figure 1). In this way geographical miss (when the length of the 
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stent and the peri-stent segments are not covered by radiation therapy) (14) could be 
avoided.
Evaluation of endothelial function 
Long-acting vasoactive drugs had been stopped for > 24 hours. However, restrictive use of 
intracoronary nitrates was allowed during the procedure. 
Endothelium-dependent and independent coronary vasomotion was studied as described 
in detail by Ludmer (15).  The segment distal to the stent receiving radiation was studied.  
A selective intracoronary infusion catheter (Multi-functional Probing Catheter, Boston 
Scientific, Galway, Ireland) was advanced over the guidewire and positioned in the stented 
segment. To avoid wire-induced coronary spasm, the wire was retracted within the 
catheter. The region of interest was the first 11 mm distal to the stented segment and care 
was taken to select an angiographic view without fore-shortening of this segment. To 
determine baseline angiographic diameter, an initial infusion of vehicle solution, normal 
(0.9%) saline, was administered at an infusion rate of 2 ml/min for 2.5 minutes, followed by 
angiography. Endothelium-dependent vasomotion was studied by infusion of incremental 
doses of acetylcholine (Ach), 10 –8, 10 –7 and 10 –6 Molar, 2.5 minutes at each 
concentration followed by angiography. Subsequently, endothelium-independent 
vasomotion was studied after an intracoronary administration of Isosorbidedinitrate (ISDN) 
(2-3 mg). Throughout each infusion heart rate, systemic arterial blood pressure and 
electrocardiogram were monitored continuously. 
Quantitative Coronary Angiography  
Off-line quantitative analysis of the effect of Ach on coronary diameter was performed as 
described previously with a validated computer-based edge detection system ( CAAS II, 
Pie Medical Imaging, Maastricht, NL) (16).Angiograms were performed in a way to ensure 
minimal fore-shortening of the coronary segment distal to the stent. During analysis, the 
distal end of the stent was marked. The coronary segment distal to the stent was analyzed, 
beginning at two mm from the stent edge, to minimize effects of restrictive movement of 
the vessel wall due to constraints of the scaffolding stent. The next 9 mm was analyzed. 
With a zone of 5 mm of full-dose radiation distal of the stent and a 4 mm zone of fall-off 
radiation dose, this covered the total radiated area distal to the stent. (see figure 1). 
Coronary Flow Reserve 
CFR measurement was performed to evaluate microvascular resistance in both groups 
(17). In short, a 0.014-inch Doppler tipped guidewire (FloWire, Volcano Therapeutics Inc., 
Rancho Cordova, CA, USA) was positioned in the coronary artery, just distal to the 
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implanted stent. After baseline flow velocity measurement, adenosine was administered in 
a dose of 140 mcg/kg/min by i.v. infusion for 2 minutes for assessment of hyperemic flow 
velocity and CFR. Measurements were done in duplicate. 
Intravascular Ultrasound 
As structural changes, like unhealed dissections, may influence the ability to vasodilate, 
IVUS study was performed in all patients following endothelial function testing and after 
CFR measurements. 
IVUS was performed according to standard techniques, using a 30Mhz, 2.9 F mechanical 
ultrasound catheter (UltraCross, Boston Scientific Scimed Inc, Fremont, CA,USA) using 
automated pullback at 0.5 mm/sec. Images were analyzed off-line from recorded video-
tape by two blinded observers (JL, JA). 
Statistical Analysis 
Data are presented as mean ± SD. Unpaired student-t tests were used to compare 
diameter changes between groups and paired student-t tests within groups and between 
baseline and follow-up. For non-continuous variables Pearson Chi-Square test was used. 
ANOVA analysis of variance with correction for difference in baseline values was used for 
the change in IVUS measured mean plaque area between irradiated patients and non-
irradiated patients.  A value of P < 0.05 (two-tailed) was considered to indicate statistical 
significance. (SPSS; release 11.0.1). 
Results
Patient characteristics were very similar between the groups, but only the irradiated group 
contained also female patients (table 1). 
Endothelial function 
At baseline, vasoconstrictive reaction to maximal dose of acetylcholine of 10-6 Molar was 
observed (-17 ± 14 % vs.  -17 ± 15 % respectively, p = 0.98), in both irradiated and non-
irradiated groups (table 2). 
A trend to less vasoconstriction to Ach can be seen in both groups at FU (-8 ± 11 % for 
irradiated patients; p = 0.06 vs. baseline, and -9 ± 13 % for non-irradiated patients; p = 
0.15 vs. baseline; p = 0.84, and p = 0.88 for the difference in percentage change between 
groups).
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CFR
Coronary flow reserve (CFR) did not differ between groups and between baseline and 
follow-up: (2.9 ± 0.6 vs. 3.0 ± 0.9 for irradiated and non-irradiated groups at baseline, and 
3.1 ± 1.2 vs. 3.0 ± 0.9 at follow-up).
IVUS
IVUS investigation discovered two short distal stent edge dissections (max 2 mm in length, 
< 20 degrees circumference) directly after the procedure in the group without additional 
irradiation. Both were resolved at follow-up studies. 
Quantitative IVUS data could be obtained from 7 patients with additional irradiation and 5 
patients without irradiation (table 3). The 2 mm immediately distal to the stent was 
excluded from analysis. The segment studied had a mean segment length in the irradiation 
group of 9.1 ± 1.8 mm and 9.2 ± 1.7 mm at baseline and follow-up respectively, and in the 
non-irradiation group of 9.6 ± 1.6 mm at baseline and 9.6 ± 1.5 mm at follow-up. 
At follow-up a non-significant, less reduced vessel area was seen in the irradiated group 
than in the non-irradiated group (-6 % vs. -15 %, p = 0.6) (fig. 2). Despite this a larger 
luminal area reduction was measured in the irradiation group (-14 % vs. -7 %, p = 0.6), due 
to minimal increase in plaque area in the irradiation group as opposed to a large decrease 
in the non-irradiation group ( + 4 % vs. – 25 %, p = 0.02).  
Discussion
The present study compared the vasodilatory response to the endothelium-dependent 
vasodilator acetylcholine of atherosclerotic coronary segments, receiving irradiation or no 
irradiation.
The main result of the study is that endothelial dysfunction at 6 months did not differ after 
intracoronary irradiation compared to no radiation. However, the change in plaque area 
over time was significant between groups (p = 0.02), with minimal increase in plaque area 
in the irradiated segments and a decrease in non-irradiated segments. 
Radiation and endothelial function 
Intracoronary radiation therapy is an effective treatment of in-stent restenosis. Radiation 
blocks cell proliferation, induces apoptosis and inhibits cell migration, resulting in reduction 
of neointimal accumulation. Radiation also prevents constrictive remodeling after balloon 
angioplasty, probably mediated by reduction of healing response together with radiation 
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induced fibrosis (18). Despite favorable mid-term results and acceptable long-term results 
(19, 20), late thrombotic occlusions, edge restenosis and delayed in-stent restenosis have 
severely mitigated the enthusiasm for intracoronary radiation therapy. At 4 years follow-up 
MACE of up to 60 % has been reported in unselected patients (10). An unusual high 
percentage up to 9 % of late thrombotic events was seen, from 2 to 15 months after the 
intervention (11, 12). Without radiation, thrombotic events are extremely infrequent beyond 
2 weeks after the intervention.  
Late thrombosis and neointimal proliferation have been related to delayed healing 
response and incomplete endothelialization after radiation therapy. Farb et al. 
demonstrated delayed healing of the intimal surface after implantation of radioactive stents 
in normal rabbit iliac arteries, with incomplete endothelialization up to 12 months after 
stenting (8). Cheneau et al. showed only 40 % endothelial cell coverage of  rabbit iliac 
arteries 6 months after stenting and gamma-irradiation. No increase in endothelial 
coverage was seen between 1 and 6 months, while control stented segments were almost 
fully covered with endothelial cells after 1 month (9). Incomplete endothelialization 
associated with increased recruitment of platelets 1 month after balloon angioplasty and 
beta-radiation of pig coronary arteries was shown by Salame et al. while complete 
endothelial coverage without increase in platelet recruitment was present in the non-
radiated ballooned arteries (21). 
Recovery of endothelial function after radiation therapy has been studied by Menendez et 
al. showing impaired endothelium-dependent and independent vasomotion response of the 
abdominal aorta of rats, 6 months after external beam radiation therapy. Vascular sclerosis 
with medial fibrosis was present, typical for radiation vasculopathy and the possible 
explanation for the impaired non-endothelium-dependent vasomotion (18). Impaired 
endothelium-dependent vasomotion response in humans has also been reported, several 
weeks after external beam radiation of cervical arteries (22) and in axillary arteries, more 
than 3 years after external beam radiation for breast carcinoma (23).  
Data on endothelial functional recovery after intracoronary radiation is, however,  
equivocal. Li et al. reported impaired endothelium-dependent vascular response of normal 
non-injured porcine coronary arteries, 1 month after 20 Gy 32P beta radiation, using the 
same delivery device as in our study (24).  Surprisingly, Sabate et al. reported restored 
endothelium-dependent vasomotion 6 months after balloon angioplasty and additional 
beta-radiation with a 90Sr/90Y source delivering 12 to 16 Gy at 2 mm from the source (25). 
The present study was conducted to study the endothelium-dependent vasomotion 
response after irradiation of non-injured atherosclerotic coronary arteries.  
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At the index procedure, moderate vasoconstriction could be seen in both groups, with or 
without additional irradiation. As radiation was only administered a few minutes before 
vasomotion studies, no acute effect of radiation was expected and vasoconstriction in both 
groups was indeed comparable. At 6 months follow-up, persistent but less vasoconstrictive 
reaction was present in both groups. No significant indication was seen of worse 
endothelium-dependent vasomotion in the irradiated group.  In our study the segment was 
distal of the interventional trauma, but long-term endothelial dysfunction of this segment 
distal to the stent was already shown by Caramori et al.(6). This lack of late effects of 
irradiation is in agreement with the above mentioned study by Sabate et al., though they 
reported even complete restoration of endothelial function with a vasodilatation reaction to 
Ach. Sabate et al. however, investigated vasomotion of the treated segment itself and only 
at 6 months follow-up, not excluding possible differences in vasomotion at the index 
procedure. In the present study baseline data is available, showing comparable 
vasoconstriction in both groups directly after the procedure, suggesting no substantial 
difference in endothelial dysfunction in these distal coronary segments without 
angiographic disease. Moreover, CFR was comparable in both groups excluding major 
differences in microvascular disease. 
IVUS and radiation 
Complete IVUS studies were possible in most patients and analysis showed less decrease 
in vessel area over 6 months in the irradiated patient group. Despite the larger loss in 
vessel area in the non-irradiated patient group, loss of mean lumen area was less because 
of a significant reduction in plaque area. This was not seen in the irradiated group. Despite 
this reduction in plaque area distal to the 6 months earlier treated lesion, endothelial 
function did not improve compared to the irradiated patient group. It may be hypothesized 
that in the irradiated patients endothelial function did not improve, but rather that reduced 
vasoconstrictive remodeling with vessel wall sclerosis limits constrictive vasomotion after 
acetylcholine stimulation.  
Study limitations  
This study included only a limited number of patients. Because intracoronary irradiation 
therapy was substituted by the use of drug-eluting stents in our center, no additional 
irradiation patients could be included after the completion of inclusion of patients for the 
BRIDGE trial.  However, based on the current results and earlier studies by Sabate et al., it 
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is very unlikely that we would have found an opposite outcome by increasing the number 
of patients. 
Conclusions
6 Months after irradiation of atherosclerotic coronary arteries with 20 Gy, no evidence 
could be found of worse endothelial function compared to patients without additional 
irradiation therapy.  
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Table 1. Patient baseline characteristics 
  Irradiation 
(N=8) 
Bare stent 
(N = 7) 
p- value 
Age in years (SD)  66 (12) 65 (11) 0.93 
Male Sex  5 (63%) 7 (100%) 0.07 
Coronary Risk Factors Smoking 1 (13%) 1 (14%) 0.92 
 Diabetes 1 (13%) 1 (13%) 0.92 
 Hypertension 1 (13%) 2 (29%) 0.44 
 Hypercholesterol
emia
3 (38%) 3 (43%) 0.83 
 Family History 5 (63%) 3 (43%) 0.45 
Prior Myocardial 
Infarction 
 2 (25%) 1 (14%) 0.61 
No. Diseased 
Coronary Vessels 
One 4 (50%) 4 (57%) 0.78 
 Two 4 (50%) 3 (43%) 0.78 
Statin use 5 (63%) 4 (57%) 0.83 
ACE inhibitor use 1 (13%) 1 (14%) 0.92 
Mean diameter of 
analyzed coronary 
segment  in mm (SD) 
At index 
procedure  
2.5 (0.6) 2.5 (0.4) 0.99 
 At follow-up  2.3 (0.5) 2.4 (0.3) 0.80 
Data are presented as number of patients (%). 
SD = Standard deviation 
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Table 2. 
Mean percentage coronary segment diameter change from baseline (± SD) after maximal  
Ach dose (10 –6 molar) and endothelium independent vasomotion (intracoronary nitrates), 
at index procedure and 6 months follow-up. 
 irradiation 
N = 8 
no irradiation 
N = 7 
p- value 
Index procedure Ach - 17 ± 14 % -17 ± 15 % 0.98 
 nitrates 0 ± 12 % -4 ± 7 % 0.35 
Follow-up Ach -8 ± 11 % -9 ± 13 % 0.84 
 nitrates 1 ± 11 % 2 ± 8 % 0.86 
Ach: acetylcholine 
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Figure 1. 
A schematic diagram, depicting the stent and the different zones. A: Transitional zone:
diameter change is believed to be (restrictively) influenced by stent margin. B: Full dose 
zone: In radiation group full dose irradiation is received, without mechanical balloon 
damage. C: Fall-off dose zone: In radiation group progressive fall-off of irradiation dose to 
distal, without mechanical balloon damage. The segment used in the current analysis is 
depicted as the 9 mm region of interest, distal to the stent. 
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    Hier figuur 2 van pdf invoegen 
Figure 2. (Figure in separate PDF file) 
Quantitative IVUS measurements in patients with additional radiation therapy(R) and 
without additional radiation(NR). Black bars represent data at index procedure, grey bars 
data from 6 months follow-up studies. 
Numbers represent mean cross-sectional area of the investigated coronary segment in 
mm2.
* p = 0.02 for difference in Mean Plaque Area change between groups. 
MLA: mean lumen area; MPA: mean plaque area; MVA: mean vessel area. 
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Abstract:
Aim 
Endothelial dysfunction has been related both to progression of atherosclerotic disease 
and to future cardiovascular events. No study has addressed the potential impact of drug-
eluting-stent implantation on endothelial function. We assessed local epicardial endothelial 
function 6 months after sirolimus-eluting stent (SES) or bare metal stent (BS) implantation.  
Methods and Results  
In 12 patients (7 SES, 5 BS) endothelium-dependent vasomotion of a coronary segment 
15 mm in length, starting 2 mm distal to the stent, was assessed, with quantitative 
coronary angiography immediately after the procedure and at 6 months follow-up, after 
intracoronary infusion of acetylcholine. Intravascular ultrasound was performed and 
coronary flow reserve (CFR) assessed in all patients. At follow-up significant 
vasoconstriction was seen in SES (32% diameter reduction from baseline) but not in BS 
(no change) patients after acetylcholine infusion (p=0.03 for SES vs. BS); endothelium-
independent vasodilatation to nitrates did not differ significantly between groups (15% 
SES, 7% BS, p=0.14). IVUS revealed no late unhealed dissections and CFR was 
comparable between groups (SES 3.2 ± 0.6, BS 3.2 ± 0.5, n.s.).    
Conclusion
SES implantation may have an adverse effect on local endothelium-dependent vasomotor 
responses compared to BS implantation at six months. Long-term clinical consequences of 
this observation are yet unknown.  
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Introduction
Sirolimus-eluting stent (SES) implantation significantly reduces restenosis compared to 
bare stents (BS) (1,2). Inhibition of restenosis by sirolimus is related to cell-cycle arrest in 
the late G1-phase. This salutary effect on restenosis may be accompanied by delayed 
healing of the traumatized vessel wall (3). Long-term endothelial dysfunction after bare 
stents has been reported in porcine and human coronary arteries (4,5). No data exists on 
endothelial function after implantation of SES. We assessed endothelial-dependent and -
independent vasomotion after stenting and at 6 months after SES or BS implantation.  
Methods
Patient selection 
We prospectively studied 15 patients, 9 with a SES (Cypher, Cordis Co, Warren, NJ, USA) 
and 6 BS (DepoStent, Conor Medsystems, Inc., Menlo Park, CA, USA) patients.  
Stents were implanted for single de novo lesions. In the Thoraxcenter, the SES was the 
default stent at the time of the study. Six patients receiving a DepoStent with comparable 
lesion characteristics and vessel size were included in this study.  This stent was the only 
bare metal stent implanted at the Thoraxcenter during the study period. Except for a 
different stent design, both stents are made of 316L stainless steel and stent strut 
thickness is identical (140 µm) (6). Allocation of patients to either group was dependent on 
availability of stents and patient informed consent. 
One of the 9 SES patients refused follow-up. One additional patient in each group was 
excluded because of in-stent restenosis. Thus 7 SES and 5 BS patients were analyzed. 
Mean duration until follow-up studies was very similar (188 ± 4 days for BS and 191 ± 8 
days for SES group, n.s.). The Erasmus MC Ethics Committee approved the protocol and 
written informed consent was obtained from all patients. 
Evaluation of endothelial function 
Studies were performed directly after completion of the interventional procedure and at 
scheduled six-month angiography. Long-acting vasoactive drugs were stopped for at least 
24 hours before angiography. Endothelium-dependent and independent coronary 
vasomotion was studied using standard protocols (7). The intracoronary stent scaffolds the 
arterial wall and virtually abolishes vasomotion. For this reason, we analyzed the 17 mm 
segment immediately distal to the stent, excluding the first 2 mm. A selective intracoronary 
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infusion catheter (Multi-functional Probing Catheter, Boston Scientific, Galway, Ireland) 
was advanced over the guide wire and positioned in the stent. To avoid wire-induced 
coronary spasm, the guide wire was subsequently withdrawn into the catheter. As 
baseline, an infusion of vehicle solution, normal (0.9%) saline, was performed for 2.5 
minutes at an infusion rate of 2 ml/min, followed by baseline angiography. Thereafter, 
endothelium-dependent vasomotion was studied by infusion of incremental doses of 
acetylcholine (Ach), 10 –8, 10 -7 and 10 –6 Molar, for 2.5 minutes at each concentration. 
Subsequently, endothelium-independent vasomotion was assessed after an intracoronary 
bolus of nitrates (2-3 mg).  
Quantitative Coronary Angiography 
Off-line quantitative analysis of coronary angiography was performed with the CAAS II  
system (Pie Medical Imaging, Maastricht, NL), blinded to knowledge of stent type.  
Endothelial dysfunction was defined as abnormal vasoconstriction of ≥ 3% mean vessel 
diameter change from baseline (saline infusion), beyond the variability of the method of 
analysis, of the segment studied after the maximal dose of Ach (10 –6 Molar). 
Coronary Flow Reserve 
CFR measurement was performed to exclude differences in microvascular coronary 
resistance between groups. This was performed after completion of endothelial function 
testing. A 0.014-inch Doppler tipped guidewire (FloWire, Volcano Therapeutics Inc., 
Rancho Cordova, CA, USA) was positioned in the coronary artery just distal to the 
implanted stent. After baseline flow velocity measurement, adenosine (140 mcg/kg/min for 
2 minutes through the femoral vein) was administered for assessment of hyperemic flow 
velocity and CFR. Measurements were done in duplicate. 
Intravascular Ultrasound 
IVUS was performed in all patients at the end of the study protocol, as unhealed 
dissections may influence late recovery of endothelial function. IVUS was performed 
according to standard techniques, using a 30 MHz, 2.9 F mechanical ultrasound catheter 
(UltraCross, Boston Scientific Scimed Inc, Fremont, CA, USA). 
Statistics
Data are presented as mean ± SD and as median and range as appropriate. For 
continuous variables of baseline characteristics Student-t test was used, for categorical 
data the Fisher’s exact-test. Mann Whitney U test were performed to analyse diameter 
               endothelial function after SES 
91
changes between groups. A value of P < 0.05 (two-tailed) was considered to indicate 
statistical significance. 
Results
SES patients were younger and more often female whereas hypercholesterolemia and a 
family history of coronary artery disease were more common in the BS group (Table 1).  
Mean coronary diameters at follow-up were similar between SES and BS (2.0±0.2 mm vs. 
2.2± 0.4 mm).
Table 2 shows results of maximal dose of Acetylcholine of 10-6 Molar at follow-up. In the 
SES group, a 32±23 % reduction in mean coronary diameter compared to baseline was 
observed, after infusion of Ach 10 –6 Molar, whereas there was no significant change in the 
BS group (0±7%), (p=0.03 SES vs. BS, Figure 1; Table 2). Endothelium-independent 
dilatation to nitrates did not differ significantly between groups (Table 2).  
Figure 2 highlights the vasomotion reaction of the coronary segment to incremental doses 
of acetylcholine and nitrates in both groups. 
Endothelial function studies were also performed directly after implantation to exclude 
major differences between groups at baseline. Constrictive response was seen in both 
groups ( -20 ± 14 % vs. -11 ± 10 % for SES and BS groups respectively; p=0.25). 
However, absolute values are not comparable between index procedure and follow-up, 
because all patients in both groups did receive intracoronary nitrates during the 
interventional procedure, i.e. before endothelial function study.  
CFR at follow-up did not differ significantly between groups (SES 3.2 ± 0.6 vs. BS 3.2 ± 
0.5, n.s.). Absolute flow increased from 16 ± 7 cm/sec for SES and 16 ± 4 cm/sec for BS to 
52 ± 26 cm/sec and 51 ± 15 cm/sec for SES and BS respectively.  CFR at baseline is not 
included in the data as CFR immediately after the intervention can greatly be influenced by 
the procedure itself, which was not the purpose of the measurements in this study. 
On IVUS no stent-edge dissections were seen in either group.   
Discussion
Drug eluting stents have shown a large reduction of restenosis compared to bare metal 
stents (1,2). However, their mechanism of action may have unwanted effects on vessel 
healing after stent implantation (3,8). The major finding of the present study was that SES 
implantation suggests an adverse effect on local endothelium-dependent vasomotor 
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responses six months after SES compared to BS implantation distal to the interventional 
segment.
Possible mechanisms for endothelial dysfunction after SES implantation 
Direct drug effect? 
Sirolimus (rapamycin) is a potent immunosuppressive agent, which has anti-proliferative 
capacity through cell-cycle arrest in the late G1-phase. It has been shown to be effective in 
inhibiting in-stent neointimal hyperplasia. The amount of drug on the stent is extremely 
small (< 3%) compared to the doses employed systemically in kidney transplant patients to 
treat rejection. Around 80% of the drug is released within 30 days of implantation. It is, 
therefore, unlikely that the drug can affect vasomotion in the distal segment by diffusion 
from the blood stream late after implantation. However, it cannot be excluded that the drug 
can reach the vessel wall directly distal to a drug-eluting stent, for example by diffusion 
through the tissue and through the vasa vasorum. As recently shown, the vasa vasorum 
interna in porcine coronary arteries originating directly from the lumen of the artery can 
extend over several centimeters along the coronary artery wall (9). Clinical data support 
the hypothesis of drug elution distal to the stent. In recent trials SES stent implantation 
resulted in higher restenosis rates at the proximal edge of the stent compared to the distal 
edge (2).
Data on the effects of sirolimus on vasomotion is limited and not conclusive. Early reports 
showed vasodilatory effects of sirolimus after acute exposure to high doses in isolated rat 
aortic rings (10). More recent data showed severe impairment of endothelial function in the 
coronary segments of swine in vitro, after incubation for 48 hours with sirolimus (11). Guba 
et al. reported anti-angiogenic activities of sirolimus, linked to a decrease in production of 
vascular endothelial growth factor (VEGF) and to a marked inhibition of the response of 
vascular endothelial cells to stimulation by VEGF (12). The authors suggested that this 
might reduce the chance of recurrent or de novo cancer in organ transplant patients. 
However, this might also delay endothelial recovery after vascular injury. 
The effects of sirolimus on vasomotion can hypothetically be caused by a direct effect on 
the endothelium, on the signaling pathway of the endothelium to the medial smooth muscle 
cells or a direct effect on the media.  The data of Guba et al. suggest a direct effect on the 
endothelium and/or the signaling pathway.  A preserved medial vasomotion is also 
suggested by the preserved vasodilatation after intracoronary nitrates in the current study.  
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General effect caused by delayed healing response? 
A delayed healing response associated with prolonged endothelial dysfunction is shown 
after stenting versus balloon angioplasty in porcine coronary arteries (4). Caramori et al. 
demonstrated persistent vasomotor dysfunction distal to coronary stents impanted 6 
months earlier (5). 
The anti-proliferative activity of sirolimus may merely cause a prolonged healing response 
with concomitant delayed recovery of endothelial function. In this respect it would be very 
interesting to repeat the vasomotion studies at later timepoints to evaluate the timeframe of 
endothelial functional recovery, if present. In future studies this should be incorporated in 
the protocol as this may have implications for the duration of anti-platelet regime and other 
possible interventions to improve endothelial function such as ACE-inhibitors and high 
dose cholesterol lowering medication. 
Procedural differences between groups? 
In both groups direct stenting was performed in all but one patient. Predilatation was done 
with a balloon 1 mm smaller in diameter than the subsequently implanted stent and 
balloons were shorter than the stent. No bare stents were postdilated, while 3 out of 7 SES 
were postdilated. As clearly visible in figure 1, in all but one SES patient, vasoconstrictive 
response to Ach was seen. The one patient not showing significant constriction was 
treated with direct stenting without postdilatation. Postdilatations were within the stent at all 
times. These implantation characteristics together with the fact that measurements started 
2 mm distal to the stent make significant differences in the vessel wall trauma distal to the 
stent very unlikely.
The coronary segments distal to the stent had a normal angiographic appearance in both 
groups. IVUS study revealed no unhealed distal stent edge dissections, which could have 
influenced endothelial recovery. 
Though our main interest was the vasomotory response at 6 months follow-up, studies 
were also performed immediately after the intervention itself to exclude major difference in 
baseline vasomotion between groups. However, in our center interventions are performed 
with liberal use of intracoronary nitrates to appreciate vessel diameter and reduce spasm. 
This means that acetylcholine studies were performed after the use of nitrates and results 
between baseline and follow-up are not comparable. Despite this, significant 
vasoconstrictive response to acetylcholine could be seen in both groups. Though a trend 
to more vasoconstrictive response was seen in the SES group at baseline, response had a 
tendency to improve in the BS group at follow-up (-11 ± 10 % to 0 ± 7 %, p= 0.07) while a 
trend towards worsening  was seen in the SES group ( -20 ± 14 % to -32 ± 23 %, p = 
0.25). This means that the large difference in vasomotion response to acetylcholine seen 
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at follow-up between bare stent and sirolimus-eluting stent patient groups could not be 
explained by a difference in vasomotion at baseline. 
During the intervention, the interventional guide wire is distal to the treated segment. 
Endothelial damage or even local endothelial denudation distal to the implanted stent due 
to wire manipulation cannot be excluded. However, it is very unlikely that six months after 
the intervention, the vasoconstrictive response to Ach, as seen in this study, would be the 
result of a persistent denudated coronary artery, instead of a regenerated but still 
dysfunctional endothelial layer.  
Studies were performed 6 months after SES implantation. Persistent drug elution from the 
stent is unlikely. If present, the drug concentration would be extremely low. If the alteration 
in endothelial response we observed is a consequence of SES implantation, it likely 
represents the late sequelae of earlier high dose exposure. The clinical relevance of this is 
unclear as even 3 year clinical follow-up in the first SES treated patients does not show 
delayed restenosis or vessel closure, though some late catch-up effect was recently 
reported (13). Moreover, we report a localized endothelial dysfunction, while generalized 
coronary endothelial vasodilator dysfunction has been linked to long-term atherosclerotic 
disease progression and cardiovascular event rates (14). However, our results do suggest 
that prolonged follow-up to exclude late adverse consequences is warranted in patients 
who receive a drug-eluting stent.
Study limitations 
The baseline characteristics of both groups were not completely balanced. However, in the 
BS group, patients were older, more often men and more often suffered from 
hypercholesterolemia, all of which are known to predispose to endothelial dysfunction. 
Despite this, endothelial dysfunction was significantly more marked in the SES patient 
group.
Our patient groups were small, due to the very limited number of patients receiving a bare 
stent in our center at the time of the study on one hand, while on the other hand our center 
changed from SES to a paclitaxel-eluting stent as the new default stent during recruitment 
of our study patients, preventing us from inclusion of more SES patients. Despite the 
finding of a statistically significant difference in vasomotory response to Ach, these results 
should be confirmed in larger studies to overcome the limitations of statistics on small 
sample sizes. 
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The stent design was not the same in both groups. Ideally, the BS and SES should have 
had the same design. However, both stents were made from 316L stainless steel and strut 
thickness was identical. Moreover, the segment studied extended 17 mm distal to the 
stent, making an effect of stent design 6 months after implantation and without restenosis 
unlikely.
No vasomotion study was performed in a control vessel of the SES patients to rule out a 
stronger vasoconstrictory response to Ach in this patient group, not related to sirolimus. 
However, as the trend to vasoconstriction in the SES patients was very uniform compared 
to the reaction in the bare stent patients (figure 1), an intrinsic stronger response of the 
vessel wall to Ach is not very likely. 
Conclusions
SES implantation may have an adverse effect on local endothelium-dependent vasomotor 
responses six months after SES compared to BS implantation. The long-term clinical 
consequences of this observation are yet unknown.  
Acknowledgements:
We thank J. Brouwer, MD, PhD for his assistance in statistics. 
This study was supported by a grant from the Dutch Heart Foundation number: NHS 2000 
B 032. 
Chapter 8 
96
References 
1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-
eluting stent with a standard stent for coronary revascularization. N Engl J Med 
2002;346:1773-80. 
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents 
in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
3. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces 
neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193. 
4. van Beusekom HM, Whelan D, Hofma SH, et al. Long-term endothelial dysfunction is 
more pronounced after stenting than after balloon angioplasty in porcine coronary 
Arteries. J Am CollCardiol.1998;32:1109-17. 
5. Caramori PRA, Lima VC, Seidelin PH, et al. Long-term endothelial dysfunction after 
coronary artery stenting. J Am Coll Cardiol 1999;34:1675-79. 
6. Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with 
programmable release pharmacokinetics. Circulation 2003;107:777-784. 
7. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by 
acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51. 
8. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after 
implantation of a paclitaxel derivate-eluting polymer stent system in humans. 
Circulation 2002 ;106:2649-51. 
9. Gössl M, Rosol M, Malyar NM, et al. Functional anatomy and hemodynamic 
characteristics of vasa vasorum in the walls of porcine coronary arteries . Anat Rec 
Part A 2003;272A:526-537. 
10. Corbin F, Blaise GA, Parent M, et al. Effect of rapamycin on rat aortic ring vasomotion. 
J Cardiovasc Pharm 1994;24:813-17. 
11. Jeanmart H, Malo O, Carrier M, et al. Comparative study of cyclosporine and 
tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on 
coronary endothelial function. J Heart Lung Transplant 2002;21:990-998. 
12. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and 
metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial 
growth factor. Nature Medicine 2002;(8):128-135.  
13. Molnar F, Hayashi EB, Sousa JE et al. Three-year follow-up of the RAVEL study: A 
randomized study with the sirolimus-eluting Bx Velocity stent in the treatment of 
patients with de novo native coronary artery lesions.  J Am Coll Cardiol 
2004;43(5)Suppl A:843-6(Abstract).               
               endothelial function after SES 
97
14. Schächinger V, Britten MB,  Zeiher AM. Prognostic impact of coronary vasodilator 
dysfunction on adverse long-term outcome of coronary heart disease. Circulation 
2000;101:1899-1906. 
Chapter 8 
98
Table 1. Patient characteristics
 Bare stent (N=5) SES (N=7) p-value 
Age (SD) 65 (9) 52 (5) 0.01 
Male Sex 80% 43% 0.20 
Current smoking 40% 43% 0.91 
Diabetes    
Type 1 0% 0% 1.00 
Type 2 0% 14% 0.38 
Hypertension 40% 43% 0.92 
Hypercholesterolemia 80% 43% 0.41 
Prior myocardial 
infarction 
20% 29% 0.74 
Positive family history 80% 57% 0.51 
Statin therapy 100% 100% 1.00 
ACE-inhibitor 20% 14% 0.80 
Body surface area (m2) 1.8 ± 0.1 1.8 ± 0.1 0.91
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Table 2. 
Mean coronary segment diameter change from baseline after maximal endothelium-
dependent vasomotion (10–6 molar acetylcholine) and endothelium-independent 
vasodilation (2-3 mg i.c. nitrates). 
 SES 
N=7 
Bare stent 
N=5 
p- value 
Ach         Mean ± SD 
                Median ( 25 %; 75 %) 
- 32 ± 23 % 
- 32 ( -50; -9) 
0 ± 7 % 
-2 ( -5; 6) 
0.03
Nitrates   Mean ± SD 
                Median ( 25 %; 75 %) 
 15 ± 11 % 
20 ( 8; 23) 
7 ± 7 % 
5 ( 0;15) 
0.14
Ach: Acetylcholine; SES: sirolimus-eluting stent  
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   Hier PDF invoegen figuur 1 
Figure 1.
Mean coronary artery segment diameter at 6 months FU at baseline (saline infusion) and 
after maximal acetylcholine infusion (10-6 Molar) for individual patients. Thick line is mean 
diameter per group. SES: Sirolimus-eluting stent. 
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Figure 2. 
Mean coronary artery segment luminal diameter change at 6 months follow-up after intra-
coronary infusion of acetylcholine with incremental concentrations of 10 -8 , 10-7  , and 10-6
Molar. Comparison of patients with sirolimus-eluting stent(SES) and patients with bare 
stent implantation.
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Abstract
Atherosclerotic plaques occur at low shear stress areas in the arterial tree. Endothelial 
dysfunction is presumed to be a precursor of atherosclerotic plaque formation. The aim of 
our study was to investigate in patients whether local endothelial dysfunction is related to 
low shear stress (SS). 
Materials
In 7 patients treated 6 months earlier for coronary artery stenosis using sirolimus eluting 
stent implantation, endothelium dependent vasomotion was assessed by acetylcholine 
(ACh) provocation using a selective intracoronary infusion of 10-8 and 10-7 M. The arterial 
response distal from the stent was measured by biplane contrast angiography. The lumen 
was 3D reconstructed using the lumen contours in the angiograms of the arteries distal 
from the stent. Computational fluid dynamics in these 3D reconstructions applying patient 
specific flow and viscosity delivered local SS before and after ACh provocation. Relative 
changes in local SS were used to determine the local response of the artery to ACh. 
Results
Average SS was 1.4±0.6 Pa. Administration of ACh led to an increase in SS by 32% and 
50% for 10-8 and 10-7 M ACh respectively. Administration of ACh to local arterial sites 
exposed to low SS (<1.3 Pa, being the median of all SS values) showed an increase in 
shear stress of 52% and 73% for 10-8 10-7M ACh respectively, while local arterial sites 
exposed to normal to high SS this SS increase was much lower 11% and 26% for 10-8 10-7
M respectively. These data imply higher degree of endothelial dysfunction at arterial sites 
exposed to low SS. 
Conclusions
3D reconstruction of human coronary arteries from biplane contrast angiograms allows 3D 
study of local endothelial function. For the first time, we showed in human coronary 
arteries in vivo that endothelial dysfunction is most severe at low SS areas. 
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Introduction
Atherosclerotic plaques occur at specific locations in the arterial tree. For instance close to 
side branches (1) and at inner curves of coronary arteries (2,3). As these locations 
coincide with zones of low shear stress and flow separation, low and oscillating shear 
stress is thought to play a key role in the atherosclerotic plaque formation (2,3). The 
earliest appearance of atherosclerotic disease is local endothelial dysfunction(4) and has 
been shown to reflect the propensity to further develop atherosclerotic plaques and 
cardiovascular events (5,6). Indeed, endothelial dysfunction is initially mainly observed at 
coronary branch points (7).                                                                         
Several in vitro studies showed a close correlation between the functionality of the 
endothelium and the local shear stress conditions (8,9). However, no in vivo data are 
available confirming a direct relationship between endothelial function and shear stress in 
human coronary arteries.
A common method to determine local endothelial function is the acetylcholine provocation 
test(10). In this test the vessel response to increasing concentrations of acetylcholine is 
measured by angiography. Functional endothelium will respond to incremental 
concentrations of acetylcholine by inducing increased vasodilation, while dysfunctional 
endothelium is associated with vasoconstriction(11). Traditionally, the vessel response is 
expressed as average diameter change of a certain segment. As diameter measurements 
do not allow discriminating the local response over the circumference of the artery(Figure 
1), this measure is not suitable for comparison with local shear stress. The latter has 
shown to be heterogeneous over the circumference of a curved coronary artery.
To enable the study of shear stress related endothelial function in human coronary arteries 
in vivo, in which the circumferential heterogeneity is considered, we developed a 3D 
reconstruction technique based on biplane angiography and combined that with 
computational fluid dynamics to obtain the local shear stress.  Using this method we tested 
for the first time in human coronary arteries the hypothesis that local endothelial 
dysfunction is located at low shear stress areas.  
Methods
Patient selection 
9 patients being treated for single vessel disease using a sirolimus eluting stent (Cypher, 
Cordis) 6 months before, were eligible for this study.  Of the 9 patients, 1 patient refused 
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follow-up and 1 patient was excluded from follow-up studies because of asymptomatic in-
stent restenosis. In total in 7 patients vasomotion studies could be performed in the arterial 
segment distal from the stent. This study was approved by the Medical Ethics Committee 
of our institution and written informed consent was obtained from all patients in accordance 
with the guidelines established by the Committee for the Protection of Human Subjects. 
Evaluation of endothelial function 
Before vasomotion studies were performed, as described in detail previously(12),  long-
acting vasoactive drugs had been stopped for at least 24 hours. Because of severely 
restricted vasomotion at the stented coronary segment, the segment distal to the stent was 
studied, excluding the first proximal 2 mm. Percutaneous femoral access and a 7 French 
guiding catheter was used in all patients. A multi-functional probing catheter (Boston 
Scientific) was advanced over the guidewire and positioned in the stent. To avoid wire-
induced coronary spasm, the wire was removed. At the start of the vasomotion study, 
being 6 months after stent implantation, baseline angiography was performed after an 
initial infusion of saline solution through the intracoronary multi-functional probing for 2.5 
minutes. Then endothelium-dependent vasomotion was studied by infusion of incremental 
concentrations of acetylcholine (ACh) for 2.5 minutes at concentrations to result in final 
intracoronary concentrations of 10-8 M, 10-7M and 10-6M, assuming a mean coronary blood 
flow of 80 ml/min as described in detail before (10,12,13). Throughout each infusion heart 
rate, systemic arterial blood pressure and electrocardiogram were monitored continuously. 
Because of a significant generalized vasoconstrictive response at the highest 
concentration of 10-6M ACh,  only the lower concentrations of 10-8 M and10-7M Ach were 
used to investigate the relationship between local vasomotion response and shear stress. 
3-D lumen reconstruction derived from angiography 
Care was taken to visualize the segment distal to the stent in 2 views, with projections 
differing by more than 60 degrees and ensuring minimal fore-shortening. Angiography was 
performed in biplane and settings were not changed throughout the study. ECG gated 
biplane angiograms were selected for further analysis. 3D-lumen reconstruction was 
performed after tracing the contours of the coronary arteries distal to the stent in biplane 
contrast angiograms for baseline and the 2 acetylcholine provocation geometries (Figure 
2). After 3D reconstruction of the centerline of the contours (Figure 3A), the local cross 
sectional lumen dimensions were obtained from the perpendicular distance between 
centerline and contour at both angiograms (Figure 3B). Application of a calibration cube 
ensured the correct size, spatial location and direction of the vectors determining the local 
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vessel diameter in 2 directions. Finally, ellipses where fitted encompassing the 2 vectors 
per cross section (Figure 3B). Combining the local ellipses resulted in a 3D lumen 
reconstruction of the geometry of the coronary segment (Figure 3C).  
Doppler flow studies 
Coronary Doppler flow was measured just proximal to the region of interest using a 0.014-
inch Doppler tipped guidewire (FloWire, Endosonics, Rancho Cordova, CA, USA). Doppler 
recordings were taken 1 and 2.5 min after the start of each infusion. A blood sample of 5 
cc was drawn for viscosity measurements using a capillary viscometer.  
Computational fluid dynamics 
Shear stress was determined applying a well-validated finite element software package 
(Sepran, Sepra, Leiden, the Netherlands). This software solved the non-linear 
incompressible fluid flow Navier-Stokes equations in a multitude of nodes contained in 
brick-like elements (axial resolution 0.5 mm, circumferential resolution approximately 0.5 
mm, being 1/16 of the length of the circumference), which filled the luminal space of the 3D 
reconstruction.  Blood was modeled as a Newtonian fluid using patient specific viscosity 
and a density of 1050 kg/m3. Entrance flow was determined from the Doppler 
measurements taken at 2.5 min after ACh infusion, using a parabolic inflow profile. At the 
wall no slip was assumed and at the outflow zero stress conditions were applied. 
Convergence was reached when differences in velocity between iterations fell below 0.1 
mm/s(3). In order to study only how changes in geometry relate to shear stress 
distribution, the shear stress after provocation was computed applying the same baseline 
flow for all the 3 geometries, i.e. baseline and 10-8 M and 10-7M ACh geometries. 
Analysis and statistics 
The studied segment length per patient was dependent on the quality of the angiograms at 
baseline and after acetylcholine provocation. Per patient, the final studied segment length 
was determined by the segment length being appropriately visualized in all the three 
angiograms (baseline, 10-8M 10-7M ACh). Anatomical landmarks and the location of the 
stent were used to match the baseline geometry and the geometries observed after 
acetylcholine provocation in both axial and circumferential direction, to allow local 
comparison between the 3 geometries. The local spatial discrimination is determined by 
the local resolution of the mesh, being approximately 0.5 x 0.5 mm. 
The baseline shear stress distribution observed in all the patients was used to subdivide 
the data points into 10 categories being each 10th percentile of that distribution. For each 
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patient, in each category, the average of the baseline shear stress (SSbas), shear stress 
after administration of acetylcholine 10-8 M (SS8) and 10-7M (SS7) and relative change 
was determined: RSS8 = (SS8-SSbas)/SSbas*100% and RSS7 = (SS7-
SSbas)/SSbas*100%. The relative change in shear stress (RSS8,RSS7) was used to 
derive changes in geometry. RSS7(8)>0% means relative increase in shear stress 
attributed to acetylcholine provocation, which implies local vasoconstriction representing 
endothelial dysfunction. Likewise, RSS7(8)<0% implies vasodilation and thus healthy 
endothelium.
The data from local arterial sites exposed to low shear stress at baseline, being the 
average of the data points from category I-V (Group A) were compared to local arterial 
sites exposed to high shear stress, being the average of data points from category VI-X ( 
Group B) applying paired t-test (N=7). Per group one sample t-test was applied to evaluate 
differences from baseline (N=7). 
To evaluate whether the response of the endothelium was dependent on the distance from 
the stent, we investigated whether the axial local distance contributed significantly to the 
observations. Therefore, the cross sections were subdivided into 3 groups based on the 
axial distance to the stent (I:2-7 mm, II: 7-12 mm and III: 12-17mm).  Subsequently, a 2-
way ANOVA was performed in which the shear stress group (A or B) and location (I,II or 
III) were included in the model. A p-value of <0.05 was considered significant. All values 
were expressed as mean ± SD. The software package  SPSS 11.0.1 (SPSS Inc. Chicago, 
Illinois, USA) was used for all statistical calculations. 
Results
Patient population and hemodynamics 
Patients were 52 ±5 years old. Risk factors for atherosclerosis were distributed over the 
studied patient group as follows: 57% of the patients had a positive family history, 43% 
hypertension, 43% hypercholesterolemia, 14% Diabetes.  The flow in the studied coronary 
arteries changed from 30 ml/min to 45 ml/min and 60 ml/min respectively, after 
administration of 10-8M and 10-7M acetylcholine. 
Geometry 
The length of the studied segments ranged from 7.5 mm to 31.5 mm (17±9 mm). The 
baseline vessel diameter was 2.4±1.3 mm and showed a trend towards vasoconstriction 
with increasing acetylcholine concentration: 2.3±1.3 mm 2.2±1.3 mm for 10-8M and 10-7 M 
acetylcholine concentration respectively. Because  Ach 10-6M induced a significant 
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generalized vasoconstrictive response, only the lower concentrations of 10-8 M and10-7M
ACh were used to investigate the relationship between local vasomotion response and 
shear stress. 
Shear stress
Average shear stress in the coronary arteries at baseline was 1.4±0.6 Pa.  In general, 
acetylcholine provocation induced an increase in shear stress by 32% and 50% for 10-8M
and 10-7M ACh respectively (p<0.05).
The borders of the 10 categories based on the 10th percentile of all baseline shear stress 
values range from 0.16-8.49 N/m2 (figure 4). In Figure 4A, B the relative shear stress 
increase attributed to 10-8 and 10-7M ACh is depicted dependent on the 10 SSbas 
categories for each patient individually. In general, the arterial sites exposed to the lowest 
baseline shear stress showed the highest RSS8 or RSS7 (maximal 300%), which 
gradually decreased with rising SSbas.  
Figure 5 shows the significant differences in relative shear stress for local arterial sites 
experiencing low (Group A being 0.16-1.3 Pa) versus normal to high SSbas (Group B 
being 1.3 –8.5 Pa).  RSS8 was 52% (p<0.05) for group A, while RSS8 was not different 
from 0% (11%±3%, N=7, p=NS) for group B. Administration of 10-7M ACh resulted in an 
increase in shear stress for both groups (A:RSS7=73±64% B:26±23%), with a similar trend 
for group A versus group B (Figure 5). This data imply that sites exposed to low shear 
stress constrict more after administration of ACh than high shear stress areas suggesting 
variations in local endothelial dysfunction related to shear stress. We found no differences 
in shear stress related endothelial dysfunction between the 3 different axial locations. 
(N=30, 2-way ANOVA RSS7: p=0.004; RSS8: p=0.034).  
Discussion
The main finding of this study is an enhanced endothelially mediated vasoconstrictive 
reaction to acetylcholine at local arterial sites exposed to low shear stress (below 1.3 
N/m2). This is the first time an in vivo correlation between low shear stress and endothelial 
dysfunction could be demonstrated in human coronary arteries. 
Determination of local endothelial function versus shear stress 
Because of the localized appearance of atherosclerotic plaques known to be related to low 
shear stress areas(2) and because endothelial dysfunction precedes plaque formation(4), 
we aimed to investigate in human coronary arteries the relationship between local shear 
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stress and local endothelial function such that the circumferential heterogeneity is 
considered. Acetylcholine is a vasoactive agent commonly used to assess the endothelial 
function in human arteries in vivo(10). Administration of a vasoactive agent to the 
circulation shifts the existing balance between vasodilator and vasoconstrictor agents 
produced by the endothelium and results in an arterial diameter change. If the endothelium 
is intact ACh works at endothelial muscarinic receptors, evoking additonal production of 
NO, which causes smooth muscle cell relaxation. However if the endothelium looses its 
integrity, ACh can work directly, with declining interference of the endothelial cells, at the 
smooth muscle cells causing vasoconstriction(11). For this in vivo testing incremental 
concentrations of ACh are used that increasingly shift the balance between vasodilation 
and vasoconstriction.  
Although biplane angiography permits optimal assessment of the full 3D response of the 
coronary artery to ACh, current analysis methods to assess endothelial function are based 
on measuring changes in local diameter(12). Diameter measurements do not include any 
information on the spatial 3D orientation. Moreover, it excludes the measurements of local 
arterial response at 1 side of the artery (Figure 1).  For instance, a vasoconstriction 
exclusively in the inner curve of a coronary artery (Figure 1C) would result in the same 
change in diameter as a local vasoconstriction in the outer curve (Figure 1D).  Therefore, 
this approach does not allow determination of endothelial function considering 
circumferential heterogeneity. Furthermore, this 2D approach hinders the computation of 
local shear stress requiring a 3D geometry. Hence, we developed a method based on 
biplane angiography to 3D reconstruct the coronary arteries. Using the 3D reconstruction, 
local shear stress could be determined applying computational fluid dynamics at baseline 
and after administration of ACh.  In order to assess the local response of the artery to 
acetylcholine administration, we opted for studying relative changes in shear stress rather 
than local changes in geometry. Increase in local shear stress by ACh administration was 
associated with vasoconstriction and thus endothelial dysfunction. 
Endothelial function versus shear stress 
In the present study we showed a close relationship between enhanced endothelial 
dysfunction and low shear stress <1.3 N/m2 distally from a 6 months prior implanted 
sirolimus eluting stent (Figure 5).  This observation is very much in line with the known 
association between low shear stress and parameters of endothelial dysfunction observed 
in in vitro and animal studies, including the diminished eNOS expression(14)  and NO 
production, increased endothelin synthese expression (14), increased expression of 
adhesion molecules (15) and decreased production of antioxidant enzymes (16). 
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In another study Hofma et al. (17) observed that the arterial segments distally from a 
sirolimus eluting stent 6 months after implantation responded to 10-6 M ACh with significant 
constriction compared to bare metal stents. In the present study we analyzed the arterial 
response to 10-7 and 10-8 M ACh, which were not different from the response to bare metal 
stents using the angiographic method.  However, since shear stress changes are very 
sensitive to small and local changes in diameter, we were able to identify local regions with 
endothelial dysfunction.  If the sirolimus effect also manifests itself at low doses ACh, we 
suppose a diminished effect going from proximal to distal.  Therefore, we investigated 
whether the observed relationship between endothelial function and shear stress was still 
present after accounting for the axial location. Since we did not find differences in the 
observed shear stress related response between proximal and distal arterial segments, it 
is most likely that the shear stress was responsible for the circumferential heterogeneity. 
Conclusion
This study demonstrates the 3D local assessment of endothelial function in human 
coronary arteries based on biplane contrast angiograms. Moreover, for the first time, we 
showed in human coronary arteries in vivo that local endothelial dysfunction is enhanced 
at low SS areas. 
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A B C D
Figure 1: Cartoon of an angiogram of a coronary artery A) before administration of acetylcholine 
and after administration of acetylcholine showing 3 different possible arterial responses of 
endothelial dysfunction resulting in an equal diameter decrease, in which B) shows a combined 
arterial constrictive response at inner and outer curve, while C and D exclusively show a constrictive 
response at the inner or outer curve respectively. 
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A B
Figure 2: Biplane angiogram of coronary artery with contours delineated 
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A B
C
Figure 3: Principle of 3D reconstruction from biplane angiography. A) the centerline is 3D 
reconstructed from the center of the two angiograms B) at each location of the centerline, 2 vectors 
are spanned such that the projection of them on the respective two X-ray intensifiers, is 
perpendicular to the centerline and correct in size. The 2 vectors form the basis for an ellipse C) to 
obtain the ellipses at each location along the centerline, which delivers the 3D object. 
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Figure 4:
Relative increase in shear stress attributed to acetylcholine provocation (A: 10-8M; B: 10-7M) for 
each patient individually related to the 10 baseline shear stress categories based on the 10th
percentile of the shear stress distribution. 
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Heparin-coated stent trials
Sjoerd H. Hofma, Patrick W. Serruys, Willem J. van der Giessen 
Department of Cardiology, Thoraxcentre, Erasmus Medical Centre Rotterdam, Rotterdam, 
The Netherlands. 
Effects of heparin on blood coagulation and cellular proliferation 
Heparin is a highly sulphated linear polysaccharide that was discovered in 1916 as an 
anticoagulant. Heparin binds to antithrombin III, thereby inducing a conformational change. 
This results in inhibition of thrombin and other serine proteases involved in the blood 
clotting cascade immediately after administration. The actions of heparin on neointimal 
proliferation are complex. This was demonstrated by Edelman et al. (1). They found an 
increase of intimal hyperplasia after arterial injury in the rat model when heparin was 
administered once daily. Twice daily had different effects depending on time-interval of 
dosing but very significant reduction in intimal hyperplasia was seen with continuous 
administration. Clowes et al. showed that heparin should be administered for 4 to 7 days to 
have an antiproliferative effect after injury (2). 
Therefore, the need for continuous heparin administration for 7 days after stent 
implantation provides the rationale for a heparin-coated stent. 
Methods of heparin-coating 
There are several ways to attach heparin to the stent surface. These include: adsorption of 
benzylkonium alcohol solution (3,4), ionic bonding (5,6), dispersion in polymer (7-9), 
surface grafting (10-12), covalent coupling of functionalized surface with mid- or end-point 
attachment ( 13-17) and heparin-polymer block copolymers (18).
The first methods result in a weak binding and heparin will be lost within a short time span. 
Most research and all clinical trials have been performed with covalently bound heparin- 
coated stents.  
The Palmaz-Schatz- and BX-stent with HepacoatTM
In the early development of heparin coatings, a reduction of heparin activity was frequently 
seen after covalent attachment of the molecules to the surface. Larm et al (19) immobilized 
Chapter 11 
136
heparin fragments with end-point attachment on materials coated with polyethylamine. By 
this method heparin activity was preserved after attachment. Based on this principle the 
Carmeda BioActive Surface coating (CBAS, Carmeda AB, Stockholm) was developed and 
applied to extracorporeal systems.  This coating was used as a base for the heparin-
coated  Palmaz-Schatz stent. However, in a demanding environment, like the porcine 
coronary model, this coating was not sufficient to eliminate stent occlusion. Elimination of 
subacute stent thrombosis could be shown with higher-activity heparin coating (12 to 20 
pmol anti-thrombin III binding activity per stent;HepacoatTM, J & J Cordis, Warren, NJ)(20).  
In the early 90's, stents were still implanted with a strict anti-coagulant regime and 
prolonged heparinization. In four phases of Benestent-II pilot, using this heparin-coated PS 
stent, anti-coagulant regime was reduced and finally coumadin and postprocedural heparin 
were replaced by aspirin and ticlopidin. Stent thrombosis did not occur and bleeding 
complications dropped to 0 % (21).  
The BENESTENT-II trial randomized  827 patients to heparin-coated stent implantation or 
standard balloon angioplasty. The patients were more challenging with 45 % unstable 
angina pectoris.  Stent thrombosis occurred in only one patient ( 0.2 %) (22). This is well 
below the 1- 2 % of stent thrombosis seen in contemporary trials. Restenosis rates at 6 
months were 16 % in the heparin-stent group. Similar restenosis rates have been achieved 
with non-coated stents. Data suggest no reduction of neointimal hyperplasia within the 
stent in comparison to uncoated stents. (20-22). 
The heparin-coated Palmaz-Schatz stent has also been used in chronic total occlusion 
(TOSCA) and acute myocardial infarction (Stent-PAMI trial). In the TOSCA trial 410 
patients with chronic total occlusion of a native coronary artery were randomized to 
heparin-coated stent vs. balloon angioplasty. The incidence of MACE after 6 months was 
similar with both strategies ( PTCA:23.6 vs. stent: 23.3 %) but restenosis rate was reduced 
from 70 % in the PTCA group to 55 % in the stent group (23). Evaluating the 721 patients 
with stable and unstable angina pectoris as well as acute myocardial infarction who have 
been treated with a heparin-coated Palmaz-Schatz stent in the Benestent-II pilot, the 
Benestent-II trial and PAMI trials, the incidence of subacute stent thrombosis (SAT) was 
extremely low (incidence of 0.12 %!!). 
A recent registry from a single, large cardiac center evaluated primary thrombotic outcome 
(defined as angiographically documented SAT and/or sudden unexplained cardiac death 
(SCD)) in 337 patients receiving 543 BX velocity Hepacoat stents and 939 patients 
receiving 1688 bare-metal stents. SAT or SCD was seen in 3.03 % of procedures in the 
bare-metal stent group and 0.58 % in the heparin-coated stent group. 96 % of SAT within 
30 days occurred in patients with an acute coronary syndrome ( 24). 
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Hep@net Registry and HOPE 
This internet-based registry compares the Hepacoat BX-Velocity stent with the bare BX-
velocity stent. Last data available on  www.TCTMD.com  show 0.5% stent  thrombosis with 
the Hepacoat (n=1062)  vs 1.2% with the bare stent (n=1301) P= 0.14. Enrollment in this 
registry is continuing. In another registry, the HOPE Registry ( Hepacoat and an 
antithrOmbotic regimen of  asPirin alone) 200 patients were stented with the BX Velocity 
stent with Hepacoat. SAT rate was acceptable with  1 % at 30 days despite only aspirin 
use post procedure and no ticlid or clopidogrel. However, IIb/IIIa – inhibitor use was 55% in 
this study (25).   
The HepamedTM-coated Wiktor stent and beStent 
The conditioning layer of the coating of the Hepamed coating (Medtronic Bakken Research 
Center, Maastricht, NL) is completely covalently coupled. (26). This makes this coating 
potentially more stable than HepacoatTM.In addition, the heparin molecules are neither 
fragmented nor enriched with the active antithrombin binding site, resulting in a predictable 
heparin layer on the stent, but with a lower antithrombin binding capacity per picomole of 
attached heparin. Therefore, additional heparin has been added. 
In the MENTOR trial theWiktor stent with Hepamed coating was implanted in 132 patients. 
A subacute occlusion rate of  0.8 % was seen despite the fact that 43 % of patients had 
unstable angina. The 6 month event-free survival was 85 % and angiographic restenosis 
rate was 22 % (27). The Wiktor Stent with Hepamed coating has also been studied in 
saphenous vein bypass grafts. In 50 patients 55 stents were placed in lesions in very old 
vein grafts (11.7  +/- 3.9 years).  MACE free survival was 86%  at 6  months and 
angiographic restenosis rate was 22%. This is a favourable result for this challenging 
patient subset. (28).
A randomized , multicenter trial has been initiated in Scandinavia (Stents in Small 
Coronary Arteries, SISCA), comparing the efficacy of the Hepamed coated  beStent 
(Medtronic Instent, Minneapolis MN, USA) with balloon angioplasty in 145 patients with 
stable angina pectoris due to a de novo lesion with a reference diameter between 2.1 and 
3.0 mm. There were no differences between the groups regarding early events ( mean 
reference diameter 2.4 mm). Event-free survival at 6 month follow-up was significantly 
better with the heparin-coated stent than with balloon angioplasty (90.5% vs 76.1%, 
respectively; P = 0.016). (29). 
This clinical benefit was maintained at 1 year follow-up with no change in eventfree 
survival between 6 months and 1 year. (30). 
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The CorlineTM coated Jostent
In the Corline coating a single modified polymeric amine conditioning layer is used. 
Unfractionated heparin is linked with specific covalent bounds to form a macromolecular 
heparin conjugate. The anti-thrombin activity per cm2 may be lower than in the Hepacoat 
and Hepamed coatings. However, in the Corline coating unfractionated heparin is used as 
opposed to fragmented heparin in the Hepacoat. Theoretically, important properties of the 
heparin molecule, like antiproliferative actions, which are not necessarily associated with 
the antithrombin binding site, may be retained. 
A small pilot study using this stent was performed in Russia. The stent was implanted in 46 
patients with 93.4% acute angiographic succes. However, follow-up was limited to the in-
hospital phase (31). 
The Corline coating has been used in the only trial that has been initiated thusfar to 
compare heparin-coated with bare stents( COAting of STents : COAST trial). In this study 
the Jomed stent was compared side-to-side with the Corline Jo stent in a three-armed 
study of  588 patients. Patients with stable or unstable angina pectoris due to single or 
multiple stenoses were included when the reference diameter of the coronary artery was 
between 2.0 and 2.6 mm, thus providing additional information on performance of coated 
and non-coated stents in small arteries. COAST, however, lacks the power to discriminate 
between the (sub)acute thrombosis rates, even when the incidence of stent thrombosis in 
these small vessels would have been as high as 5 %. In COAST, patients were 
randomized to balloon angioplasty ( n= 195), bare stent ( n=196) or heparin-coated stent ( 
n=197). In the balloon angioplasty arm 27% ( n=53) of patients crossed over to recieve a 
stent, which is a considerably higher percentage than usually seen in trials in larger ( mean 
diameter 3.0 mm) vessels. Only 3 patients in the bare stent arm and four patients in the 
heparin-coated stent arm crossed over to recieve balloon angioplasty. In a per-protocol 
analysis 6 month restenosis rates were 32%, 27% and 30%, for balloon, stent and heparin-
coated stent groups respectively. The “intention to treat”results are summarized in the 
table (table 78-1). There were no statistical differences between the groups. The only 
suspected stent thrombosis occurred in the heparin-coated arm. (32). 
WĘhrle et al. reported a non-randomized study in which 368 stents were implanted in 303 
lesions from 278 patients, comparing uncoated and Corline heparin-coated Jomed stents. 
More patients included in this study were high risk than in any of the studies cited above, 
since > 60% had multivessel disease, 8% total occlussion, 17 % of patients had acute 
infarction and 19 % of lesions were restenotic lesions, equally divided over both groups. 
No benefit of heparin coating could be detected on the incidence of stent thrombosis, 
myocardial infarction, restenosis rate or re-intervention rate (33). 
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Table 51-1: Clinical trials with heparin-coated stents (references: see text) 
 Coating Study Patients 6 or 7 
month MACE 
6 months
Restenosis 
Benestent II 
pilot
1996 (21) 
Hepacoat  4-phased registry; 
AP/UAP
N=207;  
angio success  98% 
14 % 13 % 
Benestent II 
randomized 
1998 (22) 
Hepacoat Balloon vs HC-stent; 
AP/UAP
Balloon n=410 
Stent      n=413 
19 %
13 %  p=0.013 
31 %
16 %  p< 0,001 
Stent-PAMI
pilot
1999 
Hepacoat Registry;  
acute MI 
N=101;  
angio success 96% 
19 % 18 % 
Stent-PAMI
randomized 
1999 (34) 
Hepacoat Balloon vs. HC-stent; 
acute MI 
Balloon n=448 
Stent      n=452 
20 % 
13 %   p< 0,01 
34 % 
20 %  p< 0,001 
TOSCA
1999 (23) 
Hepacoat Randomized; 
Total occlusion 
Balloon n=208 
Stent     n=202 
24 % 
23 %   ns 
70 % 
55 %  p= 0,001 
Mentor
2000 (27) 
Hepamed 
coating 
Registry 
AP/UAP
N=132 15 % 22 % 
WĘhrle 2001 
(33)
Corline 
coating 
Alternating cohorts of 
50 coated or 
uncoated 
Bare  133 
HC    144 
25.7
25.2     ns 
30.3
33.1     ns 
SISCA
2001 (29) 
Hepamed 
coating 
Randomized; 
AP, small vessels 
Balloon n= 71 
Stent      n= 74 
23.9
 9.5    p= 0.016 
18.8
9.7     p= 0.15 
COAST 
2003 (32) 
Corline 
coating 
Randomized; 
AP/UAP, small 
vessels
Balloon n=195 
Coated Stent n=197 
Bare Stent     n=196 
15.4
11.7   ns 
11.7
32.2
29.6   ns 
24.8
Russian Pilot 
1998 (31) 
Corline 
coating 
Feasibility Stent n=46 
93.4 % angio succes 
No follow-up No follow-up 
South Korean 
study 
1999 (35) 
Corline 
coating 
Registry 
Acute MI 
Stent n= 102 13.7% 17.2 % 
Lev 2004 (36) Hepacoat Registry, AMI primary 
and rescue 
Bare n=114 
HC n=124 
21.1%
16.1%
14.9%
10.5%
Heparin coated stents in acute myocardial infarction 
The heparin-coated Palmaz-Schatz stent was used in the Stent-PAMI trial(34). In this trial 
patients with acute myocardial infarction (AMI) were randomized to angioplasty alone (448 
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patients) or angioplasty with stenting (452 patients). Abciximab was only used in 5.8 % of 
stented patients and 4.5 % in the angioplasty group. The combined primary endpoint at 6 
months of death, reinfarction, disabling stroke, or target-vessel revascularization was 
significantly lower in the stent group (12.6 % vs. 20.1 % for PTCA, p<0.01). At 1 month 
and at 6 months no significant difference was seen in reinfarction. This suggests no lower 
thrombotic occlusion rate with a heparin-coated stent. Restenosis rate at 6.5 months was 
20.3 % for the stent group vs. 33.5 % for the PTCA alone group. (P<0.001) 
Recently, a study comparing 124 patients receiving a heparin-coated stent (HepaCoat BX 
Velocity, Cordis, NJ) for acute myocardial infarction with 114 patients receiving a bare 
stent showed reductions in stent thrombosis (0.8% vs 6.1%, p=0.03) and recurrent MI (4% 
vs 10.5%, p=0.05) at 30-day, but no significant effect on 180-day outcome (composite 
uotcome death/MI/TVR 16.1% vs 21.1%) (36). 
A South-Korean group reported a registry of 102 patients with acute MI treated with 111 
Corline heparin-coated stents(35). Postprocedural heparin or abciximab was not used. 
Mortality at 6 months was 6.0 %, 1 patient with recurrent infarction was seen and 
revascularisation rate was only 8 %. Restenosis rate at 6 months was 12.7 %. This registry  
lacked a control group, which is especially regretted since the outcome was quite good, 
even in the absence of abciximab. 
Conclusions
The high thrombotic occlusion rate of stents in the early nineties prompted research to 
develop a heparin-coated stent.  
The very low incidence of less than 0.2 % subacute thrombosis after implantation of a 
heparin-coated stent in the setting of stable angina, unstable angina and even acute 
myocardial infarction holds promise. However, whether this is truly the result of the heparin 
coating or of improved interventional techniques is difficult to distinguish. Though apparent 
in ‘real-world registries’,  a trial directly comparing Corline-coated versus non-coated stents 
showed no benefit in small ( mean diameter 2.4 mm) arteries (COAST). In the meantime it 
seems justified to use a heparin-coated stent in situations of high thrombus burden or high 
platelet reactivity. Adverse effects of this choice have at least never been seen. Another 
niche may be treatment of patiens with known aspirin or clopidogrel intolerance.  
No significant reduction of in-stent restenosis has been demonstrated compared to bare 
metal stents.
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Introduction
In-stent restenosis has long been considered the main
complication limiting the long-term efficacy of coronary
stenting. Although stent implantation itself has been
shown to reduce restenosis compared to balloon angio-
plasty, in-stent restenosis still occurs in 10-40% of the
patients. Although a number of “predictors” have been
described and are helpful in characterizing “high-risk”
populations, the occurrence of restenosis remains largely
unpredictable for a particular patient.1-3 Moreover, in-stent
restenosis in its more complex forms may re-occur in up to
80% of patients following percutaneous re-treatment with
conventional techniques.4 Although intracoronar y
brachytherapy has been proven effective in reducing the
recurrence rate of in-stent restenosis, treatment failure still
frequenlty occurs. In a recent study, 60% of patients have
been reported to experience at least one major cardiac
event up to 4 years after endovascular irradiation (unpub-
lished data).
A large body of evidence has been accumulated in an
attempt to understand the processes involved in restenosis.
The initial injury caused by the mechanical dilatation and
stent implantation triggers a “normal” healing vascular
response that ultimately leads to neointimal formation,
which, when excessive, may re-narrow the vessel lumen
(restenosis). An array of local reparative processes have
been shown to occur after the initial vascular trauma,
involving platelets, inflammatory cells, smooth muscle cells,
endothelial cells, and the secretion of a number of growth
factors and cytokines.5,6
Based on the accumulated knowledge about the cellular and
molecular mechanisms of restenosis, an endless list
“concepts”, “strategies”, devices, and drugs have been tested,
and failed, to decrease restenosis.7 More recently, however,
drug-eluting stents have emerged as an effective therapeutic
option to reduce the incidence of in-stent restenosis. The
present chapter will focus on describing the current clinical
and pre-clinical information available for drug-eluting stents,
as well as the limitations and future research directions for
these devices.
Rationale
A proposed explanation for the repeated failure of clinical
pharmacological studies with systemically administered drugs
is that these agents cannot reach sufficient tissue levels at the
site of dilatation without increasing the risk of systemic side
effects. In this regard, local administration offers advantages
by applying the drug to the precise site of injury, therefore
yielding very high concentration of the active agent with low
or negligible systemic concentrations.
Utilizing the stent itself as the platform for local drug delivery
is an appealing approach. Coronary stents have been exten-
sively proven to be safe and effective in mechanically allevi-
ating coronary obstructions, with predictable and stable
short-term results in a wide range of clinical situations. By
combining an agent with antiproliferative properties to a
“conventional” metallic stent, one is able to preserve the
mechanical scaffolding properties of stenting while the active
agent is administered to the very spot of vascular injury, with
no time delay, with high local doses, and with the potential to
control the time (short- vs. long-course) and site (mural vs.
luminal) of drug release, among other characteristics.
The delivery vehicles
Coated stents have been subjected to extensive investigations
long before being available for implantation in humans. The
process of binding pharmacological agents to a metallic mesh
has been early recognized to be challenging. The coating
should be resistant to mechanical abrasion during the
frequently laborious process of stent implantation, and should
comply with a number of pharmacological practical require-
ments, such as drug release in a predictable (dose and time)
way and suitability for sterilization. Furthermore, the coating
itself should not induce an increased vascular reaction. It
should be noted in addition that a potential universal coating
is unlikely, and that different pharmacological agents may
require different delivery vehicles. Currently, a variety of
different formulations have been developed that provide
appropriate stent coating for clinical use, including direct drug
binding, and coatings with phosphorylcholine, nonerodable or
bioabsorbable polymers, or ceramic layers.
The agents
The local agent should be one that inhibits the complex
cascade of events that leads to neointimal formation after
stent implantation. The inflammatory and proliferative mecha-
nisms of the general tissue healing response and the specific
role of blood and vessel wall components on the vascular repar-
ative processes are all potential targets for therapeutic
approaches aiming at reducing neointimal proliferation. A
variety of potential candidates are available (Table 1) and an
increasing number of clinical studies have been conducted to
evaluate the efficacy of different eluting-stents.
It is important to recognize that the clinical effect of these
devices is highly dependent on each one of the components of
the complex platform/vehicle/agent, as well as the interactions
among these elements. It is therefore unlikely that a drug-
eluting stent “class-effect” might exist, due to the myriad of
possible therapeutic combinations. Indeed, different drug-
eluting stents have been shown to significantly vary in their
ability to reduce restenosis. Indeed, several drug-eluting stents
have been already shown ineffective, as summarized in Table 2.
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Polymer-coated sirolimus- and paclitaxel-eluting stents have
the largest clinical experience to date, with a total of 8 already
completed randomized trials comparing the effect of these
devices against conventional stents. Sirolimus-eluting stents
are available for clinical use in Europe, Asia, and South America
since 2002 and in the US since 2003. Polymer-coated pacli-
taxel-eluting stents have been commercialized in Europe, Asia,
and South America since 2003 and are expected to be launched
in the US in the beginning of 2004. The main clinical infor-
mation derived from randomized trials and from other clinical
studies including post-marketing registries are detailed below.
In addition to sirolimus and paclitaxel stents, an increasing
number of other drug-eluting stents have been tested in
preliminary clinical trials with promising results and are
summarized in the sections below.
Sirolimus
Sirolimus (Rapamycin; Rapamune®) is a naturally occurring
macrocyclic lactone with a potent immunosuppressive action,
which was approved by the US Food and Drug Administration
for use in renal transplant recipients in September 1999.
Sirolimus inhibits cellular proliferation by blocking cell cycle
progression at the G1 to S transition. Its action is mediated by
binding to an intracellular receptor, the FK506 binding protein
(FKBP12). The complex rapamycin-FKBP12 then inhibits the
activity of a key regulatory kinase denominated mammalian
Target Of Rapamycin (mTOR). The inhibition of mTOR
suppresses cytokine-driven (IL-2, IL-4, IL-7 and IL-15) T-cell
proliferation. Its inhibition has several important effects,
including the inhibition of translation of a family of mRNAs
Table 1. Overview of possible anti-restenotic approaches for stent-based strategies
Anti-proliferative Anti-thrombins Immunomodulators Migration inhibitors/ Promote healing/
ECM modulators endothelialization
Paclitaxel Hirundin sirolimus and analogs Halofuginone VEGF
QP-2 Iloprost tacrolimus Propyl hydroxylase inhibitors 17-E estradiol
Vincristin Abciximab Biorest C-proteinase inhibtors Tkase inhibitors
Methotrexate Mizoribine Metalloproteinase inhibitors BCP 671
Angiopeptin Cyclosporin Batimastat Statins
Mitomycin Biorest Probucol NO donors
BCP 678 Interferon J1b EPC antibody
Antisense c-myc Leflunomide
ABT 578 Tranilast
Actinomycin-D Cyclosporin
RestenASE Corticosteroids
1-chloro-deoxyadenosine Micophenolic acid
PCNA ribozyme Biphosphonates
Celecoxib
Table 2. Failed pharmacologic stent-based strategies to prevent restenosis
Trial Agent Vehicle Stent platform Reason of clinical failure
SCORE47 Taxol derivative QP2 (4000Jg) polymer sleeves QuaDS-QP2 stent excessive incidence
of stent thrombosis 
and myocardial
infarction possibly due
to the polymer sleeves
DELIVER38 Paclitaxel (3µg/mm2) direct binding Multi-link penta lack of efficacy
ACTION48 Actinomycin-D (10 and 2.5µg/mm2) Polymeric coating Multi-link tetra lack of efficacy
BRILLIANT-EU49 Batimastat Phosphorylcholine coating BiodivYsio stent lack of efficacy
PRESENT trials50 Tacrolimus (60 and 230µg) Nanoporous ceramic coating FlexMaster ceramic stent lack of efficacy
EVIDENT50 Tacrolimus (352µg) PTFE PTFE-covered stent graft lack of efficacy
IMPACT51 Micophenolic acid “Unicoat” polymer Duraflex stent lack of efficacy
(14-day or 45-day release 3.3 (µg/mm2)
Chapter 12 
150
that code for proteins essential for cell cycle progression. The
inhibition of mTOR prevents mitogen-induced downregulation
of p27Kip1.8,9 In addition, smooth muscle cell proliferation is
shown to be inhibited by rapamycin-FKBP12 in p27Kip1(-/-)
knockout mice, suggesting that neointimal inhibition may also
operate via a pathway that is independent of p27Kip1.8 Human
neointimal tissue extracted during atherectomy exhibited a
peculiar upregulation of FKBP12 at mRNA and protein levels,
indicating the potential for sirolimus in preventing coronary
restenosis.10
Systemic and local administration of sirolimus in porcine
models of restenosis have been shown to significantly reduce
neointimal hyperplasia.11,12 Sirolimus-eluting stents have been
first implanted in patients with coronary disease in the pioneer
First-In-Man experience, which included 45 patients with
relatively non-complex de novo lesions treated between
December 1999 and February 2000.13-18 Patients were treated
in São Paulo, Brazil (n=30), and Rotterdam, The Netherlands
(n=15) and received sirolimus-eluting stents in 2 formulations.
Both formulations contained 140 µg of sirolimus per cm2, but
with different delivery kinetics (fast-release formulation [<15-
day drug release], or slow release formulation [>28-day drug
release]). Angiographic in-stent restenosis was not detected in
any case up to 2 years and only one case had a 52% diameter
stenosis proximal to the stent.13,18 Two-year intravascular
ultrasound examination showed only minimal neointimal
proliferation, with 6.3±5.5% percent intimal hyperplasia
within the stent in the fast release group (São Paulo),
7.5±7.3% in the slow-release group (São Paulo), and 4.4±3.1%
in the slow-release group Rotterdam.13,18 Moreover, the 2-
year event-free survival was 90.1%, with no extra major events
occurring between 2 and 3 years.16
Four randomized trials comparing the outcomes of patients
treated with sirolimus-stents and conventional bare stents
have been concluded to date, and are summarized in Tables 3,
4, 5, 6, and 7).19-23 The Randomized Study with the Sirolimus-
Eluting Bx Velocity Balloon-Expandable Stent in the Treatment
of Patients with de novo Native Coronary Artery Lesions
(RAVEL) trial included 238 patients with single non-complex de
novo lesions. At six months follow-up, the angiographic
restenosis rate of the treated group was zero, the loss in
minimal lumen diameter was zero. The clinical outcomes were
significantly better among patients treated with sirolimus
stents, with 94% of patients being free of any major cardiac
events at 1 year (compared to 71% in the bare stent group;
p<0.01).20 Recently, data from the RAVEL trial with a more
prolonged follow-up period have shown maintenance of the
initial results, with a 2-year event-free survival of 90%.19
The subsequent SIRolImUS-Eluting Bx Velocity™ Balloon-
Expandable Stent (SIRIUS) trial, which randomized 1101
patients with de novo lesions to sirolimus or bare stents,
confirmed the clinical efficacy of sirolimus-eluting stents.21 In-
stent binary restenosis (within the margins of the stent) was
reduced by 91% (3.2% vs. 35.4%; p<0.01) and in-segment
restenosis (including the stented portion and the 5mm
segments proximal and distal to the stent) was reduced by 75%
(8.9% vs. 36.3%; p<0.01).21 At 9 months, the incidence of
major adverse events was significantly lower in the sirolimus
group (7.1% vs. 18.9%; p<0.01), mainly due to a decrease in
the need of target lesion revascularization (4.1% vs. 16.6%;
p<0.01). Prolonged follow-up data (up to 2 years) were
recently presented and showed sustained benefit of sirolimus-
eluting stent implantation in the SIRIUS trial.24 The recently
published E-SIRIUS trial has enrolled 352 patients with longer
lesions and smaller vessels than the RAVEL and SIRIUS trials.23
Nevertheless, the 8-month in-stent restenosis rate was 3.9% in
the sirolimus and 41.7% in the bare stent group (p<0.01).
Similarly, the incidence of in-segment restenosis (5-mm edges
included) was significantly reduced (5.9% vs. 42.3%; p<0.01).
The 9-month incidence of major cardiac events was 8% vs.
22.6% in the sirolimus and bare groups (p<0.01). Similarly, in
the C-SIRIUS trial, which randomized 100 patients to sirolimus
or conventional stenting, in-segment restenosis was not
detected in any patient after sirolimus-eluting stent implan-
tation.22 Differently from the previous trials, in the C-SIRIUS
direct stenting was allowed (at the discretion of the operator),
which did not affect the incidence of restenosis (i.e. zero
restenosis rate in patients treated with pre-dilatation or direct
stenting). Intravascular ultrasound examination at follow-up
further confirmed the marked neointimal inhibition after
sirolimus-eluting stent implantation. In the RAVEL trial, the
percent neointimal obstruction at 8 months was 1 ± 3% in the
sirolimus group versus 29 ± 20% in the bare group (p<0.001).25
Also, in the SIRIUS study, sirolimus-eluting stents were
associated with a significant reduction of in-stent percent
obstruction (3.1 % vs. 33.4%; p<0.001).21
Subgroup analysis of patients included in the RAVEL and
SIRIUS have shown that the overall benefit of sirolimus-
eluting stents was also observed across many subsets of
patients and lesion types.21,26 However, in the SIRIUS trial,
post-sirolimus restenosis was significantly increased in
diabetics, long lesions, and small vessels. Indeed, post-
sirolimus restenosis has been shown to frequently occur in
association with higher complexity characteristics.27 The
impact of sirolimus-eluting stents for the treatment of more
complex lesions has been addressed in recently released
studies evaluating some patient subgroups not enrolled in the
early randomized trials (Table 8).
The Rapamycin Eluting Stent Evaluated At Rotterdam Cardiology
Hospital study (RESEARCH) was a single-center registry which
included patients treated with SES according to a non-restrictive
inclusion criterion. Virtually all consecutive patient subsets were
considered eligible. Long-term (12-month) outcomes of the first
508 patients with de novo lesions treated exclusively with SES
                     drug-eluting stents 
151
Table 3. Randomized trials comparing bare metal stents with polymer-coated sirolimus- or paclitaxel-eluting stents
- Study characteristics
Study groups Design Inclusion criteria Exclusion criteria Antiplatelet
SIROLIMUS
RAVEL19,20,26 Polymer-coated randomized de novo lesion total occlusion Aspirin lifelong
sirolimus-eluting double-blind native vessel ostial Clopidogrel for 2 months
stent (n=120 pts) single lesion thrombus containing lesion
Bare stent (n=118 pts) lesion length < 18 mm unprotected LMC with >50% stenosis
vessel diameter 3 - 3.5mm evolving myocardial infarction
left ventricular ejection fraction <30%
SIRIUS21 Polymer-coated randomized de novo lesion total occlusion Aspirin lifelong
sirolimus-eluting double-blind native vessel ostial Clopidogrel for 3 months
stent (n=533 pts) single lesion thrombus containing lesion
Bare stent (n=525 pts) lesion length 15 - 30 mm unprotected LMC with >50% stenosis
vessel diameter 2.5 - 3.5mm myocardial infarction < 48 hours
left ventricular ejection fraction <25%
bifurcation
multivessel stenting
E-SIRIUS23 Polymer-coated randomized de novo lesion total occlusion Aspirin lifelong
sirolimus-eluting double-blind native vessel ostial Clopidogrel for 2 months
stent (n=175 pts) single lesion thrombus containing lesion
Bare stent (n=177) lesion length 15 - 32 mm unprotected LMC with >50% stenosis
vessel diameter 2.5 - 3.0mm evolving myocardial
left ventricular ejection fraction 
<25%infarction
bifurcation
multivessel stenting
C-SIRIUS22 Polymer-coated randomized Single de novo coronary total occlusion Aspirin lifelong
sirolimus-eluting double-blind lesion Recent MI (< 24 hours) Clopidogrel for 2 months
stent (n=50 pts) Stable or unstable angina Unprotected LM disease
Bare stent (n=50 pts) or documented silent ischemia Ostial location
Lesion length 15 - 32 mm Angiographic evidence of thrombus
Vessel diameter 2.5 - 3.0 mm Pretreatment with devices 
other than balloon
LV ejection fraction < 25%
PACLITAXEL (polymer-coated)
TAXUS I32 Polymer-coated randomized Single lesion, single stent total occlusion Aspirin for at 
slow-release double-blind Restenotic or de novo lesions acute myocardial infarction least 12 months
paclitaxel-eluting lesion length ≤12 mm left ventricular ejection fraction <30% Clopidogrel for 6 months
stent (n=31 pts) vessel diameter 3.0 - 3.5mm stroke < 6 months
Bare stent (n=30 pts)
TAXUS II31 Polymer-coated randomized Single lesion, single stent total occlusion Aspirin lifelong
slow-release double-blind Native vessel evolving myocardial infarction Clopidogrel for 
paclitaxel-eluting De novo lesions unprotected LMC with >50% stenosis at least 6 months
stent (n=131 pts) lesion length ≤12 mm left ventricular ejection fraction <30%
Bare stent control vessel diameter 3.0 - 3.5mm coronary intervention < 30days
for SR-paclitaxel (n=136 pts)
Polymer-coated 
moderate-release 
paclitaxel-eluting 
stent (n=135 pts)
Bare stent control for 
MR-paclitaxel (n=137 pts)
TAXUS III33 Polymer-coated series of cases Single lesion, single stent total occlusion Aspirin lifelong
slow-release Native vessel evolving myocardial infarction Clopidogrel for 6 months
paclitaxel-eluting stent In-stent restenosis lesions left ventricular ejection fraction <30%
(n=28 pts) lesion length ≤30 mm stroke < 6 months
TAXUS IV34,35 Polymer-coated randomized Single de novo lesions total occlusion Aspirin lifelong
moderate-release double-blind Length 10 - 28 mm Prior intervention in the target Clopidogrel for 6 months
paclitaxel-eluting vessel diameter 2.5 -3.75mm vessel < 9 months
stent (n=662 pts) myocardial infarction < 72 hours
Bare stent control ostial
for MR-paclitaxel (n=652 pts) bifurcation
NA=not available; pts=patients
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Table 4. Randomized trials comparing bare metal stents with polymer-coated sirolimus- 
or paclitaxel-eluting stents - Patient characteristics
diabetics (%) AMI admission (%) Multivessel disease (%) LAD (%) LM (%)
SIROLIMUS
RAVEL19,20,26
Sirolimus 16 0 NA 49 0
Bare stent 21 0 NA 51 0
SIRIUS21
Sirolimus 25 0 42 44 0
Bare stent 28 0 41 43 0
E-SIRIUS23
Sirolimus 19 0 NA 57 0
Bare stent 27 0 NA 56 0
C-SIRIUS22
Sirolimus 24 0 NA 36 0
Bare stent 24 0 NA 40 0
PACLITAXEL (polymer-coated)
TAXUS I32
Paclitaxel 23 0 NA 55 0
Bare stent 13 0 NA 27 0
TAXUS II31
Paclitaxel-SR 11 0 NA 40 0
Bare stent-SR 16 0 NA 44 0
Paclitaxel-MR 17 0 NA 42 0
Bare stent-MR 14 0 NA 52 0
TAXUS III33 14 0 25 36 4
TAXUS IV34,35
Paclitaxel 23 0 NA 40 0
Bare stent 25 0 NA 41 0
Table 5. Randomized trials comparing bare metal stents with polymer-coated sirolimus-
or paclitaxel-eluting stents - Procedural characteristics
IIbIIIa (%) ACC/AHA Lesion ISR Mehran Chronic total Stents/pt (%) Bifurcation
type C (%) Class III or IV4 (%) occlusion (%) stenting (%)
SIROLIMUS
RAVEL19,20,26
Sirolimus 10.1 0 - 0 1.0 ± 0.3 0
Bare stent 9.5 0 - 0 1.1 ± 0.3 0
SIRIUS21
Sirolimus 60 26 - 0 1.4 ± 0.7 0
Bare stent 59 21 - 0 1.4 ± 0.6 0
E-SIRIUS23
Sirolimus 14 NA - 0 * 0
Bare stent 18 NA - 0 * 0
C-SIRIUS22
Sirolimus 58 30 - 0 1.38 ± 0.57† 0
Bare stent 48 16 - 0 1.66 ± 0.94 0
PACLITAXEL (polymer-coated)
TAXUS I32
Paclitaxel NA 0 NA 0 NA 0
Bare stent NA 0 NA 0 NA 0
TAXUS II31
Paclitaxel-SR 12 NA 0 0 ‡ 0
Bare stent-SR 13 NA 0 0 ‡ 0
Paclitaxel-MR 21 NA 0 0 ‡ 0
Bare stent-MR 24 NA 0 0 ‡ 0
TAXUS III33 NA - 18 4 1.5 ± 0.5 0
TAXUS IV34,35
Paclitaxel 58 20 - 0 1.08 ± 0.29 0
Bare stent 57 22 - 0 1.09 ± 0.36 0
ISR=in-stent restenosis; MR=moderate release; NA=not available; SR=slow-release
* overlapping stents in 34% (sirolimus) vs. 31% (bare stent), † p<0.05 vs. control , ‡ One study stent was implanted in 93% of pacltaxel-SR
patients and in 94% of the remaining groups
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Table 6. Randomized trials comparing bare metal stents with polymer-coated sirolimus- or paclitaxel-eluting stents - Quantitative
Angiography Analysis
Pre-procedure Post-procedure Follow-up
RD length DS MLD time DS MLD Restenosis Late loss
(mm ± SD) (mm ± SD) (% ± SD) (mm ± SD) (months) (% ± SD) (mm ± SD) (%) (mm ± SD)
SIROLIMUS
RAVEL19,20,26*
Sirolimus 2.60±0.54 9.56±3.33 11.9±5.9‡ 2.43±0.41 6 14.7±7.0 ‡ 2.42±0.49 ‡ 0 ‡ -0.01±0.33 ‡
Bare stent 2.64±0.52 9.61±3.18 14.0±6.8 2.41±0.40 6 36.7±18.1 1.64±0.59 26.6 0.80±0.53
SIRIUS21 †
Sirolimus 2.79±0.45 14.4±0.58 16.1±9.7 2.38±0.45 8 23.6±16.4 ‡2.15±0.61 ‡ 8.9 ‡ 0.24±0.47 ‡
Bare stent 2.81±0.49 14.4±0.58 16.2±8.5 2.4±0.46 8 43.2±22.4 1.60±0.72 36.3 0.81±0.67
E-SIRIUS23 †
Sirolimus 2.60±0.37‡ 14.9±5.4 18.2±9.6 2.17±0.39 8 24.7±14.7 ‡1.97±0.48 ‡ 5.9 ‡ 0.19±0.39 ‡
Bare stent 2.51±0.37 15.1±6.5 18.0±9.1 2.10±0.39 8 48.3±23.4 1.29±0.61 42.3 0.80±0.57
C-SIRIUS22*
Sirolimus 2.65±0.30 14.5±6.3 6.1±9.1 2.53±0.30 8 20.5±10.3 2.15±0.35‡ 2.3‡ 0.09±0.31‡
Bare stent 2.62±0.35 12.6±5.2 5.6±10.6 2.50±0.28 8 47.8±24.5 1.39±0.69 52.3 0.79±0.74
PACLITAXEL (polymer-coated)
TAXUS I32*
Paclitaxel 2.99±0.46 10.70±3.27 6.12±9.49 2.95±0.34 6 13.56±11.77‡2.60±0.49‡ 0 0.36±0.48‡
Bare stent 2.94±0.52 11.89±4.93 9.84±7.06 2.87±0.43 6 27.23±16.69 2.19±0.65 10 0.71±0.47
TAXUS II31 †
Paclitaxel-SR 2.78±0.44 10.6±3.9 23.1±9.3 2.15±0.37 6 26.8±12.8‡ 2.01±0.46‡ 5.5‡ 0.31±0.38‡
Bare stent-SR 2.77±0.49 10.5±4.1 21.2±8.4 2.23±0.43 6 35.1±15.1 1.70±0.49 20.1 0.79±0.45
Paclitaxel-MR 2.72±0.46 10.2±4.8 21.5±8.0 2.20±0.39 6 26.8±13.1‡ 2.00±0.48‡ 8.6‡ 0.30±0.39‡
Bare stent-MR 2.73±0.45 10.7±4.1 22.0±9.0 2.20±0.40 6 37.1±17.8 1.66±0.56 23.8 0.77±0.50
TAXUS III33*§ 2.84±1.25 13.61±6.36 16.9±7.6 2.41±0.46 6 26.9±18.6† 1.93±0.61 4.5 0.47±0.48
TAXUS IV34,35 †
Paclitaxel 2.76±0.48 14.4±6.7 19.1±9.5 2.26±0.48 9 26.3±15.5‡ 2.03±0.55‡ 7.9‡ 0.23±0.44‡
Bare stent 2.79±0.48 14.4±7.1 19.1±9.9 2.29±0.49 9 39.8±18.5 1.68±0.61 26.6 0.61±0.57
* In-stent quantitative coronary angiography, † In-segment quantitative coronary angiography (includes the 5-mm proximal and distal edges)
‡ p<0.05 vs. control, § excludes patients with restenosis in a bare stent or in a gap between the paclitaxel-eluting stents
Table 7. Randomized trials comparing bare metal stents with polymer-coated sirolimus- or paclitaxel-eluting stents - Clinical Outcomes
Study Follow-up Death (%) Myocardial Repeat Any event (%) Stent 
(months) infarction (%) revascularization (%) thrombosis (%)
SIROLIMUS
RAVEL19,20,26 12
Sirolimus 1.7 3.3 0* 5.8* 0
Bare stent 1.7 4.2 22.9 28.8 0
SIRIUS21 9
Sirolimus 0.9 2.8 3.8* 7.1* 0.4
Bare stent 0.6 3.2 15.8 18.9 0.8
E-SIRIUS23 9
Sirolimus 1.1 4.6 4.0* 8.0* 1.1
Bare stent 0.6 2.3 20.9 22.6 0
C-SIRIUS22 9
Sirolimus 0 2 4 4 0
Bare stent 0 4 18 18 2
PACLITAXEL (polymer-coated)
TAXUS I32 24
Paclitaxel 0 0 3 3 0
Bare stent 0 0 10 10 0
TAXUS II31 12
Paclitaxel-SR 0 2.3 10.1* 10.9* 0.7 †
Bare stent-SR 1.5 5.1 15.9 22.0 0
Paclitaxel-MR 0 3.7 6.9* 9.9* 0 †
Bare stent-MR 0 5.2 19.1 21.4 0
TAXUS III33 12 0 3.6 21.4 29.0 0
TAXUS IV34,35 12
Paclitaxel 1.4 3.5 6.8* 10.6* 0.6
Bare stent 1.2 4.6 16.7 19.8 0.8
* p<0.05 vs. control, † rates of angiographically documented stent thrombosis
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were compared with 450 patients treated with bare stents in the
period just prior to the introduction of drug-eluting stents.28
Only 2 (0.4%) presented with thrombotic stent occlusion in the
first month after the procedure, while the stent thrombosis rate
in the bare stent group was 1.6% (p=0.1). There were no further
thrombotic events up to one year. Sirolimus-eluting stents
reduced by 38% the 1-year risk of major cardiac events (9.7% vs.
14.8%; p<0.01), mainly due to a risk reduction of 65% in clini-
cally driven repeat intervention (3.7% vs. 10.9%; p<0.01).
Importantly, approximately 68% of patients included in the
registry would have been excluded from the earlier clinical trials
(e.g. patients with previous coronary surgery, patients admitted
with acute myocardial infarction, and those with multivessel
stenting, among other characteristics).
Paclitaxel
Paclitaxel was originally isolated from the bark of the Pacific
Yew. It is an antineoplastic agent that is currently used to treat
several types of cancer, most commonly breast and ovarian
cancer. Paclitaxel exerts its pharmacological effects through
formation of numerous decentralized and unorganized micro-
tubules. This enhances the assembly of extraordinarily stable
microtubules, interrupting proliferation, migration and signal
transduction.29,30 Unlike other anti-proliferative agents of the
colchicine type, which inhibit microtubuli assembly, paclitaxel
shifts the microtubule equilibrium towards microtubule
assembly. It is highly lipophylic, which promotes a rapid
cellular uptake, and has a long-lasting effect in the cell due to
the structural alteration of the cytoskeleton.
Stent-based paclitaxel has been investigated by several
groups, using different stent types and preparations
(copolymer coatings for paclitaxel elution31-35 or direct dip-
coating of paclitaxel on a stainless steel stent).36-39 Clinical
studies utilizing direct dip-coating of paclitaxel stents are
summarized in Tables 9 and 10. Contradictory clinical results
have been obtained with these devices. While the European
Evaluation of Paclitaxel Eluting Stent trial (ELUTES)36 and
the ASian Paclitaxel-Eluting stent Clinical Trial (ASPECT)37
have shown a significant, dose-dependent reduction in
restenosis with paclitaxel stents, the larger RX Achieve™
Drug-Eluting Coronary Stent System In the Treatment of
Patients With de novo NativE CoronaRy Lesions (DELIVER-I)
study failed in demonstrating the beneficial effect of these
devices.
Clinical studies utilizing polymer-coated paclitaxel-eluting
stents are summarized in Tables 3, 4, 5, 6, and 7.31-35 In total,
more than 1,900 patients with de novo lesions have been
enrolled in the TAXUS I,32 II,31 and IV trials34,35 and
randomized to paclitaxel or bare stents. A marked reduction in
neointimal proliferation and binary restenosis was observed in
the active groups, leading to 12-month target lesion revascu-
larization rates that ranged from 0 to 6.8% with paclitaxel
stents, which was significantly lower than in controls (TLR
rates from 10.0 to 16.7%).31,32,34,35 Multivariate analysis from
patients included in the TAXUS IV trial34,35 have identified
several multivariate predictors of 9-month target lesion revas-
cularization. Apart from utilization of bare stents (OR 4.58
[95% CI: 2.64, 7.95]; p<0.0001), other independent predictors
were: diabetes (1.78 [95% CI: 1.10, 2.88]; p=0.02), increase in
stent length (1.04 [95% CI: 1.01, 1.07]; p=0.006), decrease in
acute gain (2.08 [95% CI: 1.11, 3.88]; p=0.02), and lesion
angulation (0.98 [95% CI: 0.97, 0.99]; p<0.03). Polymer-
coated paclitaxel-eluting stents were shown to be safe, with
rates of subacute stent thrombosis similar to those seen in the
bare stents (Table 7).
Table 8. Sirolimus-eluting stents for complex subsets
Design Restenosis (%) Late loss (mm) TVR (%)
SIRIUS bifurcation52*§ Randomized: Sirolimus+sirolimus (MV): 6.0 0.27±0.47 Sirolimus+sirolimus: 11.1
MV stenting + SB stenting (n=43 pts) Sirolimus+sirolimus (SB): 24.0 0.52±0.60
vs. MV stenting + SB balloon (n=43 pts)Sirolimus+balloon (MV): 6.2 0.14±0.24 Sirolimus+balloon: 4.5
Sirolimus+balloon (SB): 18.7 0.27±0.38
Degertekin53 † || Series of cases with ISR (n=16 pts) 13.3 0.26±0.67 6.3
Sousa54 ‡ ¶ Series of cases with ISR (n=25 pts) 4.0 0.16±0.42 0
Saia 55 * || Series of cases with 40 0.68±1.20 33.3
post-brachytherapy ISR (n=12 pts)
RESEARCH AMI56 *§ Series of cases with ST 0 -0.04±0.25 0
elevation AMI (n=96 pts)
RESEARCH de novo28 ¶ Consecutive cases treated in 2 phases: - - Bare stent: 10.9
bare stents (n= n=450 pts) Sirolimus: 3.7
vs. sirolimus (508 pts)
ISR=in-stent restenosis; MI=myocardial infarction; MV=main vessel; SB=side branch; TVR=target vessel revascularization
* angiographic follow-up at 6 months, † angiographic follow-up at 4 months, ‡ angiographic follow-up at 12 months, § clinical follow-up at 6 months,
|| clinical follow-up at 9 months, ¶ clinical follow-up at 12 months.
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Table 9. Clinical Studies with Dip-Coated Paclitaxel-eluting Stents - Study Design
Study groups Design Inclusion criteria
ELUTES36 2.7 µg/mm2 paclitaxel- (n=37 pts) randomized de novo lesion
1.4 µg/mm2 paclitaxel (n=39 pts) native vessel
0.7 µg/mm2 paclitaxel (n=39 pts) single lesion
0.2 µg/mm2 paclitaxel (n=37 pts)
Bare stent (n=38 pts)
ASPECT37 3.1 µg/mm2 paclitaxel (n=60 pts) randomized Single lesion
1.3 µg/mm2 paclitaxel (n=58 pts) lesion length <15 mm
Bare stent (n=59 pts) vessel diameter 2.5 - 3.5mm
DELIVER I 38 3.0 µg/mm2 paclitaxel (n=522 pts) randomized Up to 2 native vessels treated (1 target and 1 non-target,
Bare stent (n=519 pts) with only 1 de novo lesion per vessel)
lesion length <25 mm
vessel diameter 2.5 - 4.0 mm
DELIVER II39 3.0 µg/mm2 paclitaxel (n=1531 pts) series of cases One of the following:
- 1 target lesion: length < 25 mm, chronic total 
or subtotal occlusion, restenotic, or in a bifurcation site
- 1 target lesion: length > 25 mm, de novo,
chronic total or subtotal occlusion, restenotic, 
or involving a bifurcation site
- 2 target lesions: length < 25 mm, de novo,
chronic total or subtotal occlusion, restenotic, 
or in a bifurcation site
CTO=chronic total occlusion; NA=not available; pts=patients
Table 10. Clinical Studies with Dip-Coated Paclitaxel-eluting Stents - Angiographic and Clinical Outcomes
Restenosis Late loss Clinical follow-up Death (%) Myocardial Target vessel Any event Stent
(%) (mm ± SD) (months) infarction (%) revascularization (%) thrombosis
(%) (%)
ASPECT37* † 6
3.1 µg/mm2 paclitaxel 4‡ 0.29±0.72‡ 0 3.4 1.7 10 5.1
1.3 µg/mm2 paclitaxel 12‡ 0.57±0.71‡ 1.7 1.7 1.7 7 1.7
Bare stent 27 1.04±0.83 0 1.7 1.7 5 0
ELUTES36 § 12
2.7 µg/mm2 paclitaxel 3.1 0.10±0.12 ‡ 2.7 2.7 5.4 14 2.7
1.4 µg/mm2 paclitaxel 13.5 0.47±0.11 0 0 10.3 10 0
0.7 µg/mm2 paclitaxel 11.8 0.47±0.12 0 0 7.7 10 0
0.2 µg/mm2 paclitaxel 20.0 0.72±0.12 0 0 5.4 5 0
Bare stent 20.6 0.73±0.12 0 0 15.8 18 2.6
DELIVER I38 * || 12
3.0 µg/mm2 paclitaxel 16.7 0.43‡ 0.2 1.4 6.2 7.5 0.4
Bare stent 22.4 0.56 0.8 1.0 6.8 9.4 0.4
DELIVER II39 - - 6 2.3 4.9 9.6 15.7 NA
NA=not available
* In-segment quantitative coronary angiography (includes the 5-mm proximal and distal edges)
† all stent thrombosis events occurred in patients on aspirin and cilostazol (instead of aspirin and ticlopidin/clopidogrel)
‡ p<0.05 vs. control
§ In-stent quantitative coronary angiography
|| available for 228 pts in the paclitaxel group and fro 214 controls
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The WISDOM registry is a post-marketing registry conducted
with the objective of evaluating unselected patients treated
with paclitaxel stents in the “real world”. Preliminary results of
this multinational registry on approximately 1,000 patients
have been presented in the AHA annual meeting in November
2003 and confirmed the 30-day safety of paclitaxel-eluting
stents in more complex patients, with only 0.4% of patients
presenting stent thrombosis.
Other Drugs
To date, sirolimus- and paclitaxel-eluting stents have the most
extensive accumulated clinical experience and are the only
drug-eluting stents commercially available for clinical use.
However, a myriad of new devices have been recently tested
and are currently in various stages of development for clinical
use. New drug-eluting stents that have been already evaluated
in preliminary clinical studies are summarized in Table 11.
Several analogues of sirolimus have been investigated.
Limitations
A late “catch up” phenomenon has been described after
implantation of a high dose (800 µg) paclitaxel derivative
QP2-eluting stent, with the restenosis rate increasing from
13% at 6 months to 62% at 12 months.40,41 However, long-term
efficacy should be evaluated separately for each drug-eluting
stent assembly, since a “class-effect” is unlikely for these
devices and each platform/vehicle/agent complex should be
evaluated separately. To date, the sirolimus-eluting stent has
the largest body of long-term data available. The First In Man
study has shown persistent positive results up to 2 and 3 years,
without any evidence of late catch-up restenosis.16,18 In the
RAVEL19 and SIRIUS24 trials, no further events due to restenosis
were observed up to 2 years. With paclitaxel, no rebound effect
was seen from 6 to 12 months in TAXUS-I,32 TAXUS II,31
TAXUS IV,34,35 ELUTES,36 and ASPECT37 trials.
In the RAVEL trial, stent malapposition (as observed by
intravascular ultrasound) was more frequent at 6 months in
Table 11. Clinical studies with new drug-eluting stents
design inclusion criteria Study groups Restenosis Late loss
(%) (mm)
EVELOLIMUS
FUTURE I trial57 randomized (2:1) Single de novo lesions Bioabsorbable polymer-coated 0 0.11*
single-blind Length <18 mm everolimus-eluting stent (n=27 pts)
vessel diameter 2.75 -4.0mm Bare stent control for 9.1 0.85
MR-paclitaxel (n=15 pts)
FUTURE II trial57 randomized (1:2) Single de novo lesions Bioabsorbable polymer-coated 0 0.12*
single-blind Length <18 mm everolimus-eluting stent (n=21 pts)
vessel diameter 2.75 -4.0mm Bare stent control for MR-paclitaxel 19.4 0.85
(n=43 pts)
17E-ESTRADIOL
EASTER trial series of cases Single, de novo lesions Phosphorylcholine-coated 6.6 0.31
estrogen-eluting stent (2.54 µg/mm2)
(n=30 pts)
Vessel size 3.0 mm to 4.0 mm
DEXAMETHASONE
STRIDE trial series of cases Single, de novo lesions BiodivYsioMatrix LO stent immersed 13.3 0.45
in dexamethasone solution (15mg/ml)
(n=71 pts)
Vessel size 2.75 mm to 4.0 mm
ABT-578
ENDEAVOR trial series of cases Single, de novo lesions Phosphorylcholine-coated Driver NA 0.20
cobalt alloy stent (n=100 pts)
Vessel size 3.0 mm to 3.5 mm
Nitic Oxide drug-elution
NOBLESSE trial series of cases Single, de novo lesions Bioabsorbable polyesteramide-coated 9.5 0.69
Genic stent with oxigen free scavenger
covalently bounded (n=45 pts)
Vessel size 2.75 mm to 3.5 mm
*p<0.05 compared to controls
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sirolimus-eluting stent patients than in the control arm25.
Moreover, in SIRIUS42 late acquired stent malapposition was
more commonly observed in the sirolimus group. However, in
TAXUS-II31 patients treated with bare stents or paclitaxel-
eluting stents there were similar rates of late-acquired malap-
position. Nevertheless, these observations of late
malapposition by ultrasound have not been associated with
any adverse events throughout the follow-up period in any of
these studies.25,31,42-44 Also, late thrombotic stent occlusion
was not seen to be more frequent in patients treated with
sirolimus- or paclitaxel eluting stents, even after clopidogrel
discontinuation.
The costs of currently marketed drug-eluting stents (i.e.
sirolimus- and paclitaxel-eluting stents) have been perceived as
a major limitation for a more widespread use of these devices.
In an analysis from the RAVEL trial, the utilization of the
sirolimus-eluting stent resulted in a mean additional procedural
cost of 1,286 €, as compared to the control group based on
costs in the Netherlands.45 However, due to the decrease in re-
interventions attributable to the sirolimus-eluting stent at the
end of the first year of follow-up the estimated cost difference
had decreased to 54€. In other words, in the RAVEL trial the
reduction of major event risk from 28.8% to 5.8% after
sirolimus-eluting was accomplished at an extra cost of 54€ per
patient. Moreover, data from the the SIRIUS trial have shown
that at 1 year the costs of sirolimus-eluting stent implantation
were approximately US$ 300 higher per patient. In the SIRIUS,
investigators have reported a ratio of approximately US$1700
per repeat revascularization avoided, which has been
considered to compare favorably with other medical treatments
for patients with cardiovascular disease.46 Obviously, the cost
and effect estimations derived from the RAVEL and SIRIUS trial
cannot be directly extrapolated to other situations and formal
analyses from other clinical scenarios are warranted.
Future Directions
As restenosis rates are still not “zero” in the real world of inter-
ventional cardiology, the search for and testing of new drugs
will continue. Next to newer drugs and optimalization of the
drug carrier, other methods are currently being investigated to
locally treat the injured vessel wall. For example, stent-based
delivery of adenoviral gene vectors was recently achieved in
vitro and in carotid arteries of rats. Though stent-based local
gene delivery has not entered the clinical arena yet, it will be
possible very soon and give a lot of new opportunities to
attack coronary artery disease and the problems of restenosis.
Another possibility to contain the detrimental effects of vessel
wall injury after percutaneous interventions is to restore the
integrity of the endothelial cell lining as soon as possible. This
way, the attraction of inflammatory cytokines as well as
activated platelets and macrophages can be limited.
The most logical way to accomplish this is endothelial cell
seeding of the stent. The problems of sterilization, mechanical
stretch during implantation and endothelial cell viability have
been the major limitations in this approach. Recently, a
method has been developed to coat a stent with antibodies to
CD-34 receptors on progenitor endothelial cells. In this way
circulating endothelial cells can be captured from the circu-
lation and provide an early re-endotheliazation on the stent
surface. After promising animal data showing a confluent layer
of endothelial cells very early after stenting, clinical pilot trials
are on-going.
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Short- and Long-Term Clinical Benefit of Sirolimus-
Eluting Stents Compared to Conventional Bare
Stents for Patients With Acute Myocardial Infarction
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Willem J. van der Giessen, MD, PHD, Pim de Feyter, MD, PHD, FACC, Ron T. van Domburg, PHD,
Patrick W. Serruys, MD, PHD, FACC
Rotterdam, The Netherlands
OBJECTIVES This study investigated the clinical outcomes of patients with ST-segment elevation
myocardial infarction (MI) treated with sirolimus-eluting stents (SESs) or with conventional
bare stents.
BACKGROUND The clinical impact of SES implantation for patients with ST-segment elevation MI is
currently unknown.
METHODS Primary angioplasty was performed with SESs in 186 consecutive patients with acute MI who
were compared with 183 patients treated with bare stents. The incidence of death,
reinfarction, and repeat revascularization was assessed at 30 and 300 days.
RESULTS Postprocedure vessel patency, enzymatic release, and the incidence of short-term adverse
events were similar in both the sirolimus and the bare stents (30-day rate of death,
reinfarction, or repeat revascularization: 7.5% vs. 10.4%, respectively; p  0.4). Stent
thrombosis was not diagnosed in any patient in the sirolimus group and occurred in 1.6% of
patients treated with bare stents (p  0.1). At 300 days, treatment with SESs significantly
reduced the incidence of combined adverse events (9.4% vs. 17%; hazard ratio [HR] 0.52
[95% confidence interval (CI) 0.30 to 0.92]; p  0.02), mainly due to a marked reduction in
the risk of repeat intervention (1.1% vs. 8.2%; HR 0.21 [95% CI 0.06 to 0.74]; p  0.01).
CONCLUSIONS Compared to conventional bare stents, the SESs were not associated with an increased risk
of stent thrombosis and were effective in reducing the incidence of adverse events at 300 days
in unselected patients with ST-segment elevation acute MI referred for primary
angioplasty. (J Am Coll Cardiol 2004;43:704–8) © 2004 by the American College of
Cardiology Foundation
Routine stent implantation has been advocated for patients
with acute myocardial infarction (MI) referred for primary
angioplasty, with superior results compared to balloon
dilation (1–3). However, the late clinical efficacy is still
hampered by the occurrence of in-stent restenosis and the
need for repeat intervention.
Sirolimus-eluting stents (SESs) have proven to be effec-
tive in reducing late restenosis compared to conventional
stenting in elective patients (4–6). We have recently shown
in a relatively small consecutive series of cases that SES
implantation in patients with acute MI was safe and
associated with an extremely low (zero) incidence of angio-
graphic restenosis at six months (7). However, the clinical
benefit of SESs in comparison to conventional stent im-
plantation remains currently unknown. Therefore, we eval-
uated the long-term clinical outcomes of a large series of
patients with acute MI treated with primary angioplasty
utilizing either SESs or conventional metal stents.
METHODS
Since April 2002, SES implantation (Cypher, Johnson &
Johnson-Cordis unit, Cordis Europa NV, Roden, The
Netherlands) has been utilized as the strategy of choice for
patients treated with percutaneous intervention in our in-
stitution (8). Up until January 2003, a total of 186 consec-
utive patients with ST-segment elevation acute MI have
been treated with primary angioplasty utilizing exclusively
SESs and were included in the present report. The first 89
patients of the present series were included in an angio-
graphic substudy, of which the results have been reported
previously (7). A control group for comparison was com-
posed of 183 consecutive patients with ST-segment eleva-
tion acute MI treated with conventional bare stents in the
period immediately before the introduction of SESs. The
following bare metal stents were used: BX Sonic or BX
Velocity in 53% (Cordis, Johnson & Johnson, Warren, New
Jersey); Multi-Link Penta in 22% (Guidant Corp., Santa
From the Erasmus Medical Center, Thoraxcenter, Rotterdam, Netherlands.
Supported by the Erasmus Medical Center, Rotterdam, The Netherlands, and by an
unrestricted institutional grant from Cordis, a Johnson & Johnson Company, Miami
Lakes, Florida.
Manuscript received November 4, 2003; revised manuscript received November 20,
2003, accepted November 24, 2003.
Chapter 13 
164
Clara, California); Multi-Link Tetra in 6% (Guidant
Corp.); R-Stent in 6% (Orbus Medical Technologies, Fort
Lauderdale, Florida), and other stents in 12%. In both study
phases, all patients were enrolled regardless of the clinical or
anatomical presentation, including patients admitted with
cardiogenic shock (defined as persistent systolic blood pres-
sure90 mmHg, or the need of vasopressors or intra-aortic
balloon pumping required to maintain blood pressure 90
mm Hg with evidence of end-organ failure and elevated left
ventricular filling pressures). Therefore, the total study
population comprised all 369 consecutive patients with
ST-segment elevation acute MI undergoing primary angio-
plasty with either bare stents or SESs in the two study
phases, respectively. Patients with angioplasty after failed
thrombolytic therapy were excluded from the present anal-
ysis. This study protocol was approved by the local ethics
committee, and written informed consent was given by
every patient.
The final interventional strategy, as well as the utilization
of periprocedural glycoprotein IIb/IIIa inhibitors and anti-
thrombotic medications, was entirely left to the discretion of
the operator. Baseline and postprocedure anterograde flow
were evaluated off-line according to the Thrombolysis In
Myocardial Infarction (TIMI) criteria (9) by cardiologists
blinded to both the stent group and to the clinical outcomes.
Clopidogrel was recommended for at least one month in the
control group. In the SES group, clopidogrel was prescribed
for three months, unless one of the following was present (in
which case clopidogrel was maintained for at least six
months): multiple SES implantation (3 stents), total
stented length 36 mm, bifurcation stenting, and in-stent
restenosis.
Patients were prospectively followed for the occurrence of
major adverse cardiac events: 1) all-cause death, 2) nonfatal
MI, or 3) target vessel revascularization. Reinfarction was
diagnosed by recurrent symptoms and/or new electrocardio-
graphic changes in association with re-elevation of the
creatine kinase (CK) and CK-MB levels of 1.5 times the
previous value, if within 48 h, or3 times the upper normal
limit, if after 48 h from the index infarction (1,7). Target
vessel revascularization was defined as a repeat intervention
(surgical or percutaneous) driven by any lesion located in the
same epicardial vessel treated at the index procedure.
Thrombotic stent occlusion was angiographically docu-
mented as a complete occlusion (TIMI flow grade 0 or 1) or
a flow-limiting thrombus (TIMI flow grade 1 or 2) of a
previously successfully treated artery. Routine angiographic
follow-up was obtained only for patients treated with SESs
enrolled during the first six months; results of this subanaly-
sis have been previously reported (7).
Continuous variables were presented as mean  standard
deviation, and were compared using the Student unpaired t
test. Categorical variables were presented as counts and
percentages and compared with the Fisher exact test.
Survival free of adverse events was estimated using the
Kaplan-Meier method and differences between curves were
evaluated by the log-rank test. Cox proportional hazards
survival models were used to assess risk reduction. Multi-
variate analyses were performed to identify independent
predictors of long-term major adverse cardiac events. Base-
line and procedural characteristics associated with the inci-
dence of adverse events at univariate analysis (p value for
selection 0.2) were tested for their multivariate predictive
value (tested variables: SES utilization, diabetes, cardiogenic
shock, multivessel disease, culprit vessel, pre-procedure
TIMI flow, postprocedure TIMI flow, current smoking).
The final model was built by backward stepwise variable
selection with an entry and exit criteria set at the p  0.05
and p  0.1 levels, respectively.
RESULTS
Baseline characteristics were similar between both study
groups, except by an older age and a lower incidence of
previous MI in the sirolimus group (Table 1). Procedural
characteristics differed between both groups in terms of the
utilization of glycoprotein IIb/IIIa inhibitors (sirolimus:
37% vs. bare stents: 56%; p  0.01) and the number of
stents implanted (sirolimus: 1.9  1.2 vs. bare stents: 1.7 
1.0; p  0.03). As defined by the study protocol, the
duration of clopidogrel prescription was longer for patients
with sirolimus stents (Table 1).
No significant differences existed in the 30-day outcomes
between patients treated with sirolimus or bare stents (Table
2). Stent thrombosis was diagnosed in three patients (1.6%)
treated with bare stents and was not detected in the SES
group (p  0.1) (Table 2).
At 300 days, no differences were noted between both
study groups in the incidence of death and death or
reinfarction (Table 2). However, the incidence of 300-day
major adverse events was significantly lower in the sirolimus
stent group compared to the bare stent group (9.4% vs. 17%,
respectively; hazard ratio [HR] 0.52 [95% confidence inter-
val (CI) 0.30 to 0.92]; p  0.02) (Table 2, Fig. 1), mainly
due to a marked reduction in the risk of repeat intervention
(1.1% vs. 8.2%, respectively; HR 0.21 [95% CI 0.06 to
0.74]; p  0.01). A multivariate analysis was performed to
adjust for baseline and procedural imbalances between the
study groups (Table 3). Sirolimus-eluting stent utilization
was identified as an independent predictor of 300-day
death, reinfarction, or repeat revascularization (HR 0.53
[95% CI 0.29 to 0.95]; p  0.03).
Abbreviations and Acronyms
CI  confidence interval
CK  creatine kinase
HR  hazard ratio
MI  myocardial infarction
SES  sirolimus-eluting stent
TIMI  Thrombolysis In Myocardial Infarction
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DISCUSSION
The main finding of the present study was that SES
implantation was effective in reducing the incidence of
adverse events at 300 days in unselected patients with
ST-segment elevation acute MI, compared to conventional
bare stenting. Furthermore, the risk of subacute thrombosis
within the first 30 days did not appear higher compared
with bare metal stents. Sirolimus-eluting stents were asso-
Table 1. Baseline and Procedural Characteristics of Patients Treated With Bare Stents or SES
Implantation
Bare Stents
(n  183)
SES
(n  186) p Value
Male (%) 79 75 0.4
Age, yrs  SD 57  12 60  12 0.04
Diabetes (%) 12 11 0.9
Current smoking (%) 47 46 0.8
Previous myocardial infarction (%) 24 14 0.03
Previous angioplasty (%) 9 7 0.4
Previous bypass surgery (%) 3 2 0.3
Coronary disease 0.3
Single-vessel (%) 48 55
Double-vessel (%) 29 27
Triple-vessel (%) 24 18
Cardiogenic shock (%) 10 13 0.3
Time from symptom onset to angioplasty, h  SD 3.0  2.7 3.2  1.9 0.6
Infarct-related vessel 0.3
Right coronary artery (%) 30 37
Left anterior descending (%) 57 53
Left circumflex artery (%) 10 8
Left main coronary artery (%) 1 2
Bypass graft (%) 2 —
TIMI flow baseline 0.7
Grade 0/I (%) 73 73
Grade II (%) 15 17
Grade III (%) 13 10
TIMI flow after angioplasty 0.5
Grade 0/I (%) 4 2
Grade II (%) 17 15
Grade III (%) 79 83
Number of stents  SD 1.7  1.0 1.9  1.2 0.03
Glycoprotein IIb/IIIa inhibitor (%) 56 37 0.01
Clopidogrel prescription, months  SD 2.1  1.5 3.7  2.1 0.01
Peak CK, IU/l  SD* 3,957  5,135 3,126  3,126 0.1
Peak CK-MB, IU/l  SD† 319  230 296  255 0.5
*Upper limit of normal 199 IU/l. †Upper limit of normal 23 IU/l.
CK  creatine kinase; SD  standard deviation; SES  sirolimus-eluting stents; TIMI  Thrombolysis In Myocardial
Infarction.
Table 2. Kaplan-Meier Estimates of Adverse Events at 30 Days
and at 300 Days
Bare Stents
(n  183)
SES
(n  186)
p
Value
30-Day outcomes
Death (%) 5.5 5.9 1.0
Death or nonfatal reinfarction (%) 7.1 6.5 0.8
Target vessel revascularization (%) 4.4 1.1 0.1
Any event (%) 10.4 7.5 0.4
Stent thrombosis (%)* 1.6 0 0.1
300-Day outcomes
Death (%) 8.2 8.3 0.8
Death or nonfatal reinfarction (%) 10.4 8.8 0.5
Target vessel revascularization (%) 8.2 1.1 0.01
Any event (%) 17.0 9.4 0.02
*Angiographically documented stent thrombosis.
SES  sirolimus-eluting stents.
Figure 1. Survival free of reinfarction or target vessel revascularization in
the sirolimus-eluting stent and conventional stent groups. CI confidence
interval.
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ciated with a relative reduction of 48% in the risk of death,
reinfarction, or repeat intervention and a relative reduction
of 79% in the risk of repeat intervention at 300 days.
In our series, reperfusion treatment with SESs was
associated with similar rates of vessel patency, enzymatic
release, and 30-day complications compared to bare stents.
The death rate and the incidence of death or reinfarction
were similar in both study groups, but somewhat higher
than those reported in randomized trials with selected
patients (1,2). These findings most probably reflect the
unrestrictive inclusion criteria of our series (10), which
frequently enrolled patients not included in randomized
studies, as, for instance, cardiogenic shock, multivessel
disease, and unprotected left main lesions. Importantly,
stent thrombosis has not been identified in any patient
treated with sirolimus stents and occurred in three controls
(1.6%), with no statistical difference between the groups.
Although the incidence of stent thrombosis in the bare stent
group was at a somewhat higher range, our results in this
group were not discrepant from historical series with con-
ventional stents (1,2,11–13).
Coronary stenting for the treatment of acute MI has been
limited by the need of late repeat intervention, which has
been reported to occur in approximately 9% of cases at six
months, ranging from 3.6% to 22.7% (1–3). The incidence
of repeat intervention after conventional stenting in our
series (8.2%) was in line with these previous figures. Con-
versely, patients treated with SES implantation clearly had a
reduced risk of reintervention at 10 months. Of note,
between 30 days and 10 months, no additional patient was
referred for repeat revascularization, which is consistent
with the lack of angiographic restenosis after sirolimus stent
implantation, as previously shown in a subset of patients
from the present population (7).
The peri- and postprocedural antiplatelet therapeutic
scheme differed between patients treated with either bare or
sirolimus stents in our series. Patients in the sirolimus group
received fewer glycoprotein IIb/IIIa inhibitors but had a
longer clopidogrel prescription time. However, none of
these characteristics were identified as independent predic-
tors influencing the outcomes of patients. The impact of
clopidogrel and glycoprotein IIb/IIIa inhibitors on the
long-term clinical outcomes of patients with ST-segment
elevation acute MI remains to be established (2,14,15).
Conclusions. Sirolimus-eluting stent implantation for un-
selected patients with ST-segment elevation acute MI
was associated with similar procedural and 30-day out-
comes compared to bare stents, but markedly reduced the
risk of major adverse events and repeat intervention at 10
months. By providing effective mechanical reperfusion
with similar results to the current therapeutic standard,
and decreasing the incidence of late complications, SESs
appeared as an attractive approach for patients admitted
with acute MI. The promising results of the present study
warrant further confirmation in the context of a random-
ized trial.
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Abstract   
 
Objective  
Comparison of clinical outcome of paclitaxel-eluting stents (PES) versus sirolimus-eluting 
stents (SES) for the treatment of acute ST-elevation myocardial infarction.  
 
Design and Patients  
The first 136 consecutive patients treated exclusively with PES, in the setting of primary 
PCI for acute myocardial infarction in our single centre registry were prospectively clinically 
assessed at 30 days and 1 year follow-up and compared with 186 consecutive patients 
treated exclusively with SES, in the preceding period. 
 
Setting 
Academical tertiary referral center. 
 
Results  
At 30 days, all-cause mortality and or re-infarction was similar between groups (6.5% vs. 
6.6% for SES and PES respectively, p = 1.0). A significant difference in target vessel 
revascularization (TVR) was seen in favour of SES (1.1% vs. 5.1% for PES, p = 0.04). This 
was driven by stent thrombosis (n=4), especially in bifurcation stenting (n=2). At one year, 
no significant differences were seen between groups, with no late thrombosis and 1.5 % 
in-stent restenosis (needing TVR) in PES, versus no re-interventions in SES (p = 0.2). 
One-year survival free of major cardiac events (MACE) was 90.2 % for SES and 85 % for 
PES (p = 0.16). 
 
Conclusions 
No significant differences were seen in MACE-free survival at one year between SES and 
PES for the treatment of acute myocardial infarction with very low rates of reintervention 
for restenosis. Bifurcation stenting in acute myocardial infarction should, if possible, be 
avoided due to the increased risk of stent thrombosis.                         
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Introduction 
 
The efficacy of drug-eluting stents to treat coronary artery stenosis in stable patients has 
been proven in recent trials with single digit restenosis rates for non-complex lesions[1] [2] 
[3] [4].  
The potential risk of higher thrombogenicity however, has led to prolonged anti-platelet 
therapy and cautious use in acute coronary syndromes. We have recently shown that the 
use of sirolimus-eluting stents (SES) for acute myocardial infarction is safe and not 
associated with higher thrombogenicity[5]. The safety and efficacy of paclitaxel-eluting 
stents (PES) in this setting has not been reported yet. 
A recent meta-analysis clearly showed the benefit of primary percutaneous coronary 
intervention (PCI) over thrombolytic therapy for the treatment of acute myocardial 
infarction[6] and the superiority of (bare metal) stenting over balloon angioplasty has been 
well documented in acute myocardial infarction[7].  
We report the one year clinical outcome of a consecutive patient cohort treated solely with 
PES in the setting of primary PCI for acute ST-elevation myocardial infarction and 
compared this with an earlier published patient population treated with SES. 
 
 
Methods 
Patients 
Since February 16, 2003, PES (Taxus, Boston Scientific, Galway, Ireland) has been 
implemented in our hospital as the default stent for all patients. Data was collected for the 
Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) Registry. This is a 
prospective single-centre registry set up with the main purpose of evaluating the safety 
and efficacy of PES implantation for patients treated in daily practice.   Up until September 
2003, 134 consecutive patients received exclusively PES in the setting of primary PCI for 
acute myocardial infarction. All patients were enrolled in the analysis including patients in 
cardiogenic shock (defined as persistent systolic blood pressure< 90 mm Hg, or the need 
for vasopressors or intra-aortic balloon pumping required to maintain blood pressure > 90 
mm Hg with evidence of end-organ failure and elevated left ventricular filling pressures). 
Patients who underwent rescue PCI after failed thrombolysis were not included in this 
study.  
One year clinical outcome was compared with the one year data from the first 186 patients 
treated exclusively with SES in the setting of primary PCI for acute myocardial infarction in 
2002, when SES was the default stent in our center[5]. 
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This study protocol was approved by the local ethics committee, and written informed 
consent was obtained from every patient. 
 
Treatment strategy and definitions 
The interventional strategy and use of IIb/IIIa inhibitors was entirely left to the discretion of 
the operator. Clopidogrel was recommended for 6 months, in addition to lifelong 
acetylsalicylic acid 80 mg (ASA). The loading dose of 300 mg clopidogrel was given prior 
to the intervention.  If the patient was not on ASA, 250 mg of intravenous ASA was given 
at the start of the procedure. 
The occurrence of major adverse cardiac events (MACE) was evaluated at 1 year. MACE 
were: a) all-cause mortality, b) non-fatal myocardial infarction c) target lesion and/or target 
vessel revascularization. 
Re-infarction was defined as new symptoms and/or new electrocardiographic changes in 
association with re-elevation of the CK-MB levels of 1.5 times the previous value, if within 
48 hours, or > 3 times the upper normal limit, if > 48 hours from the index infarction.   
Target lesion revascularization(TLR) was defined as a repeat intervention (surgical or 
percutaneous) to treat a luminal stenosis within the stent or in the 5-mm distal or proximal 
segments adjacent to the stent.  Target vessel revascularization(TVR) was defined as a 
repeat intervention, driven by any lesion located in the same epicardial vessel treated at 
the index procedure. Thrombotic stent occlusion was angiographically documented as a 
complete occlusion (TIMI flow 0 or 1) or a flow-limiting thrombus (with TIMI flow 1 or 2) of a 
previously successfully treated artery. 
 
Follow-up 
Clinical follow-up was performed for all patients, while repeat angiography was clinically 
driven by symptoms or signs of ischemia. Information about in-hospital outcomes was 
obtained from our institutional electronic clinical database and by review of the hospital 
records for those discharged to referring hospitals (patients were referred from a total of 14 
local hospitals). Post-discharge survival status was obtained from the Municipal Civil 
Registries at 1, 6 and 12 months. All repeat interventions (surgical and percutaneous) and 
re-hospitalizations were prospectively collected during follow-up. Questionnaires regarding 
anginal status and medication use were sent to all living patients at 6 and 12 months. 
Referring physicians and institutions were contacted for additional information if required. 
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Statistical Analysis 
Continuous variables are presented as mean + SD and were compared using Student’s 
unpaired t- test.  Categorical variables are presented as counts and percentages and 
compared using Fisher’s exact test.  All statistical tests were 2-tailed.  The cumulative 
incidence of adverse events was estimated according to the Kaplan-Meier method and 
compared using the log-rank test.  Cox proportional hazards survival models were used to 
assess risk reduction.  Multivariate analyses were performed to identify independent 
predictors of long-term major adverse cardiac events.  Significant baseline and procedural 
characteristics at univariate analysis  (tested variables: age, diabetes, cardiogenic shock, 
multi-vessel disease, left main stem as the infarct related artery, post procedure TIMI flow, 
bifurcation treatment, multi-vessel treatment, duration of pain); gender and stent type were 
tested for their multivariate predictive value.  The first model was built by backward 
stepwise variable selection with the exit criteria set at the p=0.1 level; the final model built 
by forcing stent type together with all significant predictors. 
 
 
Results 
 
In total 136 patients were treated with PES only, in the setting of primary PCI for acute 
myocardial infarction in the study period. These patients were compared to 186 patients 
treated with SES for the same indication in the period before our centre switched to PES 
as the default strategy. Follow-up of the 186 patients with SES from our earlier report[5] 
was extended from 300 days to 1 year for the comparison. 
Baseline characteristics are depicted in table 1. PES patients had less diabetes (3.7 vs. 
10.8 %, p = 0.02), larger nominal stent size ( 3.11 vs. 2.89 mm, p <0.001), and a higher 
percentage of peri-procedural glycoprotein IIb/IIIa inhibitor use (55.1 vs. 36.6 %, p = 
0.001). Despite inclusion of consecutive patients in both SES and PES groups, there was 
a significant difference in incidence of diabetes. This does not reflect selection bias. The 
smaller nominal stent size in the SES group reflects the unavailability of  SES > 3.0 mm at 
the time of the study. 
MACE was analysed at 1 month and 1 year. Results are shown in table 2. No significant 
difference was seen in death and death or re-MI between the two groups neither in the first 
month nor at late follow-up. However, a significant difference in TVR was seen in favour of 
SES, which was already apparent at 30 days driven by stent thrombosis. 
Six out of seven patients with TVR within 30 days in the PES group received target lesion 
re-intervention. Of these, 4 interventions were necessary because of subacute stent 
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thrombosis (ST). Only one of these patients had been treated with peri-procedural GP 
IIb/IIIa inhibitor during the index procedure. 
Two out of 4 ST’s were in patients treated with bifurcation lesions (one patient with crush 
bifurcation stenting without kissing balloon postdilatation but with peri-procedural GP 
IIb/IIIa inhibitor and one patient with T-stent bifurcation stenting without kissing balloon 
postdilatation and without GP IIb/IIIa inhibitor). The two remaining cases were due to stent 
underexpansion, diagnosed after intravascular ultrasound investigation at re-intervention. 
Bifurcation stenting percentage was not significantly different between groups (8.6 % vs. 
9.6 % for SES and PES respectively, p = 0.8). Although across all strategies no significant 
difference was found in bifurcation lesion treatment between SES and PES patients, a 
trend was seen towards more crush stenting and less T-stenting in PES patients (table 3).  
 MACE-free survival at 12 months was 90.2 % for SES and 85 % for PES patients (p = 
0.16) (by Kaplan-Meier estimate)(figure 1). 
On multivariate analysis, stent type was not an independent predictor of MACE at one 
year, and when forced into the model of significant predictors, remained non-significant 
(p=0.14). (Table 4). However, independent predictors were TIMI flow 0 or 1 (HR 10.2), 
cardiogenic shock (HR 4.4) and diabetes mellitus (4.8). 
 
 
Discussion 
 
The main finding of this paper is that patients treated with drug-eluting stents for acute 
myocardial infarction have a very low rate of repeat revascularization for restenosis at one 
year follow-up. 
Although no significant difference in MACE at 1 year was found between the different drug-
eluting stents, a trend to worse outcome was seen in the patients treated with PES, 
despite more favourable baseline characteristics like less diabetes, higher use of GP 
IIb/IIIa inhibitors and larger nominal stent diameter. 
 
Short-term follow-up 
The largest difference between the groups consists of target vessel re-interventions in the 
first 30 days. These were mainly driven by stent thrombosis. 
In respect to these observations with 2/13 ST in bifurcation lesions and 2/123 in non-
bifurcation lesions, it seems prudent to try to avoid using two stents for bifurcation 
treatment in acute myocardial infarction. If unavoidable, the risk for ST may be reduced by 
kissing balloon postdilatation and peri-procedural GP IIb/IIIa inhibitor. In a separate report 
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of 2500 patients we have confirmed that bifurcation stenting in acute myocardial infarction 
was a significant predictor of stent thrombosis and conferred a 13 fold increase in risk[8].   
Overall rate of ST was 1.2% (4/322) for DES use in acute myocardial infarction. This is 
comparable to ST rate in bare stents[8,9] and DES[8] in patients treated for stable 
coronary lesions. 
 
Long-term follow-up 
Between 30 days and 1 year two patients treated with PES were referred for target vessel 
revascularization, both for in-stent restenosis (1.5 %), compared to no additional 
interventions in the SES patients.   
 No late stent thrombosis was diagnosed in either group. In this study, the risk for late stent 
thrombosis after stopping of clopidogrel, which was prescribed for 6 months in PES and 3- 
6 months in SES, does not seem to be increased for treatment of patients with acute 
coronary syndromes with drug-eluting stents.  It is important that in order to conclusively 
address this potential problem, larger studies specifically looking at this endpoint should be 
performed. Furthermore, until more is known, complete cessation of anti-platelet therapy 
should be avoided if possible, to avoid the risk of late thrombosis, as recently pointed out 
by McFadden et al [10]. 
Early and 1- year mortality was identical in both groups (5.9% at 30 days and 8.1 % at 1 
year for SES and PES). This is very comparable to earlier studies[6] despite the presence 
of cardiogenic shock in 12% of patients and multi-vessel disease in almost half.  As shown 
before, mortality is not changed by the use of drug-eluting stents[5]. Its benefit is reduction 
of re-intervention as in elective PCI. 
The recommendations in the most recent NICE guidelines explicitly exclude acute 
myocardial infarction and lesions with visible thrombus as an indication for DES[11]. Our 
results are reassuring and do not indicate that patients with acute myocardial infarction 
should be denied the benefit of very low re-intervention rates of drug-eluting stents. 
 
 
Conclusions 
 
The use of PES for the treatment of acute myocardial infarction seems safe and no 
significant differences were seen with the results of SES at 1 year follow-up with a very low 
rate of reintervention for re-stenosis. However, a trend towards more early re-interventions 
was visible, mainly due to stent thrombosis. Bifurcation stenting should be avoided in the 
setting of primary PCI, if possible.  
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Figure 1. Kaplan-Meier estimate of MACE-free survival at 360 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1 
Survival free of death, re-infarction or TVR in SES patients vs. PES patients by Kaplan-Meier 
estimate. TVR: target vessel revascularization SES: sirolimus-eluting stent; PES: paclitaxel-
eluting stent. 
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Table 1: Baseline Characteristics 
 
 SES (n=186) PES (n=136) p Value 
Male gender, % 74.7 83.8 0.06 
Age, years (SD) 59.7 (11.7) 59.2 (12.1) 0.7 
Diabetes, % 10.8 3.7 0.02 
Current Smoking, % 45.7 44.9 0.9 
Hypercholesterolemia, % 33.9 30.1 0.5 
Hypertension, % 24.2 20.6 0.5 
Previous Myocardial Infarction, % 14.4 10.6 0.4 
Previous PCI, % 6.5 5.9 1.0 
Previous CABG, % 1.6 2.2 0.7 
Coronary Artery Disease   0.9 
   1-vessel, % 54.8 52.2  
   2-vessel, % 27.4 28.7  
   3-vessel, % 17.7 19.1  
Cardiogenic Shock, % 13.4 11.8 0.7 
Time from Symptom Onset to PCI, hours 
(SD) 
3.2 (1.9) 3.1 (2.4) 0.7 
Infarct-related Vessel   0.6 
   LAD 52.7 51.5  
   LCx 8.2 8.8  
   RCA 37.4 36.0  
   LMS 1.6 2.2  
   SVG 0 1.5  
Bifurcation lesion 8.6 9.6 0.8 
Vessels Treated   1.0 
   1 84.9 86.0  
   >1 15.1 14.0  
TIMI flow Baseline   0.4 
   Grade 0/I 73.1 78.7  
   Grade II 16.5 11.0  
   Grade III 10.4 10.3  
TIMI Flow Final   0.7 
   Grade 0/I 2.1 2.2  
   Grade II 14.8 11.8  
   Grade III 83.0 86.0  
Number of stents (SD) 1.9 (1.2) 1.8 (1.1) 0.4 
Total stented length, mm (SD) 34.7 (23.5) 35.9 (22.9) 0.6 
Mean nominal stent diameter  (SD) 2.89 (0.16) 3.11 (0.33) <0.001 
Glycoprotein IIb/IIIa inhibitor, % 36.6 55.1 0.001 
Peak CK, IU (SD) 3126 (3126) 3234 (2567) 0.8 
Peak CK-MB, IU (SD) 296 (255) 359 (330) 0.2 
PES: paclitaxel-eluting stent; SES: Sirolimus-eluting stent 
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Table 2:  MACE at 30 days and 1 year 
 
 SES (n=186) PES (n=136) p Value * 
0 – 1 month    
Death (%) 5.9 5.9 1.0 
Death or re-MI (%) 6.5 6.6 1.0 
TLR (%) 1.1 4.4 0.07 
TVR (%) 1.1 5.1 0.04 
Death, re-MI or TVR (%) 7.5 10.3 0.4 
Stent thrombosis (%) 0 2.9 0.03 
0 – 12 months    
Death (%) 8.1 8.1 1.0 
Death or re-MI (%) 9.2 10.3 0.7 
TLR (%) 1.1 5.9 0.02 
TVR (%) 1.1 6.6 0.01 
Death, re-MI or TVR (%) 9.7 14.7 0.22 
Stent thrombosis (%) 0 2.9 0.03 
 
* by Fisher’s exact test 
 
re-MI: re-infarction; PES: paclitaxel-eluting stent; SES: Sirolimus-eluting stent; TLR: target lesion 
revascularization; TVR: target vessel revascularization  
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Table 3. Bifurcation lesions: treatment strategy 
 
 SES (n=16) PES (n=13) p Value 
Main branch stent only 3 (18.8%) 3 (23.1%) 0.4 * 
Crush 2 (12.5%) 4 (30.8%)  
Culotte 0 1 (7.7%)  
T-Stent 9 (56.3%) 3 (23.1%)  
V-Stent 2 (12.5%) 2 (15.4%)  
    
Final Kissing balloon 6 (42.9%) 8 (61.5%) 0.3 
 
* Across all strategies by Chi Square test 
PES: paclitaxel-eluting stent; SES: Sirolimus-eluting stent 
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Table 4: Final Cox regression model of independent predictors of MACE at one year 
with stent type forced in 
 
Independent predictor Hazard 
ratio 
95% 
Confidence 
Interval 
P value 
TIMI flow     
 Grade 3 (reference) 1.00   
 Grade 2 2.90 0.86-9.77 0.09 
 Grade 0 or 1 10.24 2.61-40.13 0.001 
Cardiogenic shock 4.38 1.63-11.8 0.003 
Diabetes mellitus 4.77 1.61-14.1 0.005 
Duration of pain (per hour increment) 1.17 0.98-1.39 0.08 
Multi-vessel disease 2.13 0.79-5.78 0.14 
Use of paclitaxel-eluting stent 2.07 0.78-5.48 0.14 
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Summary and Conclusions 
 
The aim of this thesis was to study vascular response to coronary interventions. This 
involved study of vessel wall injury, both acute and chronic, endothelial dysfunction and 
the performance of drug-eluting stents in clinical practice, as they are associated with 
delayed vascular healing due to their anti-proliferative capacity. 
 
The first part of the thesis is focussing on the vascular wall trauma, caused by the 
interventions.  
Chapter 2 describes the four phases of wound healing after intracoronary stenting, i.e. the 
early thrombotic response, followed by the recruitment phase with cellular infiltration, the 
proliferative phase and the final healing phase. In chapter 3 it is shown that the vessel wall 
injury inflicted in the acute phase by stenting is even increasing in the weeks after the 
intervention. Two very different stent types were studied in the porcine coronary model and 
the difference in response suggests that persistent inflammatory response and stent 
design may influence the chronic injury and healing response. 
Intracoronary irradiation therapy (brachytherapy) was the most effective therapy for 
treating in-stent restenosis until the recent favourable outcomes with drug-eluting stents. 
Brachytherapy was also investigated as adjunctive therapy directly after stenting or balloon 
angioplasty to prevent the occurrence of restenosis. However, long-term results are 
disappointing and a high percentage of late thrombotic occlusion has been reported. In 
chapter 4 a case-report is presented with late occlusion five years after balloon 
angioplasty and adjunctive brachytherapy, while 3 year follow-up angiography had shown 
a patent vessel! Impaired healing response of the vessel wall after radiation therapy is 
thought to be the cause of these late (thrombotic) occlusions. 
Chapter 5 shows the sequelae of the early drug-eluting stent period, when the largest 
available stent size was 3.0 mm. To achieve acceptable stent apposition in large coronary 
vessels, stents were up-sized with larger balloons. This can lead to stent strut fracture and 
as shown in this case the combination of less local drug elution and the direct trauma of 
the broken stent struts as well as damage to the polymer can lead to restenosis, even in 
large vessels and with the use of drug-eluting stents. 
 
The second part of this thesis is focussing on endothelial dysfunction after percutaneous 
coronary interventions (PCI).  
In chapter 6 vascular permeability as a parameter of regeneration of a mature endothelial 
lining after balloon angioplasty or stenting was investigated, both early and late after the 
intervention. Dye-exclusion tests showed persistent vascular permeability up to 3 months 
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after the intervention, being the most pronounced in the stented vessels. This indicates 
immature endothelial functional recovery and this was correlated with distinct morphologic 
characteristics, such as endothelial retraction, the expression of surface folds and the 
adhesion of leukocytes.  
Brachytherapy is associated with a delayed vascular healing response. In chapter 7 we 
investigated whether more endothelial dysfunction could be demonstrated in patients 
treated 6 months before with stenting and adjunctive brachytherapy or no brachytherapy. 
In both groups, endothelial function was still abnormal after 6 months, like shown before by 
Caramori et al. in bare stents, but no difference could be demonstrated. Investigating 
endothelial function 6 months after drug-eluting stent implantation in chapter 8 led to the 
remarkable observation that endothelial function was severely disturbed, while in the 
control group no significant paradoxal vasoconstriction ( as a sign of endothelial 
dysfunction) could be demonstrated. This is not in accordance with the excellent clinical 
results up to three year after drug-eluting stent implantation. This outcome should be 
investigated in a larger patient population, but is reason for some concern and may be 
related to the slight increase in stent thrombosis seen after drug-eluting stent implantation, 
particularly late stent occlusions. If confirmed, adjunctive medical therapy like ACE-
inhibitors as well as already advised cholesterol-lowering therapy for all patients after drug-
eluting stents should be considered, next to the already implemented prolonged use of 
double anti-platelet therapy. 
The subset of patients from the study reported in chapter 8 was used to study the relation 
between local endothelial function and shear stress in chapter 9. Low shear stress has 
been correlated to endothelial dysfunction but this has only been shown in vitro. Using 
sophisticated mathematical calculations, 3D reconstructions of the coronary segments 
distal to the implanted stents were made. Incorporating coronary flow velocity data and 
studying the patients after intracoronary acetylcholine infusions, correlations between local 
shear stress and local endothelial dysfunction (vasoconstriction) could be found. In regions 
with a shear stress of less than 1.3 Pa, a significantly larger vasoconstrictive response to 
acetylcholine could be seen compared to areas with shear stress of  1.3 Pa or more 
(normal to high shear stress). It is for the first time that such a correlation could be 
demonstrated in vivo. 
 
The third part of this thesis is focussing on coated and drug-eluting stents.  
Chapter 10 reports the findings of the use of a heparin-coated stent in porcine coronary 
arteries. This preclinical study led to the clinical BENESTENT 2 pilot and trial, showing a 
very low risk of stent thrombosis, despite a progressively milder anti-coagulant regime, 
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ending with dual-platelet therapy, without post-procedural heparin. Today this is still the 
clinical practice.    
Over the last 10 years further attempts have been undertaken with different heparin stent- 
coatings to minimize the risk of stent thrombosis and reduce the incidence of in-stent 
restenosis. Chapter 11 provides an update on those attempts, highlighting three different 
heparin-coatings, the HepacoatTM, the HepamedTM  and the CorlineTM coating. Clinical trials 
have shown very low rates of subacute stent thrombosis of 0.2 %. The average incidence 
of subacute stent thrombosis in bare metal stent is around 1 %.  However, the other goal 
to reduce the rate of in-stent restenosis has not been reached and no significant difference 
has emerged from the different trials. There is a nice for heparin-coated stents in highly 
thrombotic subsets of patients or patients with a contraindication for prolonged antiplatelet 
therapy, but availability of the stents has become a problem. 
After attempts with passive stent coatings newer concepts with drug-elution from a stent- 
based polymer, or even without polymer were investigated. This is a fast evolving field of 
research which has led sofar to two commercially available drug-eluting stents with 
excellent clinical results in multiple large trials, the sirolimus-eluting stent (SES) (Cypher, 
Cordis Co, Warren, NJ, USA) and the  paclitaxel-eluting stent (PES) (Taxus, Boston 
Scientific, Galway, Ireland). Next to these stents, multiple drug-eluting stents are in the 
pre-clinical or clinical testing phase. Chapter 12 is providing an update up to February 
2004 of this field. 
In chapter 13 the first registry results are reported of the use of SES in the highly 
thrombotic environment of patients with an acute myocardial infarction. Concerns of higher 
risk of stent thrombosis in drug-eluting stents have been expressed multiple times and 
though it never has been substantiated, this fear has led to restrictive use in acute 
myocardial infarction. In this series of 186 consecutive patients no stent thrombosis was 
diagnosed and only 1.1 % of patients needed target vessel reintervention at 300 days 
follow-up compared to 8.2 % in the bare stent group in this study.  
Chapter 14 investigated the safety of the PES for the same indication of primary PCI for 
acute myocardial infarction. PES is also effective, but the slightly higher risk of subacute 
thrombosis of 2.9 % raises some concern. Half of these stent thromboses were seen in 
stented bifurcation lesions. This suggests that bifurcation stenting should be avoided in the 
setting of an acute myocardial infarction if possible and bifurcation treatment should be 
kept as simple as possible. Late stent thrombosis after 30 days was not seen, which is 
very reassuring. 
 
In Conclusion this thesis demonstrated that vessel wall injury occurs during coronary 
intervention, that this vessel wall injury can even increase after the acute injury in the case 
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of stenting and that this injury leads to neointimal proliferation. Endothelial dysfunction is 
still present months after the intervention, but no worse endothelial function could be 
demonstrated late after brachytherapy compared to no brachytherapy. In contrast, after 
SES implantation severe endothelial dysfunction was still detectable after 6 months.  
A correlation could be found between local endothelial dysfunction and areas of low shear 
stress. 
Despite this, SES and PES show excellent intermediate-term clinical results and no late 
stent thrombosis could be found in patients treated during acute myocardial infarction. 
However, delayed vascular healing with prolonged endothelial dysfunction is reason for 
some concern and despite extended duration of double anti-platelet therapy, stent 
thrombosis rates are similar to those in bare stents and the timing is less predictable. More 
attention towards improving endothelial function after intervention of the culprit lesion 
seems advisable. May be this can be achieved by adjunctive medication like ACE-
inhibitors and aggressive cholesterol lowering. 
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Samenvatting en Conclusies 
 
Het doel van dit proefschrift was het bestuderen van de vaatwandreactie na interventies in 
de kransslagader. Hierbij werd gekeken naar acute en chronische vaatwandbeschadiging, 
endotheeldysfunctie en naar het gedrag van de nieuwste generatie stents, de 
zogenaamde “drug-eluting stents” (DES), waarbij na implantatie gedurende een bepaalde 
tijd langzaam een medicijn diffundeert uit de stentcoating ter voorkoming van in-stent 
restenose. Deze medicijnen worden namelijk gerelateerd aan vertraagde genezing van de 
beschadigde vaatwand, wegens de sterke anti-proliferatieve werking van deze medicijnen. 
 
Het eerste deel van het proefschrift concentreert zich op de vaatwandbeschadiging die 
ontstaat door de interventie. 
Hoofdstuk 2 Beschrijft de vier fasen van de wondgenezing na het plaatsen van een stent, 
nl. de vroege trombotische respons, gevolgd door de recruteerfase gekenmerkt door het 
aantrekken van cellen, vervolgens de proliferatieve fase en tot slot de helingsfase. In 
hoofdstuk 3 wordt aangetoond dat de initiele vaatwandschade de eerste weken na de 
interventie zelfs nog toeneemt. In een varkensmodel worden twee verschillende stenttypes 
onderzocht in de kransslagader. Persisterende ontstekingsreactie  en het verschil in 
stentontwerp lijken van invloed op de vaatwandschade en de helingsrespons. 
Voor de goede resultaten van de nieuwe DES was intracoronaire bestralingstherapie 
(brachytherapy) de meest effectieve therapie voor de behandeling van restenose in de 
stent. Daarnaast werd ook onderzocht of brachytherapy deze in-stent restenose zou 
kunnen voorkomen. De langetermijn resultaten bleken teleurstellend en vooral late 
stenttromboses werd frequent gezien, resulterend in een afsluiting van het vat. Hoofdstuk 
4 beschrijft een patient waarbij 5 jaar na de behandeling en preventieve brachytherapie het 
bloedvat alsnog afgesloten raakt, terwijl het bij de 3-jaarscontrole nog fraai open was. De 
sterk vertraagde wondgenezing door de bestraling speelt waarschijnlijk een rol in deze erg 
late complicaties. 
In de begintijd van de DES waren er alleen maar relatief kleine maten beschikbaar. Om 
toch iedereen te kunnen laten profiteren van deze goede stents werden ze ook gebruikt in 
grotere vaten. Vervolgens werd de stent met een grotere balloon nagerekt. Hoofdstuk 5 
laat zien dat dit kan leiden tot een breuk in de stent en re-stenose. Door de scherpe 
gebroken stentstruts, beschadigde polymeercoating en ter plekke minder effectieve 
dosering van het medicament dat re-stenose tegen moet gaan, kan deze stentbreuk 
alsnog leiden tot re-stenose, zelfs in grote vaten waar dit normaliter zelden voorkomt. 
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Het tweede deel van dit proefschrift bestudeert de endotheelfunctie na interventies in de 
kransslagader. 
In hoofdstuk 6 werd vaatwandpermeabiliteit as marker van herstel van een volgroeide 
endotheellaag bestudeerd, zowel na ballonangioplastiek als na stenting, zowel vroeg als 
laat na de behandeling. Abnormale permeabiliteit kon worden aangetoond tot 3 maanden 
na de behandeling, waarbij dit meer uitgesproken was na stenting dan na 
ballonangioplastiek. Dit impliceert incompleet herstel van de endotheellaag. Hierbij konden 
karakteristieke morfologische  veranderingen van de endotheelcellen worden aangetoond. 
Zoals boven reeds genoemd is de wondgenezing vertraagd na brachytherapie. In 
hoofdstuk 7 werd onderzocht of ernstiger endotheeldysfunctie aangetoond kon worden 6 
maanden na stenting en brachytherapie dan na stenting zonder brachytherapie. In beide 
groepen was na 6 maanden de endotheelfunctie nog abnormaal, zoals ook reeds eerder 
aangetoond door Caramori et al. na stenting, maar een verschil tussen stent of stent en 
brachytherapie kon niet aangetoond worden.  In hoofdstuk 8 werd de endotheelfunctie 
onderzocht 6 maanden na implantatie van de nieuwe generatie stents, de DES, en in dit 
geval de sirolimus-gecoate stent (SES). Dit leidde tot de opmerkelijke bevinding dat 6 
maanden na de behandeling de endotheelfunctie ernstig gestoord was na implantatie van 
de SES, terwijl dit veel minder het geval was na een ongecoate stent. Dit is opvallend 
aangezien de klinische resultaten met inmiddels een follow-up van ruim 3 jaar uitstekende 
resultaten laten zien van deze stent. Deze bevinding zal moeten worden bevestigd in een 
veel grotere groep patienten, maar het roept wel op tot waakzaamheid en langdurige 
follow-up. Hoewel in grote studies nooit hard aangetoond, is er toch een vermoeden op 
een iets verhoogde kans op stenttrombose bij het gebruik van DES, vooral na het 
voortijdig stoppen van bloedplaatjesaggregatieremmers. Het langdurig gebruik van 
dubbele plaatjesaggregatieremmende medicatie is inmiddels reeds gebruikelijk, maar 
misschien zou een ACE-remmer na stenting ook standaard moeten worden net als 
cholesterolverlagende medicatie. Beide medicijnen hebben bewezen gunstig effect op 
atheroscleroseprogressie en een gunstig effect op het endotheel. 
In hoofdstuk 9 werd de relatie bestudeerd tussen locale endotheelfunctie en shear stress 
(schuifspanning). Tot nu toe is alleen in “in vitro” onderzoeken een relatie tussen low shear 
stress en endotheeldysfunctie aangetoond. Door gebruik te maken van wiskundige 
rekenmodellen konden 3D reconstructies worden gemaakt van de coronairvaten uit 
angiografische plaatjes en door middel van correlatie met gemeten bloedstroomsnelheden 
tijdens acetylcholineinfusie in de kransslagaderen, kon de relatie tussen shear stress en 
endotheeldysfunctie (vaatvernauwing op acetylcholine) worden bestudeerd. Gebiedjes met 
een lage shear stress van < 1,3 Pa gaven een significant grotere vaatvernauwing na 
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acetylcholine vergeleken met gebiedjes met een hogere shear stress. Het is voor de 
eerste keer dat dit in vivo is aangetoond. 
 
Het derde deel van dit proefschrift concentreert zich op gecoate stents en DES. 
Hoofdstuk 10 beschrijft de resultaten van het gebruik van heparine-gecoate stents in 
kransslagaders van biggen. Deze preklinische studie leidde tot de bekende klinische 
studies, de BENESTENT 2 pilot en trial. Hierbij werd de veiligheid van de heparine-
gecoate stent aangetoond zonder een verhoogd risiko op stenttrombose met alleen 
nabehandeling met twee verschillende plaatjesaggregatieremmende medicamenten. Dit is 
8 jaar later nog steeds de gebruikelijke therapie. 
De afgelopen 10 jaren zijn nog diverse studies verricht met verschillende soorten 
heparine-gecoate stents om het risiko op stenttrombose te minimaliseren en het 
percentage in-stent restenose te verminderen. Dit eerste was succesvol met zelfs 
trombosepercentages ver onder de 0,5 % ten opzichte van ongeveer 1 % in metalen 
stents. Helaas is een significant reductie van in-stent restenose nooit aangetoond. 
Hoofdstuk 11 geeft een overzicht van deze studies.  
De boven reeds genoemde DES hebben inmiddels zeer goede resultaten laten zien in 
grote studies en worden in snel toenemende mate gebruikt in plaats van metalen stents. 
Tot nu toe zijn twee van dit soort stents in grote trials onderzocht en commercieel op grote 
schaal verkrijgbaar, nl. de sirolimus-eluting stent (SES) (Cypher, Cordis Co, Warren, NJ, 
USA) en de paclitaxel-eluting stent (PES) (Taxus, Boston Scientific, Galway, Ireland). 
Hoofdstuk 12 geeft een overzicht van de preklinische en klinische studies met diverse 
DES tot februari 2004. In Hoodstuk 13 worden de eerste 186 patienten beschreven die in 
het ErasmusMC werden behandeld met een SES voor een acuut hartinfarct. Hoewel een 
patient met een acuut hartinfarct een duidelijk verhoogde stollingsneiging van zijn bloed 
heeft in de acute fase, bleek het gebruik van de SES ook in deze setting veilig en zonder 
verhoogde risiko’s op stenttrombose. Ook bleek dat patienten die met een SES behandeld 
werden vrijwel nooit terug hoefden te komen voor een herinterventie in het behandelde vat 
gedurende een follow-up van 300 dagen (1,1% vs. 8,2 % voor patienten behandeld met 
een metalen stent). 
In hoofdstuk 14 werd de andere DES nl. de PES geevalueerd voor dezelfde indicatie. 
Ook deze stent liet goede resultaten zien, echter er werden enkele patienten teruggezien 
met stenttrombose (2,9 %). De helft van deze patienten waren in de acute fase behandeld 
voor een afsluiting op een vertakking in de kransslagader. Hierbij waren beide takken 
gestent, en hoewel deze getallen erg klein zijn, zou dit mogelijk een verhoogde 
stenttrombose kans geven. Late stenttromboses werden niet gezien en na 1 jaar was er 
geen significant verschil in effectiviteit tussen de SES en de PES. 
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Conclusie: Dit proefschrift laat zien dat de vaatwand beschadigd raakt tijdens de 
behandeling van vernauwingen in de kransslagader met ballonangioplastiek of 
stentplaatsing. Deze beschadiging kan zelfs nog toenemen in de eerste weken na 
stentplaatsing. Dit wordt gevolgd door een genezingsreactie met vorming van een 
neointima. Bij excessieve schade is de kans groter op in-stent restenose door meer 
neointimaproliferatie. Endotheeldysfunctie is nog maanden na de interventie in het 
bloedvat aantoonbaar. Hoewel deze genezingsfase wordt vertraagd door 
bestralingstherapie kon na 6 maanden geen verschil in endotheeldysfunctie worden 
aangetoond in bestraalde patienten tov niet-bestraalde patienten. Daar stond tegenover 
dat in patienten die een SES ontvingen de endotheelfunctie na 6 maanden nog sterk 
gestoord was. Ook kon in deze patientengroep een relatie aangetoond worden tussen 
gebieden van lage schuifspanning (shear stress) en locale endotheeldysfunctie. 
Ondanks dit zijn de middellange termijn resultaten van SES en PES uitstekend en kon 
zelfs in de zeer trombogene setting van het acuut hartinfarct geen verhoogde neiging tot 
late stenttrombose aangetoond worden, als uiting van vertraagde vaatwandgenezing. 
Desalniettemin is vertraagde wondgenezing, gepaard gaand met langdurige 
endotheeldysfunctie reden tot enige zorg. Ondanks de forse verlenging van de 
behandelduur met twee bloedplaatjesaggregatieremmers is de incidentie van 
stenttrombose vergelijkbaar met ongecoate stents en het optreden ervan minder 
voorspelbaar. Het lijkt verstandig na het opheffen van de belangrijke vernauwing meer 
aandacht te besteden aan de kwaliteit van het endotheel. Dit zou misschien kunnen door 
een groter gebruik van ACE-remmers na de PCI alsmede door aggresieve 
cholesterolverlaging. 
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Dankwoord 
 
Het voltooien van dit proefschrift is tevens een afsluiting van een periode van 11 jaren 
verbondenheid aan het Erasmus Medisch Centrum. Het begon eind 1993 als “inval” angio 
om tijdelijk een zwangere agio te vervangen, daarna als arts-onderzoeker op de 
“Experimentele Cardiologie” in de witte toren tot het geld op was en er geen 
onderzoekersplaats meer was, vervolgens opnieuw als agnio en tot slot de fel begeerde 
opleidingsplaats. Een vrij gebruikelijk scenario in die tijd. 
Gedurende mijn kliniekjaren heb ik mijn onderzoekstijd en onderwerpen nooit uit het oog 
verloren en konden mijn “biggenstudies” gecontinueerd worden met humaan onderzoek op 
het “ echte cathlab”.  
Tot mijn grote vreugde kreeg ik de mogelijkheid om na mijn opleiding tot cardioloog, mijn 
grote passie, de interventiecardiologie te bedrijven en daarnaast de lopende cathlab 
studies af te ronden. Uiteindelijk resulteerde dat in het nu voor u liggende boekje. 
Het bovenstaande was nooit gelukt zonder de hulp, begrip en geduld van vele mensen. 
Vooral de cathlab studies van de BRIEF studie (door mij verzonnen acronym voor 
BRachytherapy Induced Endothelial Function study) (hoofdstuk 7,8 en 9) waren zeker niet 
“brief” en behoorden tot de langste cathlabprotocollen in Rotterdam, en dat wil heel wat 
zeggen in deze kliniek. Dit vergde veel geduld van de uitvoerende cardiologen, 
verpleegkundigen, technici en de patienten. 
 
Allereerst wil ik mijn promotor, Professor Serruys bedanken. Beste Patrick, ik ken geen 
mensen die meer gedreven zijn op het gebied van interventiecardiologie dan jij. Schijnbaar 
onvermoeibaar, altijd op de hoogte van de nieuwste data en plannen, zelfs voordat ze op 
papier staan en altijd bereid je in te zetten om nieuwe ideeën te onderzoeken en 
concepten te testen. Daarnaast herinner ik me de complexe en soms langdurige 
procedures waarin ik mocht assisteren en ook de complicaties, die met jouw hulp goed 
afliepen. 
Vervolgens wil ik mijn grote dank uitspreken aan mijn co-promotor dr. Van der Giessen. 
Beste Wim, in 1994 ben ik dankzij jou en onder jouw hoede op de afdeling “Experimentele 
Cardiologie” terecht gekomen. Ondanks mijn spraakwatervallen, waar jij wel aan moest 
wennen, gaf jij me steeds meer verantwoordelijkheid en ik was erg trots toen ik voor het 
eerst min of meer zelfstandig een PTCA had verricht bij een big, omdat jij poli moest doen. 
Mijn voorliefde voor de interventiecardiologie die ik reeds had gekregen tijdens mijn keuze-
coschap in Zwolle, werd door mijn tijd op de 23e etage bevestigd. Terug in de kliniek heb je 
mij continu ondersteund bij het schrijven van het BRIEF protocol, het door de MEC krijgen 
hiervan, het verkrijgen van NHS subsidie ervoor en tot slot de uitvoer ervan. 
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Vanaf 1994 tot de dag van vandaag kon ik altijd bij jou terecht met mijn vragen en twijfels 
en lukte het jou meermalen mijn pessimisme over de voortgang van de studies te 
veranderen in optimisme over nieuwe mogelijkheden om de studies te continueren. 
Ook wil ik professor Verdouw bedanken. Beste Piet, ik heb nooit spijt gehad van het feit 
dat ik jouw aanbod accepteerde om op de 23e te komen werken in 1994, toen mijn “inval 
agnioschap” afliep. Goede herinneringen heb ik ook aan de uitjes, m.n. naar de European 
Heart congressen, waar we meestal goed vertegenwoordigd waren. Helaas voor jou was 
ik niet geinteresseerd in voetbal, dat bleek toch wel een moeilijk punt op de afdeling. 
Goede herinneringen heb ik ook aan de rest van de medewerkers op de “Experimentele 
Cardiologie”, m.n. Heleen van Beusekom, die mij vele uren achter de microscoop zette om 
de “vessel injury score” van vele honderden coupes van coronairvaten te laten bepalen 
alsmede het meten van neointimadiktes etc., Loe Kie Soei, die mij introduceerde in de 
acute biggenexperimenten en daarbij vele vaardigheden leerde en Ben Gho, altijd goed 
voor basale discussies over de gevonden resultaten en door de jaren heen een goede 
vriend geworden en gebleven. 
Eenmaal in de kliniek lag mijn hart bij het cathlab. Professor de Feyter, beste Pim, bedankt 
voor al het geduld dat je met me had tijdens de beginperiode van mijn fellowship 
interventiecardiologie. Jij was de eerste die mij zelfstandig een PTCA liet verrichten. 
Tevens was je altijd benaderbaar om een casus te bespreken en jij leerde me ook dat het 
soms beter is ergens vanaf te blijven.  
Ik ben blij dat ik nog heb mogen werken met Marcel van den Brand, die de dankbare taak 
had de arts-assistenten te begeleiden en onder wiens leiding je leerde fatsoenlijke films te 
maken. Nog steeds heb ik daar profijt van en nog steeds zie ik helaas regelmatig films van 
cardiologen die duidelijk niet door jou getraind zijn.  
Peter Smits, inmiddels vertrokken naar het MCRZ, bedankt voor jouw rol in mijn opleiding 
en participatie in de studieprotocollen. Jij was volgens mij niet altijd blij als je mij om de 
hoek zag komen, net op het moment dat je het programma voor de volgende dag maakte, 
aangezien ik toch vooral zeker wilde stellen dat ik prominent in dit programma aanwezig 
was. 
Mijn kamergenoten, Eugene McFadden, helaas net teruggegaan naar zijn roots in Ierland, 
bedankt voor jouw onbaatzuchtige opstelling, nooit te beroerd om nog iets te bespreken of 
mij iets te leren. Ik herinner me nog erg goed onze “live-case” waarin we onder luid protest 
uit de zaal in Parijs in een 30 % lesie in de RCA een stent plaatsten, nadat we met drie 
verschillende technieken hadden aangetoond dat de lesie “vulnerable” was, en natuurlijk 
George Sianos, een meester in het uitvoeren van complexe technieken, ik heb nog nooit 
iemand zijn guiding catheter zo diep zien positioneren als jij, maar problemen bleek het 
niet te geven.  
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Door de jaren heen zijn er ook veel buitenlandse fellows geweest, welke onmisbaar waren 
voor ondersteuning van een aantal studies en daarnaast het cathlab een gezellige 
internationale sfeer gaven. Met name ben ik dank verschuldigd aan Pedro Lemos, beste 
Pedro jij was op een natuurlijke manier de centrale spin in het web voor alle RESEARCH 
analyses zonder ooit op de voorgrond te treden. Daarnaast had je nog tijd mij te helpen 
met de analyses van de BRIEF studie. Met name jouw goede kennis van statistiek was 
zeer waardevol. Andrew Ong, naast jouw kennis van de meest uiteenlopend nuttige en 
niet nuttige internetsites was je een goede partner om mee te discussieren en artikelen 
mee te schrijven. Bedankt dat je mijn paranimf wil zijn op mijn promotie. Akis Arampatzis, 
bewondering en verbazing had ik voor het feit dat je bij ons PCI’s wilde leren en 
promoveerde terwijl je vrouw met jullie pasgeboren kind in Griekenland zat. Aan tafel staan 
met jou was wel moeilijk, want jouw brede schouders duwden de co-operator meestal tot 
aan het voeteneind van de tafel. Jiro Aoki, bedankt voor de IVUS-analyses die je voor de 
BRIEF studie geanalyseerd hebt. Verder heb ik goede herinneringen aan Francesco Saia, 
Angela Hoye, Evelyn Regar en vele anderen die ik minder goed gekend heb. 
Ook wil ik Bas van Dalen bedanken voor de hulp bij de QCA analyses van de BRIEF 
studie. Beste Bas, ik hoop dat ik jouw enthousiasme voor de cardiologie nog verder 
aangewakkerd heb en ik ben er van overtuigd dat je een goede cardioloog zult worden. 
Voorts ben ik dank verschuldigd aan de critische statistici, Ron van Domburg en Eric 
Boersma en de studiecoordinatoren Arno Ruiter en Paul Cummins alsmede de 
ondersteuning door Jolanda van Wijk, Cecile Zwiers en Maria Kramps. Beste Arno, eerst 
leerde ik je kennen als een zeer kundige en gezellige cathlabverpleegkundige, later stapte 
je over naar de research. Jouw practische kennis en kritische blik waarbij je de belasting 
voor de patient bij een bepaald onderzoek niet uit het oog verloor, waren erg waardevol. 
Paul, jij zorgde, soms vaker dan strict gewenst, voor de vrolijke noot en relativeerde elke 
tegenvaller.  
Ad den Boer en Dirk van Essen, bedankt voor de expertise en bewaking van de veiligheid 
van de straling, met name tijdens de brachytherapie behandelingen, waar toch een 
behoorlijke logistieke organisatie achter zat. 
 Zeker genoemd dienen te worden de ondersteuning vanuit de audiovisuele hoek, Jan 
Tuin en Paula Delfos. Beste Jan, al sinds 1994 kwam ik regelmatig bij je over de vloer. 
Altijd wist jij een poster om te toveren tot een glossy presentatie waar je mee voor de dag 
kon komen. Ook kon je prachtige foto’s scannen, al waren ze soms zoveel megapixels, dat 
ik moeite had ze ergens in te verwerken. Bedankt voor het maken van de fraaie cover van 
dit boekje en alle jaren waarin ik bij jou in het hok mooie filmpjes te zien kreeg, van gladde 
presentaties tot de bloopers van live-cases.  
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Roelof Pool, bedankt voor managen van zo’n kleurrijk cathlab en dankzij jou was ik mijn 
mooie appartement snel kwijt en kreeg het een waardige opvolger als nieuwe bewoner. 
Vervolgens de secretaresses van het cathlab, bedankt voor alle ondersteuning. Met name 
wil ik noemen de centrale spil voor elke patient die het cathlab passeert, Titia Bautz. Beste 
Titia, ik heb door de jaren heen erg veel aan je gehad. Al had ik slechts een naam, feilloos 
wist jij snel de patient te traceren en de film te voorschijn te toveren. Wel moest je zorgen 
dat je zelf je zaakjes goed voor elkaar had, maar dan kon je ook alles aan jou vragen. 
Mocht je nog ooit naar Friesland willen verhuizen dan moeten we maar eens praten. Edith 
de Getrouwe, een zware taak was voor jou weggelegd om zowel Eugene als George en 
mij te ondersteunen. Bedankt voor alles wat je hebt gedaan. Het was altijd zeer 
verbazingwekkend om te zien hoe snel allerlei ICT mannetjes bij jou op de stoep stonden 
als er weer eens iets mis was met de computer. 
Anja van Huuksloot, jij was bijna onpasseerbaar als je Patrick nodig had. Gelukkig lukte 
het soms toch om bij hem binnen te komen. Respect heb ik voor de enorme stapel post en 
e-mails die jij per dag te verwerken krijgt en stroomlijnt. 
Elles Schaap, bedankt voor alle keren dat jij me op de agenda van Wim kon krijgen als we 
iets moesten bespreken. Helaas kunnen we onze verjaardag nu niet meer samen vieren 
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